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i. Abstract 
In order to better replicate disease and response to therapeutics 3D cell culture 
methods have been increasingly developed for use in research and industry. Two 
key areas where 3D cell cultures are being used as alternative models to animals 
are the study of prevalent diseases such as cancer and therapeutic toxicity testing 
in key metabolising organs such as the liver. Matrix-assisted Laser Desorption 
Ionisation Mass Spectrometry Imaging (MALDI-MSI) is an untargeted molecular 
imaging technique capable of imaging multiple molecules within a single 
experiment. This can be utilised for the investigation of molecular mechanisms of 
biological function or treatment response within 3D cell cultures, however, 
optimised methods are required for the analysis of these models. 
In this thesis, a novel 3D cell culture model of osteosarcoma was developed. 
Sample preparation and MALDI-MSI workflows were optimised initially for small 
molecule analysis. Following this, doxorubicin responses in the 3D osteosarcoma 
model were assessed. Detection of doxorubicin-induced changes to lipids and 
metabolites in 3D cell culture were subsequently detected, and Principle 
Component Analysis (PCA) used to identify metabolite signatures associated 
with doxorubicin treatment.  
Methods were then adapted for MALDI-MSI of proteotypic peptides within the 
model and a novel method for peptide quantitative mass spectrometry imaging 
(QMSI) was developed. MALDI-MSI successfully allowed the identification and 
quantification of 25 proteotypic peptides, using a 120-peptide standard array, 
demonstrating, for the first time, that QMSI is possible for proteomic quantification 
in 3D cell cultures. 
Development of, and preliminary MSI analysis of, a novel 3D cell culture model 
of liver toxicity is reported. The L-pNIPAM scaffold and HepG2 cell lines used 
demonstrates hepatocyte differentiation and is potentially suitable for monitoring 
of hepatic metabolism and adverse drug reaction. Taken together, these studies 
represent a considerable development in simultaneous quantification of 
metabolites, lipids and proteins in 3D cell cultures.  
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1.1 Introduction 
Study using two-dimensional (2D) cell cultures and animal models has 
contributed greatly to current knowledge of disease mechanisms and 
development of treatment options. It has provided a large amount of information 
about biological mechanisms within the human body and interactions with 
pharmaceuticals; however, none of the current models provide a reliable 
translation of the complex human environment. Two-dimensional cell culture has 
been utilised for many years as it is a cost-effective option which provides a 
relatively homogenous, highly reproducible environment for experimental 
purposes. Nonetheless, there is agreement in the scientific community that 2D 
cell culture is far from a perfect model of the in vivo human environment in regards 
to limited cell type, lack of physiochemical gradients and a lack of conditional 
heterogeneity. Differences in gene expression, compared to the in vivo 
environment, alter central, significant cell functions, changes in morphology 
contribute to vast differences in drug-interactions, and there are also differences 
in cell-cell interactions and cell-matrix interactions. All these fundamental 
changes lead to large differences between limited 2D cell cultures and the in vivo 
human patient responses they are attempting to predict (Horvath et al., 2016). 
Conversely, the animal model is highly complex, consisting of hundreds of cell 
types with varying local cell environments, cell-cell and cell-extracellular matrix 
interactions, stem cell populations, difficulties in drug delivery, and hepatic drug 
metabolism. The animal model, for a long period of time has been considered the 
‘gold standard’ for models of human disease. It is the most representative, as it 
contains not only all the complexity of tissues but also interactions between multi-
organ systems which cannot be simply predicted in vitro. On the other hand, the 
animal model has also received considerable criticism, particularly in industry, 
where many pharmaceuticals pass through the time-intensive and expensive 
animal testing stage only to be retracted at the human trial stage. These do not 
get approved or have to be discontinued due to a late discovered side effect or 
ineffectiveness (Ledford, 2011; Hutchinson & Kirk, 2011; Arrowsmith, 2011).  
The predictive power of animal models and their possible replacement and 
reduction has been a focal point of discussion and was already mentioned in the 
first ever UK large scale survey where Russell and Burch’s 3R (replacement, 
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reduction and refinement) principles were first introduced (Russell WMS, 1992). 
One of the arguments made in this original publication was the need to validate 
the ability of animal models to represent human processes and keep focus on 
laboratory efficiency so that the least amount possible of an animal species is 
used, which is defined as representative of humans for the application. The inter-
species and intra-species variability have been heavily studied since then and 
significant differences in results have been found based on the species used. For 
example, when assessing pharmacokinetic variability in the testing of new 
compounds, one major risk factor was found to be higher variability in dogs 
compared to mouse, rat and monkey, particularly at high dose treatments 
(Daublain et al., 2017). This was mainly attributed to the major variability of dog 
gastric pH and gastric residence time (Sagawa et al., 2009). In the field of cancer 
biology, mouse models predominate, however these tend to display a number of 
limitations due to large biological variations such as lack of human lifespan 
compensating antineoplastic mechanisms, differing levels of DNA damage and 
vastly differing metabolic conversion mechanisms which disable their predictive 
behaviour for humans (Rangarajan & Weinberg, 2003). Genetic modification has 
been used to improve these limitations, however it is still difficult to recapitulate 
the complexity of cancer in an animal model (Heyer et al., 2010). Some mouse 
strains that are naturally cancer-prone are well characterised, e.g the min mouse 
model , and may represent a good model for hereditary cancers such as 
adenomatous polyposis coli (Moser et al., 1995). However hereditary cancers 
might not represent the genetic landscape of sporadic cancers. Syngeneic 
tumour models, e.g. myeloma 5T33 model, are propagated in genetically identical 
littermates and represent tumours that may be ‘passaged’ between animals 
(Manning et al., 1992). However these models often represent a single cancer in 
multiple different animals and may be artificially homogeneous vs. spontaneous 
cancers. Finally, xenograft models, typically growing human cancers in 
immunocompromised mice, are gaining widespread use. Initial limitations of 
growing established cell lines in mice have been super-ceded by patient-derived 
xenograft models, whereby sporadic human cancers are grown in athymic mice. 
These models suffer from a lack of endogenous tumour immunity, however drug 
responses in mouse models predicts patient responses well (Poh, 2016). 
Naturally occurring cancer in dogs has been suggested as a more predictive 
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chemotherapeutic model in this field, however further knowledge of the 
comparative oncology between dogs and humans would be required (Sultan & 
Ganaie, 2018; Lawrence et al., 2015). Overall, it is very difficult to select an 
animal model which is representative of the human disease situation and 
considerable time and funding is lost due to false positive and false negative 
results. 
Recent focus of disease modelling has been dedicated to alternative in vitro 
models such as three-dimensional (3D) cultures and microfluidic systems. 3D 
constructs employ the same cell lines, primary cells or stem-cell derived cultures 
as are used in 2D cell culture models (Ravi et al., 2017). However, 3D constructs 
produce cultures with different cell-cell interactions to 2D cell culture, and an 
altered environment, towards better mimicking of the in vivo environment (Wang 
et al., 2018). 3D culture has been shown to alter cell signalling to produce a more 
representative environment using altered adhesive, mechanical, topographical, 
soluble and extracellular matrix (ECM)-bound cues to aid cell processes such as 
migration, proliferation repolarization and matrix remodelling (Baker & Chen, 
2012). These cultures have shown similar gene expression and morphology to 
cells in vivo for biomedical applications and translational medicine (Ravi et al., 
2017; Duval et al., 2017; Dutta et al., 2017). Additionally, microfluidic systems 
may contain 2D or 3D cultures; however, the structure is designed to improve 
functionality similar to in vivo by introducing a more representative nutrient input 
and waste output, as well as dynamic therapeutic dosing (Trietsch et al., 2017).  
On the other hand, there are some drawbacks of switching to 3D cell culture 
workflows. Drawbacks of 3D cell culture vs. 2D cell culture include increased 
complexity of experimental design, and lack of standard methods of analysis, 
resulting in potentially different results depending on 3D methods employed 
(Hilton et al., 2019; Nunes et al., 2019; Shieh et al., 2017; Stock et al., 2016) 
(Table 1.1). Furthermore, cell lines grown in 3D cell culture in different scaffolds 
may exhibit markedly different drug responses, whereas responses on plastic in 
2D cell culture may be more reproducible, if not representative of the in vivo 
situation (Hongisto et al., 2013). Cost should also be considered, as some of the 
currently available in vivo-like culture methods involve the use of expensive 
medium components, such as R-spondin, or scaffolds or scaffold formation 
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techniques, such as electrospinning, which are not available in all laboratories 
(Shin et al., 2018; Sachs et al., 2018). 
1.1.1 3D cell culture methods 
There are several commonly used types of 3D culture method (Table 1.1) (Figure 
1.1). These differ greatly in production and culture approach and each method 
possesses advantages and disadvantages for a chosen application. 
 
Figure 1.1 Types of cell culture. a) 2D cell culture. Cells grown in monolayer 
directly on plastic or glass surfaces. b) Attachment prevention culture. Cells are 
cultured on top of a non-adherent surface and form spheroids. c) Embedded 
culture. Cells are cultured inside a natural/synthetic scaffold e.g. hydrogel. d) 
Interface culture. Cultures where air-liquid interface is required e.g. skin 
constructs. e) Microfluidic culture. Cells are cultured in specially designed 
microchips, with a flow present. These can be either embedded in a scaffold or 
flow trapped by preventing cell flow through a channel. f) Bioreactors. Cells are 
cultured in rotating vessels which promote aggregation. 
Table 1.1 Comparison of culture types 
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1.1.1.1 Attachment prevention 
The attachment prevention technique (Figure 1.1b) is one of the simplest and 
low-cost 3D techniques available, often used for cancer modelling. It consists of 
the use of ultra-low attachment surfaces, such as commercial ultra-low 
attachment plates or agarose coated plates, or suspension of cells within an 
environment which prevents cell adhesion to a surface, such as the hanging drop 
model (Thomsen et al., 2018; Close et al., 2018; Shri et al., 2017; Costa et al., 
2014). These are commonly used to produce multicellular tumour spheroids 
(MCTS) (Feng et al., 2017). An additional benefit of this type of culture is that the 
spheroids can be cultured separately and are often highly reproducible, which 
allows for individual monitoring and ease of handling. However, this method is 
not ideal for all cultures, and in some cases cells will not form spheroids or display 
higher functional behaviour, as could be observed in other types of 3D cultures 
due to a lack of environmental factors (Nagelkerke et al., 2013). 
1.1.1.2 Scaffolds 
Scaffold models are based on a suspension of cells within a construct, either of 
natural or synthetic origin (Figure 1.1c). Natural scaffolds, such as laminin-based 
basement membrane extract (e.g. Matrigel), collagen or hyaluronic acid based 
hydrogels are biocompatible as they are made up of ECM components (Gillette 
et al., 2008). In the case of single component scaffolds, there may be a lack of 
ECM complexity, which may lead to a lack of functional differentiation for cell 
types which are more dependent on the stroma. On the other hand, use of a 
complex cell-derived basement membrane extract (BME) would provide more 
ECM complexity, but would introduce high inter-batch variability and a higher 
possibility of unknown factor effects. Most of the BMEs available are derived from 
the basement membrane of the Engelbreth-Holm-Swarm (EHS) sarcoma the 
composition of which may have unwanted effects, due to the presence of growth 
factors and other ECM components which influence cell behaviour (Vukicevic et 
al., 1992; Kleinman et al., 1986). Other natural scaffolds, such as alginate, 
agarose and cellulose, are biologically derived however contain no animal 
derived ECM components for the cells to recognise, as they are plant-based 
(Moffat et al., 2018; Aurich et al., 2018; Modulevsky et al., 2016). Synthetic 
scaffolds, such as poly-ethylene glycol (PEG) or other polymer hydrogels can be 
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tailored mechanically to the application requirements, are known to be 
reproducible and can be sterilised prior to use. The synthetic scaffolds can also 
be enhanced with specific ECM binding motifs to improve differentiation and 
growth (Gentile et al., 2017). 
To achieve a complex environment, such as that of tissues and organs, some 
research has focused on the use of decellularised organs as matrices. In these 
cases an organ is decellularised, commonly by perfusion, and the native macro 
and micro-architecture remains intact. These scaffolds potentially contain all the 
necessary infrastructure, signalling cues for cell differentiation, attachment and 
function required for a highly efficient, complex model (Lorvellec et al., 2017; 
Tapias et al., 2015). However, these scaffolds are very time consuming and costly 
to produce for all applications. Additionally, the methods used to decellularize 
tissue may not remove all cells, leading to safety concerns for in vivo applications 
and concerns of cellular contamination for in vitro purposes (Saldin et al., 2017).  
1.1.1.3 Interface models 
Mechanically-supported 3D models are commonly used for skin constructs but 
have also been used for other tissue such as lung and GI tract cancers (Elbadawy 
et al., 2018; Hiemstra et al., 2018; Kim et al., 2017) (Figure 1.1d). This type of 
culture allows for presence of an air-liquid interface which aids cell differentiation 
over time. In the case of skin equivalent models a co-culture of keratinocytes and 
fibroblasts is deposited on top of a wire mesh or well inserts. For cancer models, 
epithelial cancer cells are typically grown on a fibroblast layer which acts as 
stroma and excretes important factors for continued growth (Emura & 
Aufderheide, 2016). These models have shown to have very high correlation to 
in vivo yet they are relatively expensive, and there is a significant difference in 
organisation complexity between different model types (Zscheppang et al., 2018; 
Lee et al., 2014). 
1.1.1.4 Microfluidics 
Microfluidic methods are of much higher complexity, yet there are many benefits 
(Figure 1.1e). The cells are cultured in micron-sized fluidic chambers, with either 
a continuous or transient media exchange. These models allow easy integration 
into automation, high throughput, drug studies and simultaneous imaging. Recent 
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technological advancements make production of chips easier, more affordable 
and the materials chosen more amenable to analysis (Knowlton et al., 2016). For 
example, dependant on the material used for the microfluidic construct, rapid 
evaporation may occur (Mehling & Tay, 2014). Microfluidic constructs have been 
combined with scaffold cultures to produce complex cultures. For example, a 
commercially available Mimetas microfluidic plate was used in combination with 
a collagen scaffold to mimic vascular permeability in vivo (van Duinen et al., 2017).  
1.1.1.5 Bioreactors 
Bioreactor models consist of either free flowing or bead-attached cells in a 
constant flow environment (Figure 1.1f). This model type encourages proliferation 
and cell-cell attachment by increased contact and produces reproducible, large 
spheroids at high-throughput whilst still maintaining nutrient and waste flow. 
Bioreactors have been used  for enhanced hepatogenic, osteogenic, 
chondrogenic stem cell differentiation (Khurshid et al., 2018; Egger et al., 2017; 
Cipriano et al., 2017). Perfusion systems have also shown use in long-term 
organotypic, specifically tumour, cultures by maintaining their physiological state 
(Wan et al., 2017). Scaffolds can also be combined with bioreactors in order to 
improve the culture perfusion to O2, nutrients and release of waste products like 
CO2 and lactate which would usually have a varied distribution (Schmid et al., 
2018; Yi et al., 2018).  
1.1.2 Cell culture origin 
An important decision in choice of 3D culture is the cell source required for a 
functional construct. The cell viability, phenotypic functionality and activity in the 
construct must be at sufficient levels to predict the reactions of its target tissue.  
In the cases of all 3D constructs, similarly to 2D cultures, primary cells are most 
often incorporated due to their high equivalence to in vivo cells in human subjects. 
There are, however, disadvantages to the use of primary cells such as their 
phenotypic instability during culture, scarce and irregular availability, inter-donor 
variability and their poor plating efficiency. Phenotypic instability of primary cells, 
leading to loss of key functions, has been shown to occur less in 3D models (Lee 
et al., 2013). This expansion and self-organisation, with exhibition of correct 
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morphology and behaviour, was observed in primary human breast epithelial 
cells grown within hydrogel scaffolds (Sokol et al., 2016). 
Use of immortalised cell lines for 3D culture has been common over the past few 
years, not solely for the study of cancer. The main disadvantage of the use of 
immortalised cell lines is the loss of cell type function-specific activity compared 
to primary cultures. On the other hand, benefits of immortalisation include 
robustness, reproducibility and unlimited availability, which simplifies the culture 
process. With use of 3D models, research has also partially overcome the loss of 
functional activity of cell lines (Gago-Fuentes et al., 2014).  
Over the years, stem-cell derived cultures were developed as an attractive option 
for pharmacodynamic and pharmacokinetic models. However, these 
differentiated cells, until recently, possessed very low phenotypic function and the 
differentiation methods were too complex and time consuming. By incorporating 
the use of 3D scaffolds, several recently produced models show an improvement 
in functional activity and highly optimised differentiation protocols (Khetan et al., 
2013). The use of stem cells in 3D cell culture was improved greatly by the 
Clevers group (2016), who developed a method of growing organoids from a 
patient derived stem-cell population, using a mixture of Wnt/R-Spondin and 
Noggin conditioned medium and specific growth factors combined with a BME 
gel matrix, and are now able to use this method for a variety of tissue types 
(Clevers, 2016; Jung et al., 2011). 
An increasing amount of 3D models include stromal, supporting cell types in co-
culture with parenchymal, tissue function defining cells. Cell-cell interactions are 
highly relevant to all tissues as they have a dramatic influence on the tissue 
environment. An increased amount of cancer 3D models are incorporating 
cancer-associated fibroblasts with the tumour culture, as these have been shown 
to play a supporting role in cancer. For example, a recent 3D cell culture platform, 
Tissue Roll for the Analysis of Cellular Environment and Response (TRACER), 
probed cell-cell interactions by incorporating cancer associated fibroblasts 
(CAFs) in head and neck tumour cultures (Young et al., 2018).  In other cases, 
co-culture shows that changes in drug interaction may not always be due to 
signalling but may be physical. A triple co-culture model made up of epithelial 
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cells, monocyte-derived macrophages, and dendritic cells, demonstrated barrier 
ability. Polyelectrolyte microcapsules were not able to pass through the triple co-
culture, though in previous studies the passing of small nanoparticles was 
observed between macrophages and dendritic cells (Kuhn et al., 2015). 
 
1.1.3 3D culture of cancer cells 
3D models have been introduced over the last few decades to improve 
predictability of pre-clinical oncological drug studies (Ibarrola-Villava et al., 2018). 
This has been achieved with 3D modelling using cell lines, differentiated stem 
cells and primary tumour cells.  
Use of cell lines is a cost effective and simple method, however confirmation of 
its validity and representability is required for these models to be used for 
chemotherapeutic testing and biological studies. In several cases, cell signalling 
pathways has been thoroughly analysed to determine tumour cell changes in 3D 
compared to monolayer culture. Altered signalling has been observed in the 
Mitogen-activated protein kinase (MAPK) pathway and a general reduction in cell 
cycle progression (Stadler et al., 2016). An evaluation of 3D cultured breast 
cancer cell lines showed a higher resistance to classical chemotherapy drugs and 
increased expression of cell survival and drug resistance proteins, such as Akt 
and p-glycoprotein (Pgp), compared to 2D cultures, suggesting a higher 
representability of in vivo chemotherapy resistance (Breslin & O’Driscoll, 2016). 
A recent innovation created by the Clevers (2016) lab is patient derived tumour 
organoids. These can be produced from patient derived epithelial tumour material 
and form in vivo like structures which are representative of the original tumour 
(Clevers, 2016). These have the potential for long term propagation and the 
creation of disease  representative biobanks (Sachs et al., 2018; Van De 
Wetering et al., 2015). As the method used forms clonal organoids, the intra-
tumour diversification in cancers can be observed by examination of differences 
between individual clones derived from a single patient (Roerink et al., 2018). 
It is widely agreed that the tumour associated ECM contributes towards cancer 
behaviour, including its influence on the hallmarks of cancer (Pickup et al., 2014). 
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The hallmarks of cancer are defined as essential acquired capabilities for the 
development, growth and dissemination of all human cancers (Hanahan & 
Weinberg, 2011). The hallmarks of cancer include maintenance of proliferative 
signalling, evasion of growth suppressors, resistance to cell death, replicative 
immortality, promotion of angiogenesis, as well as activation of invasion and 
metastasis. By influencing each of the different hallmarks of cancer using 
biophysical and biochemical cues the ECM can have a significant effect on 
cancer behaviour and malignancy (Pickup et al., 2014). Even sarcomas, which 
arise from mesenchymal origin and are part of the stroma, should benefit from 
3D cell culture. In these tumours, however, the presence of ECM components, 
such as collagen, laminin, or glycosaminoglycans (GAGs), within the scaffold and 
mechanical characteristics may be of importance for differentiation and 
maintenance (Gao et al., 2017; Teicher, 2012). Several 3D models of sarcoma 
have been developed using cell lines, which demonstrated restoration of chemo 
sensitivity in chondrosarcoma and vascular-like formation in a co-culture model 
of osteosarcoma and endothelial cells (Chaddad et al., 2017; Van oosterwijk et 
al., 2012). 
As increased culture time period and high-throughput capabilities are required to 
integrate these models into industry workflows, more focus has been 
concentrated on microfluidic constructs. A microfluidic platform has been created 
recently for the study of chemotherapeutic drug efficacy, employing U251 human 
glioma cell lines to form spheroids by physical trapping during flow. Physical 
trapping consisted of creating a microfluidic design which sequestered cells in 
designated areas in order to create aggregates. They observed long-term (over 
one month) culture stability and increased apoptotic response as well as 
decrease in spheroid size due to treatment with clinical chemotherapeutic drugs 
Vincristine (VCN) and Bleomycin (BLM) (Liu et al., 2015). Another highly versatile 
microfluidic system was developed to try and overcome some challenges posed 
by typical microfluidic models, such as nutrient availability (McMillan et al., 2016). 
These systems overcome the ‘static’ nature of in vitro cultures, which do not 
represent the in vivo situation of vasculature-based nutrient and metabolite 
delivery. The model could maintain spheroid cultures for long time periods 
whether they were in medium or within a scaffold (McMillan et al., 2016). 
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1.1.4 3D cell culture strategies for models of hepatoxicity 
Idiosyncratic drug hepatoxicity is an adverse reaction to drugs occurring in a 
minority of patients, which cannot be predicted using usual animal tests. This is 
a major cause for concern during drug discovery and development and the 
highest contributor to post-clinical trial withdrawal of pharmaceuticals  (Kaplowitz, 
2005). The liver is an exceptionally important organ for drug development studies, 
as it is the major site of drug metabolism elimination and toxicity. Presently, 
pharmaceutical absorption, distribution, metabolism and excretion (ADME) 
studies include extensive testing of drug hepatotoxicity and metabolism on firstly 
2D cultured primary hepatocytes, microsomes or cell lines then moving onto 
animal studies for more complex tests such as metabolite profiling in order to 
identify the full adverse outcome pathway (AOP) of a therapeutic candidate, as 
illustrated in figure 1.3. 
Figure 1.3 3D cell culture applications for identification of an adverse outcome 
pathway for a chemical of interest (adapted from the OECD AOP handbook). 
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There have been many 3D cell culture models based on cell lines due to their 
robustness, reproducibility and unlimited availability. In 2D cell culture, cell lines 
such as HepG2 have undergone criticism as these lack the basal gene 
expression profile that hepatocytes possess, therefore they lack the metabolic 
activity required from a pharmaceutical study model (Zeilinger et al., 2016; Godoy 
et al., 2013). However, in an extracellular matrix-based hydrogel (Matrigel) 3D 
culture the HepG2 cell line has been shown to recover hepatic function, increased 
Cytochrome P450 (CYP) enzyme activity and form hepatic culture associated 
structures, such as bile canaliculi (Ramaiahgari et al., 2014). Several other 
immortalised lines, such as HepG2/C3A and HepaRG have been used more 
recently due to a more hepatic differentiated phenotype (Nelson et al., 2017). 
These have also been employed in 3D cell culture, showing promising results. 
For example, the HepaRG cell line hepatic differentiation relies on high 
concentrations of dimethyl sulfoxide (DMSO) in the cell media in 2D cultures, 
which may interfere with many pharmaceutical studies (Anthérieu et al., 2012). 
By suspending this cell line in an alginate-based 3D scaffold Rebelo and 
colleagues could culture the cells in DMSO-free media, whilst still obtaining 
comparable phase I drug metabolism enzyme activity, formation of phenotypic 
structures and excretory functionality, assessed by specific activity of multidrug 
resistance-associated protein 2 (MRP2) (Rebelo et al., 2014). 3D cell line models 
are being utilized in drug adverse outcome studies. For example, a recent 3D 
model study has emerged, using an in vitro HepG2/C3A microfluidic model, in 
combination with in silico pharmacokinetic mathematical simulations, to 
investigate N-acetyl-p-aminophenol (APAP), otherwise known as acetaminophen, 
toxicity in detail. Levels of reactive oxygen species were shown to increase after 
APAP treatment, metabolism was determined by monitoring biotransformation 
products APAP-sulphate and APAP-GSH and growth inhibition due to treatment 
was also measured. Using the experimental information and combining it with 
other information in the literature, predictions could be made of the intracellular 
concentration of APAP and N-acetyl-p-benzoquinone imine (NAPQI) 
accumulation in a cell (Leclerc et al., 2015). 
Even with the progress made with immortalised cell line cultures, primary 
hepatocytes still possess a higher basic hepatic functionality, and these are also 
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commonly incorporated into 3D cultures. By using 3D cell culture techniques, the 
dedifferentiation that primary cells undergo in 2D cultures are slowed or reversed 
and these cells have been observed to regain function. A bioprinted human liver 
tissue mimetic, comprised of patient-derived hepatocytes and non-parenchymal 
cells in a defined architecture, maintained adenosine 5′-triphosphate (ATP), 
albumin and CYP450 enzyme activity over 4 weeks in culture (Nguyen et al., 
2016).  
Development of stem-cell derived hepatic 3D cultures has also increased in the 
past few years. Broutier and colleagues utilised a basement membrane extract 
matrix and defined medium for the propagation of stem-cell derived human and 
mouse adult liver organoids and demonstrated their differentiation into functional 
cells which were genetically stable (Broutier et al., 2016). Further work has 
focused on adapting these culture protocols for drug screening purposes by 
increasing throughput and generation of robust, simple conditions (Sgodda et al., 
2017; Carpentier et al., 2016). 
 
1.1.5 Molecular analysis of alternative models 
Alternative models can be defined as ex vivo or in vitro models of disease or 
tissue function, which have been designed to represent their in vivo human 
equivalent tissue. These models are developed as an alternative to experiments 
involving patients, which are limited to clinical trial studies and cannot be invasive, 
and animal models, which are also limited and not always representative of 
human function and response to therapeutics. The majority of alternative models 
are analysed by methods such as commercial biochemical activity assays, 
immunohistochemistry (IHC), enzyme-linked immunosorbent assay (ELISA), 
fluorescent probes and colorimetric assays in order to observe specific cell 
activity or determine abundance of molecules involved in pathways of interest. 
This type of analysis is typically moderate/low-throughput and relatively costly. 
Additionally, not all methods can retain spatial information, i.e. western blotting 
and biochemical assays, and others are not capable of detecting high levels of 
multiple analytes within a single experiment i.e. fluorescent microscopy. To 
integrate use of these models in research and the higher-throughput required by 
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industry, high content analytical methods, such as mass spectrometry imaging, 
should be applied to this field. Using mass spectrometric tools allows for the 
simultaneous detection, and even quantification, of multiple molecular species, 
minimizing sample required and increasing experimental efficiency. 
1.1.5.1 Mass Spectrometry of alternative models 
Mass spectrometry is an analytical method which involves ionization of chemical 
species within a sample of interest and subsequent sorting of the ions formed 
based on their mass-to-charge ratio (m/z). This enables the specific and sensitive 
determination of the molecular make-up in the sample of interest. In a typical MS 
experiment a sample may be solid, liquid or gas and each type of instrument can 
handle different forms of sample. For example, Liquid-chromatography mass 
spectrometry (LC-MS), which is the most commonly used mass spectrometric 
method, is capable of liquid sample analysis. However, samples can be 
manipulated and prepared for analysis, whilst maintaining the original levels of 
analyte. In the case of some solid samples, for example biopsies, homogenisation 
and extraction can be used in order to obtain a suitable form for analysis. The 
data, consisting of m/z values and abundances of each chemical species present, 
is displayed as a spectrum. Tandem MS (MS/MS) could be further used to 
confirm identities of the molecules by selected collisional dissociation inside the 
instrument and analysis of the fragment ions produced. 
A large number of ex vivo and in vitro models are commonly investigated using 
mass spectrometry methods for characterisation of the model and its 
translatability to in vivo results. LC-MS has been applied to analysis the 
metabolome of 3D constructed cultures in order to study the metabolic 
reprogramming that occurs in cancer (Rodenhizer et al., 2016). The 3D cancer 
model was developed specifically to rapidly unroll after culture, exposing different 
biocomposite layers for hypoxic gradient investigation. The design limits 
metabolomic changes by reducing the time between culture and analysis. Using 
this unique TRACER system and mass spectrometry they could observe changes 
in the metabolome consistent with known hypoxia mechanisms, such as the 
glycolytic switch and decreased levels of glutathione (Rodenhizer et al., 2015). 
LC-MS was also used to characterise the processed human cardiac extracellular 
matrix protein composition, to improve a decellularised human cardiac tissue 
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model. The method allowed detection of residual protein material 'contamination' 
which was not previously apparent with conventional assays for residual DNA 
and ECM proteins (Kappler et al., 2016). Recently, a microfluidic culture method 
was used to maintain the metabolic functionality of primary hepatocytes for 
modelling of Hepatitis B virus infection. In this study, mass spectrometry was 
used to indirectly quantify the increased activities of P450 drug metabolism 
enzymes by quantification of their metabolites; tacrine (CYP1A2), diclofenac 
(CYP2C9), and midazolam (CYP3A4) (Ortega-Prieto et al., 2018). In a different 
study, an increased complexity immune-competent co-culture liver model was 
established and characterised in order to capture human toxicities, which arise 
from immune responses. Here, LC-MS/MS was used to analyse the acute phase 
response to diclofenac and demonstrate the applicability of the model in the drug 
discovery workflow (Sarkar et al., 2017).  
1.1.5.2 Mass spectrometry imaging of alternative disease models 
Mass Spectrometry Imaging (MSI) is a novel molecular imaging method which, 
due to its many applications, is increasingly popular in many fields (Doerr, 2018). 
The use of MSI for the analysis of alternative disease models has several 
advantages. The main two advantages are the potential for untargeted de novo 
discovery, and the capability to observe multiple analytes of interest in a single 
experiment. Unlike LC-MS, the mass spectrometry-based method mostly used in 
the analysis of alternative models, MSI is also able to preserve spatial information, 
requiring no homogenisation of the sample. Furthermore, less sample 
preparation is involved. Many MSI methods are also non-destructive, which may 
lead to the sample being used again, commonly for a histological stain. 
Considering these advantages, MSI will become a powerful, regularly used 
technique for the investigation of alternative, in vitro disease models. 
Several MSI methods are suitable for the analysis of alternative disease models. 
When looking for a high spatial resolution method to observe the alternate model 
microenvironment in detail, Secondary Ion Mass Spectrometry (SIMS) imaging 
must be considered due to its high spatial resolution imaging capabilities. The 
technique was demonstrated recently to detect the subcellular distribution of 
cardiolipin and a multitude of phospholipids and instrumental developments were 
carried out in order to increase the mass range capabilities of SIMS (Tian et al., 
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2019). SIMS is a mass spectrometry method based on pulsed sputtering of a 
sample surface using a primary ion beam and analysing the generated secondary 
ions (Vanbellingen et al., 2015).  A static SIMS instrument is capable of imaging 
a wide range of samples or a dynamic SIMS instrument could be chosen which 
possesses the ability to depth profile to create three-dimensional images, with 
some loss of range. SIMS is an imaging method currently capable of single-cell 
and even sub-cellular imaging, as shown by Passareli and colleagues who 
observed the cellular uptake of a pharmaceutical compound in a single 
macrophage cell (Passarelli et al., 2015). As of yet, this methodology hasn’t been 
used for the analysis of 3D cell cultures, however it would provide extremely 
detailed information of the composition and interaction of cells and the 
heterogeneity within a model. This ability was demonstrated by Barnes and 
colleagues, who were able to distinguish between two different cell types within 
a culture using SIMS (Barnes et al., 2012). 
Laser Ablation Inductively Coupled Plasma Mass Spectrometry (LA-ICP-MS) is 
a molecular imaging method commonly used for trace elemental imaging in tissue 
sections, as it can provide elemental information and, with the use of matrix 
matched standards, or more recently isotope dilution, is capable of quantitative 
imaging (Moraleja et al., 2018). LA-ICP-MS has been used in its imaging modality 
in order to examine the cellular uptake of a second generation photosensitizer 
into a tumour spheroid, with and without the assistance of a nanoparticle delivery 
system. A more homogenous distribution of nanoparticle delivered 
photosensitizer was determined using imaging, compared to freely dissolved 
drug (Niehoff et al., 2014). In order to achieve high sensitivity with this system, 
the drug was tagged with palladium. Having to tag the analyte of interest is a 
significant disadvantage as, since a target has to be known, it means that the 
technique is not suitable for de novo discoveries. However, as shown in a more 
recent study using LA-ICP-MSI, tagging is not always required as long as the 
analyte of interest has a suitable metal component. Niehoff and colleagues 
developed a methodology for the imaging of platinum group containing drugs, 
such as cisplatin, in tumour spheroids, as well as the previously imaged palladium 
tagged photosensitizer. Quantitation of all the imaged drugs was also achieved 
by using different matrix-matched standards (Niehoff et al., 2016) .  In both cases 
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of using LA-ICP-MSI, high spatial resolution was used (<10µm), which is an 
advantage of the technique, as well as the need for very little sample preparation. 
Nevertheless, this method can only be used for de novo discovery when looking 
at changes in metal groups. 
Another commonly used imaging method, Desorption Electrospray Ionisation 
(DESI), is also potentially capable of alternative model imaging. DESI requires 
minimal sample preparation compared to other methods, is set up at ambient 
conditions (no high-pressure vacuum) and can analyse many different sample 
types, though it is presently used mainly for small molecule and lipid analysis. 
Although in the past it was limited by spatial resolution capabilities and 
robustness, recent improvements have led to >20m consistent spatial resolution 
(Tillner et al., 2017).  
 
1.1.5.2.1 Matrix Assisted Laser Desorption Ionisation Mass 
Spectrometry Imaging 
Matrix Assisted Laser Desorption Ionisation Mass Spectrometry Imaging (MALDI-
MSI) is an imaging method which was introduced by Spengler (1994) and 
developed primarily by Richard Caprioli and colleagues in 1990 and is currently 
the most popular ionisation source used for mass imaging worldwide for biological 
applications (Caprioli et al., 1997; Spengler, 1994). The approach consists of 
coating a sample with a suitable energy absorbing material (matrix) that is then 
fired upon with an ultraviolet/infrared (UV/IR) laser. Most commonly, a highly 
focused laser is fired on a large array of two-dimensional positions on a sample 
plate, which creates a set of sample mass spectra with corresponding x and y 
coordinates. This then allows for reconstruction of the results into an image made 
up of spatial information and abundance of ions at each ionisation point 
(Francese & Clench, 2010). Reducing the raster distance increases the number 
of ionisation points on the sample and number of subsequent pixels on the image, 
leading to a higher spatial resolution. This can either be done by oversampling, 
where the laser diameter is slightly smaller than the step size and the raster points 
overlap slightly, or by reducing the laser diameter and therefore reducing the 
ablation area. 
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Figure 1.2 A typical MALDI-MSI workflow 
There are several advantages to using MALDI as an ionisation instrument for the 
imaging of biological substances (Aichler & Walch, 2015). The main advantage 
is its ability to produce highly resolved mass spectral data without damaging the 
sample, which could then be used for other experiments such as histological 
stains and data can be combined for an enhanced understanding of the 
substance involved. This is particularly useful in situations where samples are 
limited or differences between serial sections are too large for comparison. 
Because it is regarded a 'soft' ionisation technique it can analyse a very wide 
mass range of analytes compared to other ionisation techniques, typically from 
100 Da to over 100kDa, as the ionisation process does not degrade certain 
molecular groups as much as other methods. In addition, the MALDI mode of 
ionisation produces mostly singly charged ions, which makes data analysis of 
complex mixtures more straightforward (Cornett et al., 2007). Because the 
ionisation of analyte is performed using a UV/IR, laser the irradiation area size 
and location can be controlled very precisely. The irradiation area can vary from 
around 5µm to over a 100µm and can be simply manually controlled (Francese 
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& Clench, 2010). The instrumentation for MALDI-MSI instruments has also 
improved greatly in recent years leading to greater resolution, high sensitivity and, 
most importantly, higher throughput. These features are key for making these 
instruments efficient to use in every day research in pharmaceutical research and 
development and oncology fields (Schulz et al., 2019; Baker et al., 2017; 
McDonnell et al., 2017). 
1.1.5.2.2 Drawbacks of MSI  
However, use of MSI for the analysis of biological samples also has some 
drawbacks.  As mass spectrometers are highly complicated instruments the cost 
of a suitable instrument, particularly one capable of MSI, is much higher than the 
cost of more common benchtop analytical techniques. Therefore, currently these 
instruments are only present in MSI focused research group institutes and in 
analytical departments within industry. Additionally, in order to obtain and 
interpret MSI results at least some knowledge of the methods and software is 
required, as the methods are far more complicated and less user friendly than 
commercialised standardised assays. Although methods for specific molecular 
groups can be created, these often require optimisation in terms of sample 
preparation and changes in instrumental methods for optimal analysis of a new 
sample. As most mass spectrometric methods are often lab-developed these can 
be substantially different from one another. Standardisation is principally an issue 
in the MSI field as many different sample preparation techniques and instrumental 
set-ups are currently used all over the world to achieve similar goals. This leads 
to a discrepancy between different labs and an inability to create reference 
intervals when detecting specific analytes, which have potential for clinical impact 
(Addie et al., 2015). For a method where results differ by a significant level with 
different sample preparation, standardisation is important to note for any 
experiment. Some effort within the field has been made towards standardisation 
primarily under the support of the European network COST Action BM1104. 
When considering shortcomings of MSI, the fact that some molecules are more 
readily ionisable than others should be mentioned. The technique is dependent 
on ionisation efficiency of molecules of interest which, for example in the case of 
hormones, is not always high. This is partially being overcome with derivatization 
methods in order to add charges to otherwise neutral molecules (Barré et al., 
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2016; Beasley et al., 2016; Holst et al., 2016). Additionally, once a molecule of 
interest is identified using MSI, it is often difficult to fully confirm its identity. This 
is often done in the form of tandem MS techniques, however due to poor peak 
separation, low molecular abundance or inability to narrow the mass selection 
window, peak identifications are not always easily confirmed through MS/MS. 
1.1.5.2.3 Laser types commonly used with MALDI-MSI 
The MALDI technique involves the use of a laser as the energy source which 
triggers the desorption ionisation process by irradiation of the sample surface. 
There are several types of lasers currently used for MALDI-MSI. Since the matrix 
is the energy absorbing molecule within the reaction, the laser wavelength 
doesn’t need to be matched to a specific analyte but to the matrix absorption 
frequency, which makes MALDI more universal compared to other laser 
techniques (Robinson et al., 2018). Among the selection of lasers, UV lasers are 
the most commonly in use due to their ease of operation and affordability. 
Frequently, N2 (ƛ = 337nm) or Nd:YAG (ƛ = 266 or 355) lasers are used, although 
IR lasers such as Er:YAG (2.94 m) could also be used, which may result in less 
fragmentation but lower sensitivity. In general, it is important to optimise the laser 
pulse energy in a given wavelength for a specific spot diameter in order to achieve 
the highest molecular signal without inducing a significant amount of 
fragmentation (Hoffmann & Stroobant, 2007). 
1.1.5.2.4 Mass analysers commonly used with MALDI-MSI 
A mass analyser is the part of a mass spectrometer in which the ions are 
separated based on their m/z values. Because MALDI is a pulsed ionisation 
technique and produces ions in bundles by an intermittent process it is well suited 
for analysis with the time-of-flight (TOF) analyser. A TOF analyser separates ions 
by their velocities which are determined by initially accelerating the ions with an 
electric field and letting them drift through a free-field region, called a flight tube 
and into a detector (Hoffmann & Stroobant, 2007). As all ions acquire the same 
kinetic energy, the time taken to drift through the flight tube is then directly 
correlated to mass and charge. Benefits of MALDI-TOF-MSI include their high 
upper mass range limit, which leads to imaging capabilities of very large 
molecules, and their high transmission efficiency, which leads to high sensitivity, 
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as well as their speed (Drake et al., 2017). However, when higher mass resolution 
is required, the most common mass analyser in use for MALDI-MSI is Fourier 
Transform Ion Cyclotron Resonance (FT-ICR). This method is capable of much 
higher mass resolution than a TOF mass analyser, defined by the ability to 
resolve peaks at a much higher power, aiding distinction and identification of 
molecules (Piga et al., 2019; M. Dilillo et al., 2017). FT-ICR consists of trapping 
the ions within a magnetic field, called a cyclotron, and exciting all of them 
simultaneously by a rapid scan of a large frequency range. This induces a 
trajectory in each ion, which comes close to the detector wall perpendicular to the 
orbit. Transformation of the detected wave as a time-dependent function into a 
frequency dependent intensity function using a Fourier Transform (FT) is then 
done in order to retrieve data, which can be directly correlated to mass and 
charge (Hoffmann & Stroobant, 2007). There are downsides to this technique, 
such as the high cell vacuum necessary to achieve high resolution and the need 
for appropriate computers for the large amount of data flow, therefore a much 
higher cost, as well as it’s limit of the number of ions in the cell.  
1.1.5.2.5 Matrix application methods commonly used with MALDI-MSI 
Matrix selection and application optimisation is an important part of MALDI-MSI 
analysis because it fundamentally determines the quality of results by altering the 
method sensitivity and spatial information quality. Selection of the matrix depends 
mainly on the type of molecule being analysed, the laser wavelength and whether 
positive or negative ions are being observed. In general, matrices tend to be small 
molecules, for easy sublimation, with highly conjugated structures, which 
therefore absorb strongly at the laser wavelength, are stable under vacuum, lack 
chemical reactivity and are soluble in analyte compatible solvents (Hoffmann & 
Stroobant, 2007). However, not only the matrix choice but also its application is 
important for analysis. Automatic spraying and sublimation are the two most 
common, reproducible techniques used for the application of matrix for MSI. 
Automatic spraying is a method developed to replace manual airbrush spraying 
and remove the variability observed due to inconsistencies in spraying distance 
and speed of application and therefore any negative effects, such as poor matrix 
coverage and analyte diffusion (Gemperline et al., 2014). Using an automatic 
sprayer system generally improves the uniformity of matrix density and crystal 
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size, therefore increasing reproducibility, and has a good analyte extraction 
capability (Anderton et al., 2016). However, in the case of some matrices this 
method is incapable of producing small regular crystals, which may be required 
for higher spatial resolution analyses.  Sublimation is typically a solvent-free 
matrix application technique, which utilises the sublimation temperature of a 
matrix molecule to apply a defined amount of it onto a sample section, creating 
uniform, small matrix crystals. As it is a solvent-free method, analyte diffusion is 
reduced but this also comes with a reduction in extraction capability, particularly 
in proteins (Lin et al., 2018). This may be overcome with recrystallization post-
sublimation, however during this process the matrix crystals may once again 
become irregular (Lin et al., 2018; Dueñas et al., 2016). Use of binary matrices 
(a combination of two molecules) would also not be possible using this method, 
unless the matrices require similar sublimation conditions.  
1.1.5.3 MALDI-MSI of alternative models 
Compared to the amount of research conducted every year on ex vivo and 3D 
cell culture models, only a few research groups have utilised MALDI-MSI as a 
method of validating and facilitating the study of disease in alternative models. A 
number of research groups have begun work regarding this. 
1.1.5.3.1 MALDI-MSI of 3D models of cancer 
There is currently a vast amount of interest in analysis of 3D cultured cancer 
tumour spheroids, which are being used as in vitro models of cancer for 
characterisation and drug dynamics studies (Russo et al., 2018). The first proof-
of-principal publication on the use of MSI with these models, by Li et al. (2011) 
demonstrated that a MALDI-MSI workflow could be used to examine the changes 
in protein and peptide distributions within cancer spheroids in an unbiased 
fashion, suitable for de novo discovery (Li & Hummon, 2011). More recently, the 
same group produced a dynamic flow version of the cancer spheroid model, 
enabling the reconstruction of more representative conditions with the use of a 
fluidic device (LaBonia et al., 2016). The platform was constructed to assess drug 
penetration and metabolism and allow dynamic dosing of the chemotherapeutic 
drug, irinotecan. Drug penetration into the spheroids was observed, as well as 
the distribution of its active metabolite SN-38 inside the spheroid core, necrotic 
region (LaBonia et al., 2016). MALDI-MSI has also been used to evaluate 
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therapeutics in patient-derived colorectal tumour organoids, which are classed as 
a more representative model of the disease, by only two groups to date (Liu et 
al., 2018; Hiraide et al., 2016). Recently, MALDI-MSI was used to analyse a novel 
3D model of high grade serous ovarian cancer (HGSOC) using a completely 
novel sample preparation method which did not require sectioning (Zink et al., 
2018). An ovarian explant was co-cultured fallopian-tube-epithelium-derived cells 
engineered to represent several stages of ovarian cancer in order to study 
metastasis of HGSOC to the ovaries. Using MALDI-TOF-MSI the key role of the 
molecule norepinephrine was demonstrated (Zink et al., 2018). 
1.1.5.3.2 MALDI-MSI of ex vivo models 
Ex vivo models are also used to study human processes and some focus has 
gone towards development of methods to assess ex vivo models of disease. MSI 
of ex vivo cultured alternative samples is more straightforward to develop 
compared to 3D cell cultures, as the sample composition is identical to a human 
tissue sample, which is a common sample type analysed by mass spectrometry 
imaging techniques. The differing factor derives from the culture and treatment of 
the cells outside of the body. Explants of breast cancer cultured using a xenograft 
method have been imaged to visualise uptake of peptide drugs and probes. The 
benefit of using explants in this case was the control over the explant size and 
uniformity compared to spheroid culture (David et al., 2018). The use of ex vivo 
human skin for the study of disease and treatment penetration has become more 
prevalent, possibly due to an increase in sample availability with an increasing 
popularity in cosmetic surgical solutions.  MALDI-MSI has been recently used to 
generate quantitative skin distribution profiles of four different drug molecules 
(roflumilast, tofacitinib, ruxolitinib, and LEO 29102) applied topically to human 
skin explants (Bonnel et al., 2018). Each of the drugs of interest had different 
physiochemical properties and therefore demonstrated the applicability of the 
method as a screening tool for topical drug products. Not only MALDI-MSI but 
also SIMS has been employed for the imaging of ex vivo skin.  The aim of the 
study was to determine the fatty acid enhancing effect on drug penetration into 
human skin, yet using MSI it was discovered that all fatty acids used in the 
experiment penetrated the skin, however only oleic acid demonstrated significant 
enhanced penetration of the drug (Kezutyte et al., 2013). However, the rapid 
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dedifferentiation and loss of viability of the explanted tissue is the main 
disadvantage of ex vivo models and these currently cannot be used in a majority 
of cases (Meijer et al., 2017). 
1.1.5.4 Challenges of MALDI-MSI analysis of 3D models 
Several parameters would require consideration when analysing 3D cell models, 
as they are both similar to tissue and 2D cell culture models. These parameters 
will depend on the type of model used, its size, composition and sample 
preparation required. For instance, the majority of 3D cell culture models are 
relatively small (m scale), which leads to many of these requiring an embedding 
step. This additional step also introduces more time to the sample preparation 
process, which should be considered particularly in the analysis of small 
molecules. The size of the sample will affect the spatial resolution and ionisation 
method to be used. As there are many alternative disease models available, 
sometimes the most appropriate model can be chosen to suit the method plan. 
MALDI-MSI does require a matrix application step and does not routinely provide 
spatial resolution in the very low µm range. In general, 3D cell culture models are 
not large in size. For instance, certain types of single clone tumour spheroids in 
the current literature are <300 µm in diameter, although use of macropellet 
spheroids of around 1-2mm is also common (Schultz et al., 2016; Feist et al., 
2015). This does not result in issues for commonly used techniques such as 
fluorescent microscopy, however in order to observe small spheroid molecular 
microenvironment, higher spatial resolution is required for MSI. Attachment 
prevention methods can produce macropellet spheroids, which are currently the 
only spheroid type, excluding two organoid culture publications, analysed using 
MALDI-MSI (Liu et al., 2018; Hiraide et al., 2016; LaBonia et al., 2016). However, 
this spheroid production method has been shown to be limited for the study of 
the tumour microenvironment as it does not always produce a representative 
model of a specific tumour type (Fennema et al., 2013). Common use of 
attachment prevention methods in combination with MALDI-MSI is due to the 
ease and speed of production of these spheroids, compared to other methods 
involving growth inside scaffolds, as well as the benefit of the reproducible, large 
spheroid size that the method produces. The time required generating the 
engineered model and ease of production, as well as possibility for integration 
 
 
48 
into high throughput protocols, are all parameters which require consideration. 
However, there are many different alternative models available for study of 
disease, many of which are suitable for MSI. As interest in the investigation of 
these models grows, the emergence of more specialised, functional method 
workflows will emerge focused on the analysis of more complex types of 3D cell 
culture.  
The two main issues which commonly arise during MALDI-MSI of 3D cell cultures 
are lack of spatial resolution and small sample size which leads to a low 
abundance of molecules and reduces the probability of confirmed identities of 
molecules of interest. Firstly, since the samples are usually much smaller in size 
than the commonly optimised tissues, spatial resolution of the instrument used 
must be improved to see differences between specific regions of interest. Mass 
spectrometric images can now be achieved by several mass spectrometer 
designs to a pixel size as low as 1µm, although these require further optimisation 
in order to achieve better result quality (Zavalin et al., 2015). For example, 
decreased sensitivity at lower pixel sizes is a problem which could be solved with 
derivatization or post-ionization steps (Barré et al., 2016; Soltwisch et al., 2015). 
Recent work has indicated that spot size dependent thermodynamic conditions 
may need to be optimised for the ideal signal to be observed (Niehaus & 
Soltwisch, 2018). In order to increase the number of confirmed identities of 
molecules of interest, high mass accuracy (<5 ppm) and resolving power 
(>50,000) capabilities of orbital trapping (Orbitrap) and Fourier-transform ion 
cyclotron resonance (FT-ICR) are being used (Ly et al., 2016; Sun et al., 2016; 
Prideaux et al., 2015). These detector systems are capable of producing much 
higher mass resolution spectra than the commonly used Q-TOF hybrids and 
identify more peaks which would be overlapping at a lower resolving power 
(Spraggins et al., 2016). 
In order to be representative of tissues, which are quite diverse in general, ideally 
the model design should involve as much detectable heterogeneity as possible. 
This would mean that, for example, in the case of a cancer model ideally physio 
chemically differing areas within the model should be large enough to be 
detectable, as well as clonal differences within the tumour spheroid. Currently, 
clonal spheroid formation methods are limited in size (<300m) and therefore 
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clonal differences can only be detected with high spatial resolution. However, 
techniques such as MSI are not always capable of spatial resolution high enough 
to detect differences within low micron-scale samples. Creation of MSI 
compatible models, which still maintain the information provided by classical 3D 
cell culture models would be beneficial for the study of disease. Additionally, 
currently there is an insufficient amount of sample handling methodologies 
available for working with 3D cell culture models in an MSI setting. Most MSI has 
been performed on attachment prevention based models, which are not 
necessarily representative of all 3D cell cultures available and are not effective 
for culture of every cell type. MSI methodology should be developed for a variety 
of different 3D cell culture models in order to increase its utilisation within this 
field. Once optimised for this sample type, the technique will be capable of 
analysis of metabolites, lipids and proteomic changes in a spatial distribution in 
3D cell cultures which will provide useful information for study of disease. 
This thesis aimed to develop 3D cell culture models which are still representative 
of their human in vivo counterparts but are also compatible with MSI. Following 
this, sample preparation and analysis methods were developed and optimised to 
gain useful molecular insights into disease and treatment.  
1.2 Aims 
1. To create more representative 3D cell culture models of their in vivo cell 
counterparts, working towards the 3R principles. 
2. To develop methods using MSI tools applicable to 3D cell culture analysis. 
3. To demonstrate the use of these methods to gain insights into disease and 
treatment. 
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1.3 Objectives 
1. To create a 3D cell culture model of osteosarcoma for the study of potential 
therapeutic options for the tumour (Chapter 2).  
2. To develop MSI methods for the small molecule and lipid analysis of 
osteosarcoma spheroid aggregates (Chapter 2). 
3. To demonstrate the use of these methods to assess osteosarcoma drug 
response (Chapter 3). 
4. To develop MSI methods for the proteotypic peptide analysis of 3D cell 
cultures (Chapter 4). 
5. To develop an MSI method for quantification of proteotypic peptides within 
a spheroid aggregate (Chapter 4). 
6. To create a 3D cell culture model of liver for the study of ADME responses 
to therapeutics (Chapter 5). 
7. To assess the use of the small molecule MSI methods on a polymer 
scaffold-based model of liver for the evaluation of AOPs (Chapter 5). 
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Chapter 2: Optimisation of 
cancer spheroid culture and 
development of small molecule 
and lipid Mass Spectrometry 
Imaging  
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2.1 Introduction 
In the field of cancer research, typically in vitro two -dimensional cell cultures are 
employed to investigate mechanisms involved in metabolism, metastasis and 
drug resistance. However, it has been shown that 2D cultured cells are not 
necessarily representative of in vivo mechanisms and environment (Rodrigues et 
al., 2018; Seo et al., 2018; Lhuissier et al., 2017; Shamir & Ewald, 2014). 2D cell 
cultures display differences in cell-cell interactions and a lack of interactions with 
the extracellular matrix. Gene expression profiles of 2D cells are considerably 
altered from their in vivo counterparts (Senkowski et al., 2016). Deviations in gene 
expression lead to modified cell function, changes in morphology, and contribute 
to vast differences in drug-interactions. All these fundamental changes lead to 
large differences in responses between 2D cell cultures and the in vivo human 
response, which they are attempting to replicate. 3D cell culture is a method 
developed to overcome some of the limitations of 2D cell culture (Ravi et al., 
2015; Pampaloni et al., 2007; Birgersdotter et al., 2005).  
2.1.1 3D cell culture of cancer 
There are many methods to generate 3D cancer models, dependant on the 
experiment application and different cell sources can be used (Sections 1.1.1 and 
1.1.3). Choice of model is dependent on the application. For example, cancer 
heterogeneity is well known to contribute to chemotherapeutic and immune 
resistance (Alizadeh et al., 2015). Cell heterogeneity as well as the hypoxic 
gradients within a tumour lead to different behaviour between cell populations 
within a tumour (Rankin & Giaccia, 2016), therefore these features have to be 
considered when developing a cell culture model to study drug response. There 
is also communication observed between tumour and its surrounding stroma, 
immune cells, blood vessels and extracellular matrix components. This promotes 
specific cancer related behaviours leading to a more complex tumour 
microenvironment. Several tumour models aim to replicate these complex 
features within an in vitro culture(Yang & Lin, 2017; Rimann et al., 2014). 
2.1.2 3D cell culture scaffold models 
Scaffold models are widely used in order to replicate the native environment to a 
larger extent and maintain more in vivo like behaviour in culture (Sitarski et al., 
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2018; Bäcker et al., 2017; Caliari & Burdick, 2016). Naturally derived scaffolds of 
non-animal origin are extensively used for 3D cell culture of mammalian cells due 
to biocompatibility, homogeneity, reproducibility and the mild gelation. Dependant 
on the type of experiment an exact replication of the in vivo extracellular 
framework is not always required. Close mimics of the native environment are 
sometimes sufficient (Magin et al., 2016). Biocompatibility of animal-derived 
scaffolds is sufficient and basement membrane extracts such as Matrigel® or 
Cultrex® are used successfully for many applications (Cavo et al., 2018; Sachs 
et al., 2018). However, these are susceptible to batch to batch variations due to 
the extraction and solubilisation processes (Saldin et al., 2017; Nath & Devi, 
2016; Sharma et al., 2010). Homogeneity and reproducibility of synthetic 
scaffolds is much better than naturally derived scaffolds as the composition is 
designed avoiding this variability. The benefit of these types of scaffolds, is their 
mechanical stability, controllable degradation and structure, which are important 
factors in both in vitro modelling and regenerative medicine (Annabi et al., 2014). 
An increased number of highly biocompatible synthetic scaffolds are being 
utilized, including cell-degradable hydrogels (Sawicki et al., 2018). 
Alginate is a naturally derived polysaccharide extracted from brown algae 
(Phaeophyceae). The scaffold polymerises by an ionic cross-linking process. The 
process involves linking units of alginic acid with a cross-linking ion, commonly 
Ca2+ (Figure 2.1), but can be controlled by adjusting the composition and 
concentration (Augst et al., 2006) as well as adjusting the rate of gelation 
(Growney Kalaf et al., 2016) and combination with other biomaterials 
(Venkatesan et al., 2015). The first instance of alginate use to culture cells was 
in the 1980s where it was used to encapsulate islet cells in order to culture and 
implant these into rats as a way to correct their diabetic state (Lim & Sun, 1980). 
Since then the use of alginate for tissue engineering and in vitro cell culture 
purposes has been extensively considered and some of its benefits include its 
non-toxicity, soft gelation, control over matrix stiffness and simple cell recovery 
(Diekjürgen & Grainger, 2017). 
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Figure 2.1 Alginate chains are composed of guluronic acid and mannuronic acid 
units. In the presence of cross-linking ions such as Ca2+ alginate polymerises 
reversibly. 
2.1.3 The challenges of 3D cell culture analysis 
Although the use of 3D cell culture models is more representative of the in vivo 
environment, it has also generated some analytical challenges. The 3D structure 
has resulted in a requirement to adapt or create new methods of analysis, as 
certain current methods are no longer suitable. For example, fluorescence 
microscopy is often used to characterise tumour spheroids without the need for 
sectioning, however sample thickness and difficulty of light penetration makes 
this technique more difficult to use than with conventional cultures (Graf & 
Boppart, 2010). Confocal microscopy variants are now commonly used, such as 
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confocal laser scanning microscopy (CLSMO); light-sheet-based fluorescence 
microscopy (LSFM); Single (or selective) plane illumination microscopy (SPIM) 
and Two-photon microscopy (TPM)/multi-photon microscopy (MPM); however 
even these are limited by sample thickness due to light scattering and 3D cell 
culture samples in some cases still have to be sectioned to solve this (Costa et 
al., 2016). Auto-fluorescence of some scaffolds is also an concern preventing the 
use of fluorescence microscopy for analysis, although methods are in 
development to try and overcome this such as pre-culture in autofluorescence 
suppressing agents like Sudan Black B (Qi et al., 2017). 
Another common method of cell analysis which requires an adjusted 
methodology to study tumour spheroids is flow cytometry. In order to analyse 
cells using flow cytometry, these have to be completely separated to a single 
suspension. This means the spheroids cannot be observed in their native state 
and have to be disaggregated using non-enzymatic cell dissociation reagents 
such as Versene (Florczyk et al., 2016) or cellular detachment promoting 
enzymes such as trypsin (Tung et al., 2016). Recently, Sart and colleagues 
presented a microfluidic platform which could be combined with cytometry 
methods at population, spheroid as well as single cell scale capable of analysing 
small spheroids (<200µm) (Sart et al., 2017). In some cases, if a fluorescent stain 
is added before dissociation of the tumour spheroid, penetration time has to be 
considered, especially with larger spheroids. Alternatively, the slow spheroid 
penetration time of the Hoechst 33342 dye may be utilised to the experimenters 
advantage as an indicator of which spheroid layer they are observing (Beaumont 
et al., 2015).  
Commonly used colorimetric cell viability assays, such as the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and lactate 
dehydrogenase (LDH) assays, have also required optimisation for use in the 
study of 3D cell cultures. In particular concerning tumour spheroid model analysis, 
assays such as MTT work in some cases without protocol adjustment, some with 
adjustment and in some cases the assay does not produce reliable results 
(Pereira et al., 2017; Galateanu et al., 2016; Ho et al., 2012). This may be due to 
difference in cell density and spheroid size in each model design, which could 
affect assay penetration. As the penetration is not complete the correct amount 
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of product is not created, and the value given by the test becomes inaccurate. 
Cells in the proliferating region would produce a relatively higher signal 
throughout due to higher cell activity, therefore smaller sized spheroids would 
produce a higher signal than large spheroids. As long as the reagent is non-toxic, 
which is the case of the Resazurin assay, which is also a redox indicator, the 
incubation time of the assay can be increased to long enough to penetrate most 
3D cultures (Uzarski et al., 2017; Riss et al., 2004). However, in the case of many 
biochemical endpoint assays, long incubations are not possible due to toxicity to 
the cells and alternatively fluorescence and luminescence assays are developed 
specifically for 3D cell culture use. Special software is required for the analysis of 
growth when techniques such as nuclei counting are not feasible. For example, 
AnaSP, a software analysing morphological parameters was developed in order 
to determine the role sphericity and volume variance play in reproducibility of 
results (Zanoni et al., 2016). Volume increase in these cases was used as a 
measure of spheroid growth. In the same study, the ability of several viability 
assays to measure correctly and reproducibly the viability of spheroids of up to 
850µm diameter was assessed. Pre-selecting spheroids for homogenous volume 
and shape and observing the overall morphological changes during treatment, as 
well as noting variability within data, allowed the researchers to assess the 
accuracy of each viability test. Results showed that the conventional Trypan blue 
method was not sufficiently reproducible and accurate at predicting cell viability 
in spheroids. The CellTiter-Glo® 3D Cell Viability Assay, which is based on a 
luminescence reaction and designed specifically for 3D cell culture analysis, 
provided the best and most reproducible results however was still hindered at 
spheroid sizes of >650µm diameter (Zanoni et al., 2016). This could have been 
either due to the penetration limit of the assay, light scattering or the presence of 
a necrotic core at this size.  
In the case of tumour spheroids, size may contribute greatly when trying to 
recapitulate pathophysiological conditions including hypoxic and necrotic areas 
and proliferation gradients. Smaller spheroid cultures can be used to represent 
certain cell-cell, cell- matrix interactions but are not always representative of the 
whole microenvironment, therefore this is a consideration for culture of each 
specific tumour type (Friedrich et al., 2009). In fact, sarcomas are known to be 
 
 
57 
least dependent upon endothelial-cell proliferation and have very little 
vasculature compared to other lesions, therefore in these cases hypoxic and 
necrotic areas in a model may be of high relevance (Azam et al., 2010). It is 
known that the initial foci of neoplastic cells receive their nutrients and oxygen by 
diffusion from a host blood vessel up to a distance of 100-200μm, therefore in 
order to represent tumour areas further away than this gradient, larger spheroid 
models are required (Baronzio et al., 2008). 
Frequently used methods such as western blotting, quantitative PCR and 
immunohistochemistry all require different levels of adaptation for  3D cell culture 
analysis. These detect important molecules of interest within the cultures, 
however all the methods mentioned thus far have been targeted analysis 
methods. Additionally, out of all the methods previously mentioned only IHC is 
capable of maintaining spatial biochemical information. 
2.1.4 MSI of cancer 3D cell cultures  
Mass spectrometry imaging (MSI), has been adapted towards the analysis of 3D 
cell culture of cancer. MSI of spheroids was first initiated by the Hummon group 
in 2011. The group published the first proof-of-principal publication on the use of 
MSI with these models and proved that a MALDI-MSI workflow could be used to 
examine the changes in protein and peptide distributions within cancer spheroids 
in an unbiased fashion, suitable for de novo discovery (Li & Hummon, 2011). 
Although MALDI-MSI is the most commonly type of MSI technique used for this 
purpose, other techniques have also been used for MSI of 3D cell cultures. 
Secondary Ion Mass Spectrometry (SIMS) imaging was used as a tool for the 
metabolic profiling of small molecules in squamous cell carcinoma MCTS. The 
MCTS in this study were treated with Doxorubicin and multivariate statistics was 
used to reveal a metabolite pattern, which indicated hypoxia-induced 
chemoresistance (Kotze et al., 2013). Using Laser ablation Inductively Coupled 
Plasma Mass Spectrometry (LA-ICP-MS) imaging, a technique capable of 
imaging elements rather than larger molecules, another research group 
developed a methodology for the imaging of platinum group-containing drugs, 
such as cisplatin, in tumour spheroids, as well as a palladium-tagged 
photosensitizer. Quantitation of all the imaged drugs was also achieved by using 
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different matrix-matched standards (Niehoff et al., 2016). Use of mass 
spectrometry imaging in order to visualise molecules within 3D cancer cultures is 
increasing due to the numerous advantages of the method. The main two 
advantages are the potential for untargeted de novo discovery, and the capability 
to observe multiple analytes of interest in a single experiment. Unlike LC-MS, a 
method which has also been used in the analysis of 3D cell culture models, MSI 
is also able to preserve spatial information, requiring no homogenisation of the 
sample, and frequently less sample preparation is involved. Many MSI methods 
are also non-destructive which may lead to the sample being used again, 
commonly for a histological stain. In light of these advantages MSI is destined to 
become a powerful, regularly used technique for the investigation of 3D cell 
culture disease models. However, prior to widespread adoption of this technique, 
more optimisation of mass spectrometric imaging techniques of several types of 
3D tumour spheroid models is required. 
2.1.5 Chapter aims 
In the following chapter the aim was to develop a suitable 3D cell culture model 
of cancer and determine whether MSI could be used to image the spatial 
distribution of small molecules within that model. Firstly, a small panel (PC-3, DU-
145, MG-63 and SAOS-2) of prostate cancer and osteosarcoma cell lines were 
cultured using alginate-based cell culture. The SAOS-2 cell line was then 
selected for further spheroid aggregate culture for the production of larger 
spheroid aggregates. The aggregates were developed to sizes large enough for 
representative physiological gradients to lead to formation of hypoxic and necrotic 
regions and for easier determination of regions using MALDI-MS imaging. Once 
the 3D cell culture model was established, optimisation of sample preparation 
was performed for MALDI-MS imaging, including choice of best matrix, sample 
fixation and embedding techniques. Finally, the samples were imaged, using 
three different mass spectrometers capable of imaging, in order to assess the 
compatibility of different sample types, preparations and to assess the effect of 
spatial resolution, small molecule and lipid signal in positive and negative modes. 
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2.2 Materials and Methods 
2.2.1 Chemicals and materials  
α-Cyano-4-hydroxycinnamic acid (α-CHCA), 2,5-Dihydroxybenzoic acid (DHB), 
9-aminoacridine (9-AA), 1, 5-Diaminonaphthalene (1, 5-DAN), N-(1-Naphthyl) 
ethylendiaminedihydrochloride (NEDC), 5-chloro-2-mercaptobenzothiazole 
(CMBT), Glycine, Pyruvic acid, Putrescine, Alanine, Lactic acid, Serine, Proline, 
Fumaric acid, Valine, Threonine, Cysteine, Leucine, Isoleucine, Oxaloacetic acid, 
Asparagine, Aspartic acid, Malic acid, Glutamine, Lysine, Glutamic acid, 
Methionine, Histidine, Phenylalanine, Arginine, Glucose, Tyrosine, Citric acid, 
Tryptophan, Glucose-6-phosphate, Cytidine 5’-monophosphate (CMP), Uridine 
5’-monophosphate (UMP), Fructose-1,6-bisphosphate, Adenosine 5’-
monophosphate (AMP), Cytidine 5’-triphosphate (CTP), Adenosine 5’-
triphosphate (ATP), alginic acid, ethanol (EtOH), methanol (MeOH), acetonitrile 
(ACN), chloroform (CHCl3), Xylene Substitute (SubX), Acetone, trifluoroactic acid 
(TFA), formic acid (FA), Paraformaldehyde, Hoechst 33342, propidium iodide (PI), 
gelatin, carboxymethyl cellulose (CMC), sodium chloride (NaCl) and calcium 
chloride (CaCl2) were purchased from Sigma–Aldrich (Poole, UK). Industrial 
methylated solvent (IMS) was obtained from Fisher Scientific (Loughborough, 
UK). X-tra® slides, Mayer's Haematoxylin, Eosin and Pertex were purchased 
from Leica Biosystems (Milton Keynes, UK). NucView™ 488 Caspase-3 
substrate was obtained from Cambridge Bioscience (Cambridge, UK). ITO-
coated slides were obtained from Visiontek Systems Ltd (Cheshire, UK). 
2.2.2 2D cell culture 
PC-3, DU-145 (prostate adenocarcinoma) and MG-63 (osteosarcoma) were 
obtained from the American Type Culture Collection and cultured in Dulbecco's 
Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum 
(FBS) and 10 U/ml penicillin and 10 μg/mL streptomycin (Thermo Scientific, USA) 
and SAOS-2 cell line was obtained from American Type Culture Collection 
(ATCC) and cultured in MEMα (Lonza Ltd, Switzerland) containing 10% foetal 
bovine serum (FBS) and 10 U/ml penicillin and 10 μg/mL streptomycin (Thermo 
Scientific, USA). All cell lines were maintained in a humidified atmosphere 
containing 5% CO2 at 37oC. These were cultured until they reached 
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approximately 80% confluency before transfer to 3D culture. Once confluent, the 
cell lines were passaged by trypsinisation, subsequent centrifugation, 
resuspension in fresh medium and seeded in new flasks. The cells were used for 
up to 15 passages from frozen stocks for experiments. 
2.2.3 3D cell culture 
2.2.3.1 Alginate culture 
Following expansion in monolayer, cell lines were suspended in 1.2% w/v 
medium viscosity alginic acid in 0.15M NaCl. The initial seeding densities of all 
cell lines were between 1x 105 cells/mL for the 4-6 week cultures and and 1x 106 
cells/mL for up to 2 week cultures of alginate. The cell concentrations were 
determined with the Countess® Automated Cell Counter and Trypan blue stain. 
Alginate beads were formed via dropping 2mL of cells in 1.2% (w/v) alginate/ 
0.15M NaCl through a 19-gauge needle into 20mL 0.2M CaCl2. After incubation 
at 37oC for 12 minutes beads were washed twice with 0.15M NaCl and washed 
twice in complete media before being placed in the appropriate culture media. All 
cell lines were cultured up to 2 weeks and the SAOS-2 cell line was cultured up 
to 6 weeks to observe potential further growth. In order for the spheroids not to 
merge in the longer-term cultures, the seeding density used was 1x105 cells/mL. 
2.2.3.2 Releasing tumour spheroids from alginate matrix 
Alginate beads were dissolved in 500µL alginate dissolving buffer (55mM sodium 
citrate, 30mM EDTA, 0.15M NaCl) per bead for 10 minutes at 37oC on a shaker 
after pipetting up and down in order to break up the bead. The solution was then 
centrifuged at 1,000g for 5 minutes at room temperature. Supernatant was 
removed and the spheroids were washed in media twice, each time centrifuging 
the spheroids according to the same protocol, then they were incubated in the 
appropriate culture media for 24 hours in order to equilibrate. 
2.2.3.3 Formation of spheroid aggregates 
In order to obtain spheroid aggregates, alginate grown spheroids were released 
from alginate using the alginate dissolving buffer and after two media washes, 
each followed by centrifugation (1,000g, 5 mins), they were immediately placed 
in 1% agarose coated 96 well plates. The tumour spheroids from half of one 
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alginate bead were added to each agarose-coated well and these were cultured 
for a further 7 days in the appropriate medium (Figure 2.2).  
 
Figure 2.2 Three-dimensional cell culture methods used for formation of cancer 
spheroid models. A) Alginate bead spheroid formation. The cells are seeded as 
a single cell suspension within an alginate bead and grow into clonal spheroids. 
B) Two-step spheroid aggregate formation. After culture of cells in alginate beads, 
spheroids are released from alginate and collected into a spheroid aggregate 
within low-attachment wells. 
2.2.4 Assessment of viability, apoptosis and necrosis  
The cells were visualised by utilising three different stains; Hoechst 33342 
(10µg/mL), Propidium Iodide (PI) (1µg/mL) and NucView™ 488 Caspase-3 
substrate (20µM). Since PI has a broad emission peak, separate spheroid and 
spheroid aggregate samples were used for Hoechst 33342/PI and Hoechst 
33342/Caspase-3 combinations in order to prevent green and red emission 
overlap within the same fluorescent image. Hoechst 33342/PI stained samples 
were incubated with Hoechst 33342 and PI for 25 minutes in a humidified 
atmosphere containing 5% CO2 at 37oC. Hoechst 33342/Caspase-3 stained 
samples were first incubated in Caspase-3 stain for 15 minutes at room 
temperature after which Hoechst 33342 was added and another incubation of 25 
minutes was carried out in a humidified atmosphere containing 5% CO2 at 37oC. 
All incubations were performed in a dark environment to prevent photobleaching. 
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After the incubations the samples were washed twicewith phosphate-buffered 
saline (PBS) and stored in PBS during fluorescent visualisation. 
Sample well plates were visualised on an Olympus IX81 microscope at 100x and 
200x magnification under blue, green, red, and merged channels.. Images were 
captured using Cell^F software. 
2.2.5 Sample preparation 
2.2.5.1 Preparation of spheroids for histological and molecular 
analysis 
Fresh frozen samples of 3D cell cultures were prepared several ways for 
comparison (Figure 2.3). The samples were all embedded in 5% gelatin + 2.5% 
carboxymethylcellulose (CMC) inside a silicone mould and immediately frozen 
using liquid nitrogen. The embedding medium was chosen by adapting the 
medium to a consistency similar to that of the sample for optimal sectioning. A 
similar mixture of gelatin and CMC was published as acceptable for whole-body 
zebrafish MALDI-MSI experiments in terms of its physical property, stability and 
lack of ion suppression and this slight variation was also found to be sufficient for 
sectioning of 3D cultures (Nelson et al., 2013). The fixed frozen sample set was 
fixed by washing twice in PBS followed by immediate immersion in 4% 
paraformaldehyde at 4oC for 15 mins. These were then processed the same as 
the fresh frozen samples. The spheroids which had been released from alginate 
beads using dissociation buffer were incubated in media for a 24-hour 
equilibration then embedded in 5% gelatin 2.5% CMC inside a silicone mould and 
immediately flash frozen using liquid nitrogen. All samples were stored inside 
sealed containers at -80oC. 
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Figure 2.3 Schematic of sample preparation methods tested of fresh frozen 
spheroid cultures. 
Sample sections were cut using the Leica 1850 UV cryostat (Leica Biosystems, 
UK), set to -30oC, at a 10 μm thickness, thaw mounted on a positively charged 
X-tra® adhesive slide (Leica Biosystems, UK) or on an Indium-Tin oxide (ITO)-
coated slide (Visiontek Systems Ltd, UK) dependant on the analysis. The sample 
thickness chosen was the lowest consistent thickness achieved with the sample 
and equipment available, as published previously (Lewis et al., 2018). The 
samples were then stored at -80oC in an air tight container.  
2.2.5.2 Preparation of spheroid aggregates 
The samples were processed by embedding the spheroid aggregates in 10% 
gelatin 2% carboxymethylcellulose (CMC) inside a silicone mould and 
immediately frozen using liquid nitrogen. The spheroid aggregates were moved 
from wells to embedding medium using a 200µL pipette tip with a cut-off end in 
order to better preserve the aggregate integrity. Care was taken to not damage 
the spheroid aggregate and to minimise the amount of media deposited alongside 
the sample. Any excess media was removed to the extent possible using a pipette.  
All samples were stored inside sealed containers at -80oC. 
These samples were sectioned according to the same method as alginate 
cultures. 
2.2.6 Optimisation of Mass Spectrometry Imaging 
2.2.6.1 Production of small molecule standard mix 
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A small molecule standard mix was made by dissolving 35 small molecule 
standards at 50pmol/µL in 70% EtOH. The standard list is presented in Table 2.1. 
This was then aliquoted and stored at -80oC in sealed containers. 
 
Table 2.1 List of small molecule standards (50pmol/µL) included in the standard 
mixture and their m/z values in negative mode. 
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2.2.6.2 Mass Spectrometric Profiling of standards 
A comparison of the use of four matrices for negative mode MALDI-MS was 
undertaken. The four matrices were 9-amino acridine (9-AA), 1, 5-
Diaminonaphthalene (1, 5-DAN), N-(1-Naphthyl) ethylendiaminedihydrochloride 
(NEDC) and 5-chloro-2-mercaptobenzothiazole (CMBT). MALDI-MS profiles of 
spotted small molecule standard mix were compared against a direct injection of 
the standard using a Finnigan LCQ (Thermo Scientific, UK). The four matrices 
were first prepared; 9-AA (10mg/mL, 100% acetone), 1,5-DAN (10mg/mL, 100% 
MeOH), NEDC (10mg/mL, 70% EtOH), CMBT(20mg/mL (4:4:1 
chloroform:MeOH:dH2O (v/v/v))). The 50pmol/L standard mix was spotted onto 
target plates (0.5µL) and matrix was deposited on top of each spot once dry 
(0.5µL).  
Mass spectra were manually acquired on an Autoflex III (Bruker Daltonik GmbH, 
Germany) equipped with a 200-Hz smart-beam laser. Negative ion mass spectra 
were acquired from 50 m/z – 1000 m/z in reflectron mode. Six hundred laser shots 
were acquired for each spectrum at a random walk setting. This instrument was 
initially chosen for comparison of matrices due to its nitrogen laser beam profile, 
which comprises of several intense spots in order to generate a quazi-Gaussian 
profile and subsequently maximise ion yield, therefore it was most likely to yield 
results from the matrix panel (Zavalin et al., 2014). External mass calibration was 
achieved using a phosphorus red standard of approximately 200 parts per million 
(ppm). Data was acquired using FlexControl (Bruker Daltonics, Germany), 
converted to .txt file format using FlexAnalysis (Bruker Daltonics, Germany) and 
analysed using Mmass v5 open source software (Strohalm et al., 2010).  
A further comparison of NEDC and 9-AA profiles was later made using a Synapt 
G2 operated with a 1 KHz Nd:YAG laser (355 nm) (Waters Corporation, UK) to 
achieve higher accuracy and reliability in the results.  The standard was spotted 
onto a target plate (0.5µL) and 9-AA (10mg/mL, 100% acetone), and NEDC 
(7mg/mL, 50% MeOH) were prepared and deposited on top of the standard 
(0.5µL). Negative spectra were acquired from 50 m/z – 1000 m/z using an 
automated spiral raster pattern set to 60s raster for increased reliability. The ion 
mobility function was also used in order to improve separation of peaks. External 
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mass calibration was achieved using a phosphorus red standard to achieve 95% 
confidence of <3 parts per million (ppm). Data was acquired, converted to .txt file 
format using MassLynx™ software (Waters Corporation, UK) and analysed using 
Mmass. 
2.2.6.3 Statistical analysis 
The data was identified as non-parametric by the Shapiro Wilkes test of normality. 
Therefore, the Kruskal-Wallis test was used to determine if there were any 
significant differences between the treatments for each ionic species. This 
analysis was combined with Conover-Inman post-hoc test when a significant 
difference was seen between treatment groups. Statistical analysis was 
performed using StatsDirect software (StatsDirect Ltd, UK). 
2.2.6.4 Mass Spectrometric Imaging of spheroids and spheroid 
aggregates 
2.2.6.4.1 Matrix deposition 
All sample sections were taken straight after cryosectioning or from -80oC storage 
and immediately placed in a vacuum desiccator for ~15 minutes prior to matrix 
application. In cases where samples were washed with ammonium acetate (pH 
6.7) the slide sections were dipped in 50mM ammonium acetate for 15 seconds 
and dried in a vacuum desiccator again for ~5 minutes before matrix application. 
X-tra® slide mounted sections were used for Synapt G2 and Q-Star Pulsar-i™ 
analysis and ITO-coated slide mounted sections were used for Autoflex III 
analysis, where conductive slides were required due to the sample stage setup 
to prevent surface charging.  
For positive mode imaging α-CHCA (5 mg/mL, 70:30 ACN:dH2O, 0.1% TFA) was 
prepared as a matrix solution. The matrix was applied to the sample section using 
the SunCollect™ automated sprayer. Five layers of matrix were applied at 3.5 
μL/min for the first layer and 3 μL/min for the remaining four layers (speed x: low 
7, speed y: medium 1, Z position: 35). 
For negative mode imaging, initially 9-AA was used (10mg/mL, 100% acetone) 
as a matrix solution. 9-AA was sprayed manually, giving 1 minute of drying time 
in between layers, until the sample was fully covered (~30 layers). In later 
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experiments, negative mode imaging was performed with NEDC (7mg/mL, 50% 
MeOH) prepared as a matrix solution. The matrix was applied to the sample 
section using the SunCollect™ automated sprayer. Fifteen layers of matrix were 
applied, at 4μL/min for the first layer and 3.5μL/min for the remaining layers 
(speed x: low 7, speed y: medium 1, Z position: 35). 
2.2.6.4.2 Mass Spectrometric Imaging 
Three separate MALDI-MS instruments were utilised for the imaging of spheroids 
and spheroid aggregates. 
Initially, sample preparation methods were compared using a low spatial and 
mass resolution capability but high throughput instrument. For the evaluation of 
sample preparation methods a modified MALDI-Q-TOF, a Q-Star Pulsar-i™ 
(Applied Biosystems/MDS Sciex, Concord Ontario, Canada) was used. These 
modifications have been reported elsewhere (Trim et al., 2010). Data were 
acquired in positive mode using an NdYVO4 laser (Elforlight “SPOT”, Daventry, 
UK). Images of 150μm pixel size were acquired over the embedded culture area. 
Data was acquired over an m/z range of 50-1,200. 
Several images of the spheroids and spheroid aggregates were obtained using a 
Synapt G2 for higher mass resolution imaging. Images of 60μm and 30μm pixel 
size were acquired. Data were acquired over an m/z range of 50–1,000 in 
negative mode and 50-1,200 in positive mode analysis. The ion mobility function 
was used in order to improve separation of peaks by addition of molecule 
separation by shape as well as mass and charge. 
A study of the regional differences within a spheroid aggregate was executed 
using an Autoflex III due to its high spatial resolution capabilities because the 
laser could be focused to a smaller diameter (~20-30). Negative ion mass spectra 
were acquired at a pixel size of 30μm from 50 m/z – 1000 m/z in reflectron mode. 
The laser was focused to around ~50μm diameter. Four hundred laser shots were 
acquired for each spectrum at a random walk setting.  
2.2.6.4.3 Data Processing 
Images acquired on the Q-Star Pulsar-i™ were processed using Biomap 
Software 3.7.5.5 (Novartis, Basel, Switzerland). Images generated using the 
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Synapt G2 were processed using the Waters High Definition Imaging (HDI v 1.4) 
software package. Images generated using the Autoflex III were processed using 
FlexImaging 2.0 software. Images generated were all normalised through the 
division of the analyte image by that of the total ion count (TIC).  
2.2.7 Histological analysis 
2.2.7.1 Haematoxylin and Eosin staining 
Haematoxylin and Eosin (H+E) staining was used to visualise sample 
morphology. Sections (10m) were initially simultaneously dehydrated and fixed 
in 95% (v/v) MeOH for 5 minutes followed by ≥99.9% (v/v) acetone for 5 minutes. 
These two steps also removed any presence of matrix if sections were processed 
after MALDI-MS imaging. Sections were put through further dehydration in 99% 
(v/v) IMS for 5 minutes 3x then immersed in Mayer's Haematoxylin for 10 minutes, 
before being 'blued' in running tap water for a further 5 minutes. This step was 
followed by 2 more incubations in 99% (v/v) IMS for 5 minutes and immersed in 
Eosin for 1 minute. Sections were then immersed in 99% (v/v) IMS for 5 minutes 
3x followed by immersion in SubX for 5 minutes 3x. Finally, sections were 
mounted using 2 drops of Pertex (Leica Biosystems, UK) per slide and coverslips 
applied. 
2.3 Results 
2.3.1 Optimisation of cancer cell line growth in alginate 3D 
culture 
Two prostate cancer cell lines and two osteosarcoma cell lines were chosen for 
3D cell culture. 3D cell culture was initially only alginate bead culture. At 14 days 
the PC-3 cell line proliferated into masses with diameters of ~200µm, with the 
larger spheroids presenting a potentially more hypoxic core (Figure 2.4). The DU-
145 cell line proliferated to form ~50µm diameter masses, the spheroids showing 
no significant sign of nutrient or oxygen starvation in the core. After 14 days 
incubation in alginate MG-63 spheroids grew to a diameter of ~200µm and 
SAOS-2 cell line spheroids grew to a diameter of ~50µm (Figure 2.5), however 
during longer 4-week cultures SAOS-2 spheroids reached ~300µm diameters, 
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with significant red PI staining in the middle of the spheroids contrasting the blue 
outer layers (Figure 2.6). 
 
Figure 2.4 Fluorescent images obtained by Hoechst/PI stain of live cells inside 
intact alginate beads up to 14 days in vitro a) PC3 and b) DU145. Blue signal 
represents Hoechst staining of nuclei (viable cells) and red signal represents PI 
staining of dead/dying cells.  
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Figure 2.5 Fluorescent images obtained by Hoechst/PI stain of live cells inside 
intact alginate beads up to 14 days a) MG-63 and b) SAOS-2. Blue signal 
represents Hoechst staining of nuclei (viable cells) and red signal represents PI 
staining of dead/dying cells.   
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Figure 2.6 Fluorescent images obtained by Hoechst/PI stain of live cell spheroids 
released from alginate beads. SAOS-2 cell line spheroids were imaged after 4 
weeks culture. Scale bar = 100 m. 
 
Differences were also observed within a bead, particularly in the later growth 
stages (Figure 2.7). The spheroids formed in the core of the beads displayed 
more PI positive dead cells than the spheroids on the outside of the beads, 
according to live cell staining with Hoechst 33342/PI.  
 
Figure 2.7 Fluorescent images obtained by Hoechst/PI stain of a whole intact 
alginate bead containing PC-3 cells (day 11). 
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2.3.2 Mass spectrometry imaging of spheroids 
2.3.2.1 Comparison of negative mode matrices 
In order to be able to compare different types of sample preparation a small 
molecule standard mixture was produced consisting of 35 small molecules 
including amino acids, organic acids associated with primary metabolism and 
glucose made up to a 50pmol/µL concentration (Table 2.1). This standard was 
first analysed on the LCQ instrument by direct injection and an average of 32 of 
the 35 metabolite standard signals were observed in negative mode from three 
separate injections. Then the standard was analysed using MALDI-MS profiling 
with four different matrices, 9-AA, 1,5-DAN, NEDC and CMBT. Both NEDC and 
9-AA matrices presented the highest amounts of detected peaks on average 
(Figure 2.8), however 9-AA crystals were more homogenous whilst spotting, 
which lead to it being initially selected for negative mode mass spectrometric 
imaging. Matrix crystallisation patterns and inconsistencies contribute greatly to 
signal ‘hot spots’ and may influence profiling results. 
 
Figure 2.8 Comparison of direct injection MS analysis on LCQ instrument and 
MALDI-MS profiling using the Bruker Autoflex III with four matrices. Four negative 
mode matrices were used; 9-AA, 1, 5-DAN, NEDC and CMBT showing the 
average number of putatively identified metabolites (from a 35-metabolite 
standard mix) for each method. Three technical repeats were performed on the 
LCQ and 9 technical repeats were performed for each matrix (n=2). 
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In later experiments a higher mass accuracy instrument Synapt G2 was used and 
the two optimal matrices, 9-AA with an average of 23 metabolites and NEDC with 
an average of 24 metabolites detected, from the previous experiment were 
compared again by MALDI-MS profiling (Figure 2.9). The standards were 
analysed using an automated spiral raster pattern, which enabled ablation of a 
consistent amount of matrix in the case of both matrices. In this more controlled 
experiment, aiming to negate any low signals due to matrix crystal heterogeneity, 
27 of the metabolite standards were observed using NEDC, compared to 24 using 
9-AA (p= 0.0213), therefore NEDC was used in later experiments. 
 
 
Figure 2.9 Comparison of optimal matrices. High accuracy MALDI-MS profiling 
using the Synapt G2. The matrices analysed were 9-aminoacridine (9-AA) and 
N-(1-Naphthyl) ethylendiaminedihydrochloride (NEDC) showing the average 
number of putatively identified metabolites (from the 35-metabolite standard mix) 
for each method. P<0.05 determined by Conover-Inman test (n=3). 
2.3.2.2 Comparison of sample preparation methods 
Comparison of the effect of different sample preparation methods was performed 
(Figure 2.3). As the alginate beads were 3mm in diameter these were too small 
to section without embedding. The beads could be directly embedded, or the 
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alginate could also be dissolved using a specific dissociation buffer and the intact 
spheroids then embedded. Initially, these two methods were compared to 
observe which one would be optimal. The FFPE method was dismissed 
immediately because this study focuses on metabolite analysis and the FFPE 
workflow solvents washed away soluble metabolites of interest, therefore would 
interfere with the analysis. In some cases of metabolite analysis formalin fixation 
can preserve metabolites of interest within the sample, however this was not 
found to be the case in these experiments (Ly et al., 2016). 
Analysis of the H+E stained comparisons of the two embedding methods (Figure 
2.10) showed that the spheroids retained their structure better when released 
from alginate and directly embedded inside the embedding medium. This is 
possibly due to shrinking of the alginate bead during the embedding in the warm 
gelatin/CMC medium or inconsistency of resistance to the microtome blade 
during sectioning.  
 
Figure 2.10 Haematoxylin and eosin stained spheroids displaying sample 
integrity. a) H+E of spheroids inside intact alginate bead embedded in a gelatin 
and CMC medium. b) H+E of spheroids released from an alginate bead 
embedded in a gelatin and CMC medium. The green arrow is indicating alginate 
and the blue arrows are indicating cell spheroids. 
There was a significant loss of spheroids during the embedding process of the 
alginate released sample set, though this was reduced by formalin fixing before 
embedding (Figure 2.11F). In general, similar small molecule and lipid signals 
were observed in alginate and released samples.  Secondly, the effect of fixing 
the cells with formalin was observed as well as the effect of washing the sections 
with ammonium acetate buffer. It was determined that fixing the samples did 
a) b) 
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improve sample integrity but reduced the amount of several small molecules 
detected in the sample. The buffer wash was useful in improving the lipid signal 
but reduced the small molecule signal as expected. The wash also resulted in 
slight sample loss. 
 
 
 
Figure 2.11 MSI of phosphocholine (m/z= 184.0736) as a cell marker inside 
spheroids. Comparison of different sample preparation methods on lipid signal 
and sample integrity; A) Alginate intact fresh frozen/ B) intact formalin fixed frozen, 
C) alginate intact and buffer washed fresh frozen/ D) formalin fixed frozen, E) 
released from alginate using dissolving buffer fresh frozen/ F) formalin fixed 
frozen.   
Due to the least sample loss, highest small molecule signal and best embedded 
spheroid integrity, the fresh frozen and released spheroid method was chosen. 
The overall signal in alginate and released fresh frozen samples was found to be 
optimal and sample integrity was improved in released samples. This cannot be 
seen in the MSI data (Figure 2.11E) since spheroid loss was mostly observed 
during the embedding step. However, this was reduced by improving sample 
preparation in further experiments. 
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The SAOS-2 cell line cultured for a 4-week period was selected for further studies 
as it produced highly intact spheroids of <300µm diameter. However, the spatial 
resolution of the MALDI-MS instruments was not sufficient to observe the intra-
spheroid environment. At a routine pixel size of 60µm only a maximum of 5 pixels 
could be attained across a spheroid. This is not sufficient in order to see 
molecular differences within the spheroids (Figure 2.12a).  
In order to increase the size of the 3D model, longer term alginate culture of the 
SAOS-2 cell line was performed up to 8 weeks, however the spheroids did not 
develop past their maximum 300µm diameter and increased cell death was 
observed with longer culture periods (data not shown). 
 
Figure 2.12 a) MSI of phosphocholine (m/z= 184.0736) inside spheroids (circled 
in red) demonstrating the number of pixels (<4) achieved within individual 
spheroids and b) the corresponding H+E stained spheroids showing diameters 
of ≤300m. Black scale bar = 200m. 
2.3.3 Optimisation of spheroid aggregate growth 
In order to create a larger 3D cancer model, 4-week SAOS-2 spheroids were 
released from the alginate beads using dissolving buffer. These spheroids were 
then aggregated by culture in 1% agarose well plates over a period of 7 days 
(Figure 2.2).  This two-step method created large ' spheroid aggregates' of ~1mm. 
These spheroid aggregates consist of several clonal spheroids, which have 
combined into a single mass. Therefore, the spheroid aggregates are still capable 
of displaying observable clonal differences whilst also containing larger 
proliferating, apoptotic and hypoxic regions. 
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The aggregation of the spheroids could be observed using live fluorescence 
staining (Figure 2.13). At day 5 the clonal spheroid shapes are still observable by 
their apoptotic regions however by 7 days aggregation there is a singular 
apoptotic and greater cell death region. Despite the size of the spheroids a 
proliferating, viable cell region is still present around the edge of the mass.  
 
 
Figure 2.13 Live cell fluorescent imaging showing the aggregation of SAOS-2 
spheroids into full size spheroid aggregates at 7 days culture on 1% agarose well 
plates. Staining was performed using Hoechst 33342 (blue), PI (red) and 
Caspase-3 (green) stains. Scale bar = 500m. 
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2.3.4 Mass spectrometry imaging of spheroid aggregates 
Two-step (alginate and agarose) 3D cell culture produced spheroid aggregates 
of ~1mm diameter, which led to MALDI-MS imaging with a higher pixel number 
within a spheroid.  At a typical pixel size of 60µm, the method allowed for around 
16 pixels across a spheroid aggregate, which was deemed sufficient to 
differentiate potential regional differences. Pixel sizes as low as 30µm can be 
achieved by oversampling in order to increase spatial resolution, however this 
can lead to a loss of sensitivity (Figure 2.14). 
 
Figure 2.14 MSI of peak m/z= 281.2596 distributed throughout a SAOS-2 
spheroid aggregate at a) 60µm pixel size and b) 30µm pixel showing the 
difference in spatial resolution and signal. 
 
Regional differences can be observed in many different small molecule and lipid 
species (Figure 2.15). There are species distributed within the inner and outer 
regions within the spheroid aggregate. This provides evidence for the capability 
of this technique to distinguish between the different regions within the mass for 
future metabolomic and lipidomic studies. There were also ionic species identified 
which localised only within certain regions of the spheroid aggregate, which could 
potentially be showing the clonal differences between the different spheroids the 
spheroid aggregate consists of.   
A B 
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Figure 2.15 Combined MSI of SAOS-2 spheroid aggregate. Above the panel is 
the haematoxylin and eosin stained sample post-MSI. Several ionic species 
localised in specific spheroid regions. Species 78.9493 phosphoric acid (green) 
was used to identify the whole spheroid. This was overlaid with a) putative fatty 
acid species 426.0657 (pink) localised heterogeneously throughout, b) unknown 
species 403.1034 (red) localised in the necrotic region, c) putative pyrophosphate 
species 158.9409 localised in the apoptotic region, d) putative fatty acid species 
281.2809 (light blue) localised in the viable region and e) putative UDP-N-acetyl 
glucosamine (606.0975, dark blue) localised in the apoptotic region. H+E scale 
bar = 500m.  
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2.4 Discussion 
The aims of the study were to design a cancer 3D cell culture model and workflow 
which was compatible with molecular imaging using MALDI-MSI. A method for 
the growth of spheroids and larger spheroid aggregates was demonstrated. The 
sample preparation workflow was optimised for improved histological and 
molecular analysis. Several aspects of the MALDI-MSI workflow were addressed 
including the culture size requirements, comparison of different matrices using a 
small molecule standard mix, effect of sample preparation steps on positive and 
negative mode molecular signal and the effect of spatial resolution. The method 
developed can be used to analyse small molecules and lipids to observe inter-
aggregate as well as intra-aggregate molecular differences. 
2.4.1 Development and analysis of alginate cultures 
2.4.1.1 Alginate 3D culture selection 
The spheroid forming potential of four different cancer cell lines within alginate 
culture was assessed. The four cell lines selected have been previously cultured 
using the alginate bead method within the research group and in previous studies 
the prostate and osteosarcoma cells formed and maintained spheroids during 
culture in alginate (Stock et al., 2016; Akeda et al., 2009). The size of spheroids 
obtained using the alginate method varied in this study between different cell lines 
as well as within the same cell line. The formation of spheroids by this method is 
clonal, where each spheroid is a clonal colony of a single cell, therefore each 
spheroid may behave differently. This may lead to inconsistency in size of 
spheroid and higher variance, however this could be advantageous in the study 
of cancer stem cell (CSC) populations and other research studies interested in 
clonal differentiation (Vermeulen et al., 2008). In general, clonal spheroids tend 
to be more compact and routinely spherical but take longer to form compared to 
aggregation method formed spheroids. In a recent comparison, MCTS formation 
methods, although MCTS were of similar size, the expression of cell contact 
genes between the spheroids varied significantly (Gencoglu et al., 2018). The 
MCTS formation method affected the cell line drug response, therefore the 
difference in gene expression could contribute to how representative the model 
is of the in vivo drug response. Additionally, differences in Hoechst 33342/PI 
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staining were observed within each individual bead. The PI stain became more 
intense towards the core of the bead, indicating an increase in cells with a 
disrupted membrane, such as dead, apoptotic and hypoxic cells. This may be 
due to the creation of a nutrient and oxygen starvation gradient towards the 
middle of a bead as a result of interference from the spheroids in the outer regions. 
As the cell number increases over culture time and the beads becomes more full 
of proliferating spheroids, diffusion of nutrients and oxygen into the core may 
become increasingly difficult. The proliferation rate and spheroid dimension limit, 
differed between cell lines and is something to consider when growing 3D 
cultures. The aim was to select an alginate culture which would create the largest 
intact spheroids, as it would be easiest to observe zonal variances within these, 
characteristic of spheroids. This was particularly important in order to develop 
these cultures for analysis using a technique such as MALDI-MS imaging, which 
is not capable of spatial resolution as high as microscopy techniques (Chapter 
1.1.5.7).  
An attempted solution to the spheroid size problem was longer period culture in 
order to give spheroids more time to grow in size. However, attempts to grow the 
spheroids for longer did not yield larger spheroids. Spheroids cultured using 
scaffold 3D cell culture techniques tend to be more limited in size, including 
alginate beads. Commonly, non-scaffold methods are used in order to achieve 
larger size diameters, such as liquid overlay techniques and bioreactors (Lu et 
al., 2017). These methods usually involve aggregation of single cell suspensions 
to form heterogeneous multicellular masses. The spheroids formed by scaffold-
based methods, in comparison, are each derived from a single cell and are 
therefore clonal spheroids. Easily discernible clonal colonies would be beneficial 
in analyses aiming to observe the effect clonal heterogeneity has on, for example, 
tumour drug resistance and angiogenesis (Katt et al., 2016). It could be argued 
that scaffold-based techniques also provide a more in vivo like environment for 
tissue cancer cell types as the spheroid surroundings have a stable mechanical 
structure, resembling tissues, unlike non-scaffold methods. Cells must produce 
and organize their own matrix in scaffold-free systems as there is no physical 
support system. In scaffold-based models the cells are provided with an 
immediate structure where they can surround themselves with extracellular 
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matrix components and communicate with other stationary cell populations 
(Diekjürgen & Grainger, 2017). 
Additionally, alginate is commonly cross-linked using Ca2+ which could potentially 
promote important biological pathways (Chan & Mooney, 2013). Scaffolds 
containing Ca2+ have been utilised in the past for differentiation of stem cells and 
bone regeneration, due to increased mimic of bone minerals, therefore it could 
be potentially beneficial to osteosarcoma model development (Tang et al., 2013). 
During the sample preparation process, leaving the spheroids inside alginate 
beads and embedding these whole proved an inferior method due to structural 
loss inside the alginate bead, leading to fracture of the spheroids and poor 
sections. This was possibly due to the fact that alginate is greatly hydrophilic, and 
its structure was compromised during the sample preparation process or due to 
the difference in composition between the alginate and embedding medium. In 
fact, alginate is a relatively stiff scaffold  commonly used for embedding small 
formalin fixed samples before paraffin embedding, due to its compatibility with 
paraffin composition. Its compatibility with paraffin embedding is confirmed by the 
fact that it is the active ingredient in the Cytoblock™ sample preparation system 
which is commonly used for routine small sample embedding for paraffin blocks 
(Dagg et al., 1992). However, the composition may be too hard when frozen, for 
the fresh frozen sample embedding media available, leading to poor sectioning. 
Washing the sections with ammonium acetate in order to remove salt 
contamination resulted in a large loss of small molecule signal and not a 
significant gain in lipid peak intensity, therefore this step was discarded. This was 
attempted as a desalting step which has been shown in the literature to increase 
lipid signal ten-fold (Angel et al., 2012). Lastly, the formalin fixing step was useful 
in protecting cell loss due to washin and during embedding released cells, 
however it was already determined that the wash step was not useful and the 
extent of formalin fixing benefit for released samples was not high enough to 
make up for signal loss of small molecules caused by the 15-minute-long 
incubation. The idea of using a formalin fixing step without putting the sample 
through paraffin embedding has been mentioned in the literature as an alternative 
protocol for both lipid and peptide imaging (Pietrowska et al., 2016). Mass 
spectrometry imaging of small molecules within FFPE samples has been 
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achieved in the past, however in this case the signal loss of molecules of interest 
solely from the fixing step was too high (Ly et al., 2016). The cell loss experienced 
during spheroid release and embedding was later reduced by improvements to 
technique.  
Nevertheless, there were still disadvantages to the chosen sample preparation 
method. There was cell loss due to steps involved during the alginate dissolving 
procedure and during cell embedding. As well as cell loss there was the issue of 
the dissolving process disturbing normal cell behaviour. In order to make sure 
there is no effect of the alginate dissolving process on the spheroids there was 
an additional 24-hour equilibration step in a culture environment. Although this 
step is required in order to make sure no effect of the releasing process is 
observed, in the case of future drug studies with this model it could be problematic. 
In these cases, the treated samples would have to be either treated after release 
from alginate or inside alginate culture and then released and equilibrated for 24 
hours where the result seen may be altered due to incubation after treatment. 
The alginate dissolving buffer has a high salt concentration as well as EDTA, a 
chelating agent, therefore spheroids require an equilibration step in order to 
control for any effects on cell behaviour and sample composition. Protein and 
peptide studies may not have to involve an alginate dissolving step since these 
can be more easily applied to FFPE processed tissues and alginate is compatible 
with paraffin embedding (Patel, 2017). Comparison of the alginate culture sample 
preparation therefore led to a preparation sequence of releasing the spheroids 
from alginate, equilibrating these in culture media for 24 hours, directly 
embedding without fixation and fast freezing. 
2.4.1.2 Alginate 3D culture MSI 
The spheroid sizes achieved through alginate bead culture were not sufficient for 
observation by MALDI-MS imaging. As mentioned previously, only up to five 
pixels can be achieved across a spheroid of ~300µm diameter. This does not 
provide enough information to determine key components and discern between 
spheroid regions and MALDI-MSI analysis of these samples did not yield results. 
There are possible instrumental solutions to this, as certain MALDI-MS 
instruments are capable of high spatial resolution imaging (up to 5µm pixel size) 
for small samples or features, or a nanoSIMS instrument, which utilises a different 
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type of ionization and has higher spatial resolution capabilities, could be used 
(Dueñas et al., 2017; Vanbellingen et al., 2015). 
2.4.2 Development and analysis of spheroid aggregates 
2.4.2.1 Spheroid aggregate 3D culture selection 
Taking into consideration previous discussion about insufficient spheroid 
diameter limiting MSI resolution, a modification of the alginate 3D culture model 
was developed in order to make larger spheroids with discernible and clear 
proliferating, apoptotic and hypoxic regions. The SAOS-2 cell line was chosen for 
these cultures as it produced the largest spheroids which were most consistent 
in size. In order to create the optimal 3D model, the alginate culture step remained 
in the protocol and an additional liquid overlay culture was added after release of 
spheroids. This decision was made in order to keep the benefits of scaffold-based 
culture and to potentially aid in aggregation of cells into larger compact masses. 
Therefore, a two-step 3D culture was designed, which could be potentially applied 
to many different cell types. Theoretically, because the cells are cultured in a 
scaffold culture initially they are given time to secrete ECM components which 
could aid in spheroid to spheroid adhesion during the aggregation process and 
longer-term culture. The spheroids were shown to aggregate into larger 
structured, termed ‘spheroid aggregates’, which displayed proliferating, apoptotic 
and necrotic regions and still remained aggregates of several clonal spheroids, 
which retained the potential of observing clonal differences within the structure.  
Culturing the cells with this two-step culture method also removed a problematic 
equilibration step in the released alginate cultures. As the spheroids are cultured 
in liquid overlay culture for a further 7 days after release they are not 
compromised when harvesting occurs. Additionally, not only were the spheroid 
aggregates much easier to analyse due to their larger size there may be a benefit 
to a larger hypoxic and nutrient deprived region in the model, which more closely 
mimics the tumour micro-environment. The SAOS-2 cell line is derived from 
osteosarcoma, which commonly grows and survives in an oxygen low 
environment. Several reports of hypoxia related osteosarcoma drug resistance 
have been made (Zheng et al., 2017; Roncuzzi et al., 2014; Garofalo et al., 2013). 
Additionally, larger spheroids are commonly used to study chemo and radio 
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therapeutic responses. The responses depend on oxygen depletion, 
compactness, apoptosis inhibition, damage repair, and permeability. All of these 
parameters feature at a greater extent in larger spheroid cultures (>500µm) 
(Zanoni et al., 2016). 
A possible disadvantage of the spheroid aggregate model is the irregular shaped 
masses it creates. A high variance in in spheroid aggregate morphology could 
lead to variance in results, as there is a difference in zone size and shape. Each 
zone will include cells of different proliferation statuses and therefore may alter 
results dependant on shape (Zanoni et al., 2016). However, the spheroid 
aggregates have been shown to develop a single necrotic core and merged 
apoptotic and proliferating regions after the 7-day liquid overlay culture step. This 
indicates a lack of separated multi-regions within a mass, therefore the irregularity 
may not have as large a difference in the reproducibility of results. The extent of 
the potential variance needs to be evaluated and steps should be taken in order 
to improve the morphology of the spheroid aggregates. Methods, such as 
adjusting the composition of the growth medium, in order to improve 
compactness and spheroidal shape of masses have been widely studied and 
could be applied in this case (Leung et al., 2015). 
2.4.2.2 Spheroid aggregate 3D culture MSI 
As the spheroid aggregates were significantly larger than the spheroids produced, 
MSI of samples could achieve up to 16 pixels across a spheroid aggregate. This 
increase in pixels per sample helped increase the amount of signal for each 
molecule of interest and aided in discerning localisation of ionic species within 
specific regions of the spheroid aggregate. By oversampling, using the Synapt 
G2 which has a laser diameter of around 70µm, the amount of pixels achieved 
across a sample could be increased but lead to loss of signal, as expected. 
Therefore, in order to observe localisation of small molecules within the spheroids 
the Autoflex III instrument was used, as it had an adjustable focus laser. Adjusting 
the focus of the laser to ~50µm led to less oversampling at 30µm pixel size and 
achieved improved spectra with higher overall molecular signal. Using this 
method, putative molecules which localised within specific regions of the spheroid 
aggregates were detected. The MS/MS capability of the instrument was not good 
enough to identify the molecules of interest. Localisation within specific nutrient 
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and oxygen dependant regions was observed as well as a potential localisation 
due to clonal heterogeneity. These results are promising for further studies of 
specific regional metabolomic and lipidomic differences as well as study of 
tumour heterogeneity and its association with drug resistance. This may be 
especially important as intra-tumour heterogeneity has been shown by several 
studies to predict cancer progression and response to therapy (Romero et al., 
2018; Rye et al., 2012; Tixier et al., 2011), even specifically for sarcoma types 
(Eary et al., 2008). Observation of the clonal molecular responses to treatment 
within the spheroid aggregate model could be beneficial for study of intra-tumour 
heterogeneity and its effect.  
However, to compare overall differences between spheroid aggregates the 
Synapt G2 was used to image at 60µm pixel size as this was found to be the most 
accurate and sensitive method. In cases where differences between spheroids 
are compared, spatial resolution was sacrificed for higher sensitivity and 
accuracy. MS/MS images were obtained in future experiments using the Synapt 
G2 due to its higher mass resolution capabilities. Due to the small size of the 
spheroid aggregates manual profiling was not possible. 
2.5 Concluding remarks 
Methods were developed for the creation of spheroid and spheroid aggregate 3D 
cell culture models. The models were examined using live cell imaging and 
histology to determine proliferating, apoptotic and necrotic regions. Observations 
of the two models using MALDI-MSI were made and methods for sample 
preparation and imaging were optimised. MALDI-MSI was not capable of 
extracting sufficient amounts of information from the spheroid model, due to lack 
of spatial resolution. Imaging of the larger spheroid aggregate model using 
MALDI-MSI was successful. The technique was capable of providing information 
on overall spheroid aggregate environment as well as specific regional 
localisation an abundance of small molecules and lipids. 
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Chapter 3: Quantitative Mass 
Spectrometric Imaging of 
doxorubicin in osteosarcoma 
spheroid aggregates and 
molecular analysis of response.  
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3.1 Introduction 
3.1.1 Osteosarcoma 
Rare cancers are defined by the RARECARE project as those with an annual 
incidence of less than 6 per 100,000 people in the European Union (EU) (Gatta 
et al., 2011). Despite their individual low incidence rate these accounted for 24% 
of all cancers diagnosed during 2000-2007. There is a significant difference in the 
average 5-year relative survival of rare cancers (48.5%) compared to common 
cancers (63.4%) (Gatta et al., 2017). This difference is likely due to the low 
numbers of cases which leads to a lack of knowledge, expertise and research.  
Bone sarcomas are rare cancers, of estimated incidence of 4-5 per million 
population per year, most frequently affecting younger patients, with 60% of 
patients under the age of 25. Of all bone sarcomas, osteosarcoma is the most 
frequent primary malignant bone tumour (Fletcher et al., 2013). 5-year survival of 
osteosarcoma has not improved significantly in Europe since the 1980s (Zhang 
et al., 2018; Gatta et al., 2011).The survival percentage for young patients in the 
UK on average is around 59%, which is slightly lower than most of Europe  and 
is even lower (~20%) when considering advanced, metastatic stages (Eyre et al., 
2009). There is a clear need for better treatment programs, higher complexity 
models and increased knowledge of the disease in order to improve survival. 
3.1.2 Osteosarcoma treatment 
Management of osteosarcoma is complex and level of expertise in diagnostics 
and treatment is low, therefore the cases are usually dealt with by specialist 
reference centres to be able to provide the best care. The current therapeutic 
protocol for treatment of osteosarcoma is a multi-modal approach of surgery 
combined with chemotherapy. Surgery alone of high-grade osteosarcoma leads 
to a disease-free survival probability of only 10-20%, whilst combination with 
chemotherapy increases this probability to 60% (The ESMO/European Sarcoma 
Network Working Group, 2015). The chemotherapy regimen of doxorubicin, 
cisplatin and high-dose methotrexate is currently the most frequently used for 
osteosarcoma treatment (Ferrari & Serra, 2015). However, resistance to this 
combination is high and many studies and clinical trials are now focused on 
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finding novel drugs of differing mechanisms of action, some of which affect 
multiple targets or target the tumour environment (Heymann et al., 2016). 
3.1.3 Models of cancer 
To understand the full effects of cancer treatment and drug resistance pharmaco-
kinetic/dynamic modelling is required (Derendorf & Meibohm, 1999). By gaining 
in-depth knowledge on the path of a therapeutic once administered and the effect 
it then has on a tumour, we can improve design of treatment solutions. This would 
additionally help gain insight into the potential effect and potency of the 
therapeutic on a specific disease state. In silico, in vitro and in vivo models all 
play important roles within the pipeline and have improved greatly over the years 
(Harrison, 2016). The current process of drug discovery and development, based 
on 2D in vitro assays followed immediately by in vivo, has produced many 
effective drug candidates, however it is not efficient. This lack of efficiency is 
largely due to a drop in efficacy once in clinical trials, a lack of understanding of 
the disease biology and poor target selection (Harrison, 2016). Novel cancer 
drugs have been found to be one of the least likely to be approved by the FDA, 
with only a 6.7% likelihood of approval (LOA) of stage 1 to 2 clinical trials and a 
total LOA of 10.5% from stage 2 to 3 of trials. The major cause of this has been 
shown to be the high difference in efficacy of drugs between pre-clinical study 
models and clinical results (Hay et al., 2014). The challenges in anti-cancer drug 
development have been identified as lack of understanding of the target 
downstream and off-target effects; lack of predictive models; the balance 
between drug safety and efficacy; lack of biomarkers and knowledge of 
population variance in response and cost of development (Hait, 2010). This 
especially affects the study of rare cancers as even less information and 
resources are available. 
The issues caused by the lack of predictive models could be overcome with the 
introduction of 3D cell cultures into the pre-clinical workflow. These could be 
introduced to biomarker research workflows, chemotherapeutic efficacy and 
toxicity assays and reduce the overall cost of a drug discovery pathway due to a 
potential decrease in animal use as well as increased likelihood of approval due 
to a better understanding of the disease biology. 3D cell culture models are of an 
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advanced complexity compared to the conventional 2D cell culture models. 
Therefore, use of these would improve correlation between human in vitro and in 
vivo data. 3D cell culture would be particularly useful in the case of new 
osteosarcoma chemotherapeutics where a large inter-tumour and intra-tumour 
heterogeneity exists due to presence of different subtypes and many genomic 
rearrangements (Botter et al., 2014).  
Mass spectrometry imaging tools can be utilized to visualise the molecular 
changes within 3D cell culture models as a response to treatment. MALDI-MSI in 
particular has been used for drug response analysis in the past for other biological 
samples and is a suitable method for multiplex, untargeted analysis of cell culture 
models (Schulz et al., 2019). 
3.1.4 Chapter aims 
Knowledge of tumour and novel treatment solutions could be discovered with the 
use of mass spectrometry imaging as a high content molecular tool. In chapter 2 
methods were optimised for the small molecule MSI of spheroid aggregate 3D 
cultures. The aims of this chapter are to use the spheroid aggregate 
osteosarcoma model developed to investigate therapeutic response and utilise 
MALDI-MSI tools to elucidate molecules involved in this response. In this chapter, 
2D monolayer and 3D spheroid aggregate osteosarcoma models were treated 
with several chemotherapeutics. Doxorubicin, an anthracycline which interferes 
with DNA transcription and replication through the stabilisation of topoisomerase 
II, which is one of the most widely used drugs for the treatment of high-grade 
osteosarcoma (Hattinger et al., 2010). Paclitaxel, a taxane which binds to the β 
subunit of tubulin irreversibly, arrests microtubule function by hyper-stabilization 
of their structure and in turn arrests cell division. Paclitaxel has been used to treat 
a wide variety of cancer types, including soft tissue sarcoma (Horwitz, 1994). 
Paclitaxel has been found to induce apoptosis through binding to an apoptosis 
inhibitor called Bcl-2 (B-cell leukemia 2) and arrest its function (Jazirehi & 
Bonavida, 2004). A combination treatment of paclitaxel and doxorubicin was 
additionally performed as positive synergistic effects of combined treatment have 
been reported in the literature (Duong & Yung, 2013). Vinblastine, a vinca alkaloid, 
similarly to paclitaxel also arrests the cell cycle by binding to microtubules at 
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several sites (Himes, 1991). Vinblastine has been used as a chemotherapeutic 
in combination chemotherapy regimens for various cancer types, including 
sarcoma (Rowinsky, 2003). Following this, doxorubicin was chosen for detection 
by MALDI-MSI to observe drug distribution and identify the metabolomic and 
lipidomic response of the 3D cell culture model to treatment in order to elucidate 
novel significant response pathways. 
3.2 Methods and Materials 
3.2.1 Chemicals and Materials 
Vinblastine sulphate, paclitaxel, doxorubicin hydrochloride, Dimethyl sulfoxide 
(DMSO) and Resazurin were purchased from Sigma–Aldrich (Poole, UK). 
3.2.2 Cell culture 
Initial cell culture conditions can be found in section 2.3.2. Once confluent, SAOS-
2 osteosarcoma cells were trypsinised and seeded into 96-well plates at 
5x104cells per well. These were cultured for 24 hours before treatment. 
SAOS-2 spheroid aggregates were cultured according to the method in section 
2.2.3. These were kept in 96-well plates for treatment.  
3.2.3 Cell viability tests 
3.2.3.1 Sample preparation 2D 
The SAOS-2 cell line cultured in 2D was used for testing the chemotherapeutic 
effect of vinblastine, paclitaxel, doxorubicin and a combination treatment with 
doxorubicin and paclitaxel. 
SAOS-2 cells were treated with 200µL of each drug (Range of concentrations for 
vinblastine= 0-320 nM, paclitaxel= 0-2.56 µM, doxorubicin= 0-12.8 µM). Stocks 
of chemotherapeutics were dissolved in DMSO and serially diluted in culture 
media (vinblastine=11mM, paclitaxel=58.55mM, doxorubicin=40mM). The 
concentration of DMSO was kept under 0.1% for treatment. Fresh treatment 
media was added every 12 hours in the case of paclitaxel and doxorubicin and 
every 24 hours in the case of vinblastine. A combination treatment of paclitaxel 
and doxorubicin was also attempted in order to observe any possible synergistic 
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effect. The same ratios of the two drugs were combined as individual treatment 
e.g. 5nM paclitaxel was combined with 25nM doxorubicin as this was determined 
to be the optimal ratio for synergistic effect (Duong & Yung, 2013). Cell viability 
readings were taken at 0, 12 and 36hrs in the case of doxorubicin and paclitaxel 
and 24, 48 and 72hrs in the case of vinblastine to observe longer treatment effect. 
The doxorubicin and paclitaxel experiments were completed with 3 technical 
replicates performed within each set of experiments (n=3). 
3.2.3.2 Sample preparation 3D 
Doxorubicin treatment was selected for further analysis using SAOS-2 spheroid 
aggregates as it was the therapeutic found to be most effective in 2D experiments. 
The spheroid aggregates were treated with the range of doxorubicin 
concentrations chosen for study of drug effect (0, 0.16, 0.8, 4µM). Cell viability 
readings were taken at 0 and 48hrs and treatment media was refreshed at 24hrs. 
This experiment was completed in duplicate with six biological replicates per 
condition. 
3.2.3.3 Cell activity/viability assay 
To assess cell activity/survival during treatment a Resazurin assay was used. 
Resazurin stock was made at 3mg/mL in MEMα culture media. Resazurin (200µL 
of 0.3mg/mL) was added to each well and incubated for 1.5 hours (2D culture) or 
3 hours (3D culture) at 37oC wrapped in foil to protect from light exposure. The 
fluorescence was recorded using a 530 nm excitation / 590 nm emission filter set 
using a CLARIOstar® plate reader (BMG LABTECH, Germany). After reading the 
plates, the cultures were washed twice with culture medium and cultured further 
until the last remaining time point. Resazurin has been shown to be relatively 
non-toxic with short incubation time and subsequent washes and therefore can 
be used for continuous studies (Riss et al., 2004). In the case of SAOS-2 cultures, 
the Resazurin treatment did not have a significant effect on cell viability as can 
be seen from the control sets in each viability experiment (Figures 3.2 and 3.3). 
Additionally, Doxorubicin only controls at all concentrations used were tested in 
order to confirm the absence of fluorescent interference with the assay and 
differences were deemed insignificant (data not included). 
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3.2.3.4 Fluorescent imaging of doxorubicin in spheroid 
aggregates   
The cells were visualised by utilising Hoechst 33342 (10µg/mL) and the spheroid 
aggregate sample was treated with doxorubicin (1M) for 6 hours. The treated 
sample was then incubated with Hoechst 33342 for 25 minutes in a humidified 
atmosphere containing 5% CO2 at 37oC. All incubations were performed in a dark 
environment to prevent photobleaching.  
Sample well plates were visualised on an Olympus IX81 microscope. Images 
were captured using Cell^F software (Olympus, Germany). 
 
3.2.3.5 Data processing and statistical analysis 
The fluorescence readings were collected and media-only signal was subtracted 
from the sample set. Following this, all data was normalised to 0hr controls. The 
data was identified as non-parametric by the Shapiro-Wilk test of normality. 
Therefore, the Kruskal-Wallis test was used to determine if there were any 
significant differences between the treatments. This analysis was combined with 
Dwass-Steel-Chritchlow-Fligner post-hoc test when a significant difference was 
observed between treatment groups. Statistical analysis was performed using 
StatsDirect software (StatsDirect Ltd, UK). The Excess Over Bliss calculation was 
used to determine synergy of the paclitaxel and doxorubicin combination therapy 
(Borisy et al., 2003).  
IC50 graphs were produced by fitting a four parameter, variable slope non-linear 
regression curve using GraphPad Prism v7 software (GraphPad Software, USA). 
Data was transformed to a logarithmic plot for which 0nM control concentration 
value was changed to 1x10-10nM to enable the data to be represented 
logarithmically. The bottom value was constrained to a constant value of 0.0 since 
the basal response was subtracted earlier. IC50 and R2 (goodness of fit) was 
determined for each treatment. 
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3.2.4 Matrix optimisation 
Several matrix combinations were compared in order to determine the optimal 
one to analyse doxorubicin. The selected matrix compositions are summarised in 
table 3.1. 
 
Table 3.1 A summary of matrix compositions compared for the optimal analysis 
of doxorubicin by MALDI-MS. 
Mass spectra were acquired using a Synapt G2 operated with a 1 KHz Nd:YAG 
laser (355 nm) (Waters Corporation, UK) as this instrument was accessible for 
the highest mass resolution at the time.  A range of doxorubicin standards (0, 
0.01, 0.1, 1, 10, 100µg/mL) were spotted onto a target plate (0.5µL) and the 
matrices were prepared and deposited on top of the standard (0.5µL). Positive 
spectra were acquired from 50-1200 m/z. Negative spectra were acquired from 
50–1000 m/z. All matrices were analysed using an automated spiral raster pattern 
set to 60s raster for increased reliability. The ion mobility function was also used 
in order to improve separation of peaks. External mass calibration was achieved 
using a phosphorus red standard to achieve 95% confidence of <3 parts per 
million (ppm). Data was acquired and analysed using MassLynx™ software 
(Waters Corporation, UK). Linear regression was fitted using GraphPad Prism v7 
software (GraphPad Software, USA). Additionally, the analyte standard limit of 
detection (LOD) and limit of quantification (LOQ) were determined. This was 
performed using Excel software to calculate standard error then divide this by 
slope of linear regression for each analyte. This value was then multiplied by 3.3 
to determine LOD and by 10 to determine LOQ. These values define the limits of 
the analysis by taking into account the standard deviation and selecting values 
above the signal noise. 
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3.2.5 Production of doxorubicin spiked cell plug array 
A doxorubicin standard spiked cell plug array was made to aid quantification of 
doxorubicin inside a spheroid using MALDI-MSI. The standards were spiked into 
the cell plug array in order to mimic the signal suppression effects in the samples. 
A gelatin block was made by pouring 20% gelatin into ice cube moulds, setting 
the moulds in the fridge for at least 4 hours and transferring to -80oC for freezing 
overnight and storage. The block was transferred from -80oC to a -30oC cryostat 
and the top of the block was cut to produce an even surface. Using a pillar drill, 
nine holes were then drilled into the frozen block at a drill diameter of 2.5mm and 
depth of 10mm. The block was placed back into -80oC storage before the loading 
process. During the loading process the cell plug was mounted in a cryostat set 
to -30oC. 
SAOS-2 cells were cultured in 2D conditions as in section 2.2.2 until confluent. 
Cells were trypsinised, counted, centrifuged and the supernatant removed.  
Amount of cells required to make a full cell plug array were ≥70,000,000 cells (6-
hole array), ≥11,000,000 cells (9-hole array). A range of doxorubicin 
concentrations were produced in culture medium (0, 0.09375, 0.1875, 0.375, 0.75, 
1.5, 3, 6, 12µM). After removal of all medium the cells were mixed with drug 
standards 2:1 cell:doxorubicin v:v. The cell and drug mixture was made 2:1 to fill 
a total volume of 49.097mm2 which was calculated using the diameter and depth 
of the drill hole. In order to pipette the viscous cells, the pipette tip was cut off. 
Immediately after mixing cells with drug standard, the mixture was deposited 
inside a 10mm depth and 2.5mm diameter cell plug hole. Once all the cell:drug 
mixtures were deposited inside the cell plug this was stored in a sealed container 
at -80oC. The resultant final concentrations of doxorubicin after mixing were lower 
by a factor of 3 (0, 0.031, 0.063, 0.125, 0.25, 0.5, 1, 2, 4µM) (Figure 3.1).  
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Figure 3.1 A schematic of the Doxorubicin spiked cell plug array. 
3.2.6 MSI of doxorubicin 
3.2.6.1 Sample preparation 
Spheroid aggregates were treated with a range of doxorubicin concentrations 
chosen for study of drug effect (0, 0.16, 0.8, 4µM) and incubated in a humidified 
atmosphere containing 5% CO2 at 37oC and harvested at 0, 24 and 48 hours. 
The sample preparation for the spheroid aggregates was identical to Chapter 
2.2.4.2. Sectioning of the cell plug array and spheroids was performed as 
described in Chapter 2, however optimal sections were achieved when the cell 
plug array was sectioned immediately following transfer from -80oC.  
All sample sections were taken straight after cryosectioning or from -80oC storage 
and immediately placed in a vacuum desiccator for ~15 minutes prior to matrix 
application. Negative mode imaging was performed with NEDC (7mg/mL, 50% 
MeOH) prepared as a matrix solution. The matrix was applied to the sample 
section using the SunCollect™ automated sprayer. Fifteen layers of matrix were 
applied, at 4μL/min for the first layer and 3.5μL/min for the remaining layers 
(speed x: low 7, speed y: medium 1, Z position: 35). 
3.2.6.2 MALDI-MSI detection of doxorubicin in array and 
spheroid aggregates 
Positive mode imaging of an array was conducted using a Synapt G2 for sufficient 
mass resolution data. Spectra were acquired at a pixel size of 100µm from 50-
1200 m/z with the ion mobility function used to achieve better mass resolution. 
Data acquisition and analysis was performed using MassLynx v4.1 (Waters, UK) 
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and High Definition Imaging (HDI) Software (Waters, UK). This analysis did not 
detect doxorubicin inside the array, therefore negative mode analysis was 
attempted.  
Imaging of the doxorubicin array and 4µM spheroid aggregate in negative mode 
was executed using an Autoflex III as in negative mode Doxorubicin is detectable 
at higher signals using this instrument. Negative ion mass spectra were acquired 
at a pixel size of 50μm from 50 m/z – 1000 m/z in reflectron mode. The laser was 
focused to around ~50μm diameter. Four hundred laser shots were acquired for 
each spectrum at a random walk setting. Data acquisition was performed using 
FlexControl (Bruker Daltonics, Germany), and visualizations were obtained from 
flexImaging4.0 (Bruker Daltonics, Germany). 
MALDI-FTICR-MSI of 0, 0.8 and 4µM treated spheroid aggregates was 
performed on a 9.4T SolariX XR mass spectrometer (Bruker Daltonics, Germany) 
in negative-ion mode, using 200 laser shots per spot and 75 μm pixel size. This 
instrument was used because of its high mass resolution capabilities but was only 
available for a limited time, therefore use was limited. Data was acquired in a m/z 
range from 50 to 1000 Da. Data acquisition was performed using ftmsControl 
(Bruker Daltonics, Germany), and visualizations were obtained from 
flexImaging4.0 (Bruker Daltonics, Germany). 
3.2.7 MSI of treated spheroid aggregates 
3.2.7.1 Sample preparation 
Treated spheroid aggregates (0, 0.8, 4µM) were sectioned as in section 2.2.4.1 
at 10µm thickness, ensuring a section from the middle section of the spheroid 
aggregate was sampled. 3 sections were taken per sample, 3 samples were 
sectioned per treatment and the cultures were grown at n=3 which resulted in a 
total of 81 sections for MSI. The matrix deposition protocol used was identical to 
Section 3.2.6.1. 
3.2.7.2 MALDI-MSI of small molecules and lipids 
Imaging of spheroid aggregates was performed using a Synapt G2 because of 
its high sensitivity and substantial resolving power (10,000 in sensitivity mode). 
Images of 60μm pixel size were acquired. Data were acquired over an m/z range 
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of 50–1,000 in negative mode analysis. The ion mobility function was used to 
improve separation of peaks. Data acquisition and analysis was performed using 
MassLynx v4.1 (Waters, UK) and High Definition Imaging (HDI) Software (Waters, 
UK). Tandem MS fragmentation was performed using an isolation window of 0.3 
Da.  
3.2.7.3 Data processing 
Regions of interest (ROIs) containing whole spheroid aggregates were selected 
in Waters HDI 1.4 imaging software and exported as average spectra into 
MassLynx software. They were then centroided and exported as .txt files. The 
data was imported into Marker View software 1.2 (Applied Biosystems/MDS 
Sciex, Canada), where it could be formatted into a table. An exclusion list to 
remove NEDC peaks was applied to the dataset, to remove the influence of the 
matrix signals when observing relationships of the treatment groups between 
spectra. The data was restricted to 5000 peaks and 0.1 minimum intensity and 
autoscaled. Principal Component Analysis- Discriminant Analysis (PCA-DA) was 
performed by informing the software which samples belonged to each treatment 
group. The software then selected two components optimal for separation of the 
treatment groups. 
3.2.7.4 Statistical analysis 
Reduced data generated by the DA-PCA was initially put through a screening by 
t-test comparison of each treatment group against each other. The top 50 p-
values for ionic species of all comparison variants were chosen for statistical 
analysis. The data was identified as non-parametric by the Shapiro-Wilkes test of 
normality. Therefore, the Kruskal-Wallis test was used to determine if there were 
any significant differences between the treatments for each ionic species. This 
analysis was combined with Dwass-Steel-Chritchlow-Fligner post-hoc test when 
a significant difference was seen between treatment groups. Statistical analysis 
was performed using StatsDirect software (StatsDirectLtd, UK). 
An alternative statistical method with a higher capability of dealing with large non-
parametric data sets was also used in order to get more information from the data. 
Some significantly varying species may have been missed by using the t-test 
screening method to reduce the data size for Kruskal-Wallis analysis. The 
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compiled data in the form of a table was exported from MarkerView software into 
R Foundation for Statistical Computing Platform version 3.4.1 (R Core Team, 
2017). A linear mixed effect statistical model package called nlme was used 
(Pinheiro & Bates, 2011) in order to compare groups in the full DA-PCA reduced 
data set, taking into account the fixed and random effects. This model uses an 
Analysis of Variance (ANOVA) model in order to determine significant values. 
The Bonferroni correction for multiple testing was applied to the significance 
threshold of 0.05, making the cut-off value 1x10-5 for the list of 5000 peaks. 
Twenty four significantly differing ionic species were identified, 6 of which were 
determined possible isotopes of existing hits and dismissed from the analysis. 
The 18 significantly differing ionic species were further tested in order to observe 
the t-values (representing difference between treatment values) and p-values 
(representing the degree of significance between treatment values). The test was 
run twice for each significant ionic species, once to compare treatment 0.8µM to 
control and 4µM and repeated to compare 4µM to control and 0.8µM treatments. 
Finally, the data was represented using the lattice package on R (Sarkar, 2008) 
by scatterplot attempting to show all random data variation due to batch, culture 
and fixed variation due to dose (Figure 3.2). 
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Figure 3.2 Workflow diagram of the statistical tests used to determine 
significantly different ionic species. 
The significantly differing peaks discovered using either statistical approach were 
then given putative assignments based on a database search in the Human 
Metabolome, Metlin or LipidMaps search databases. The error allowance used 
was 30ppm for small molecules and 0.01 Da for lipid identifications which was 
acceptable for the data acquired. Following the database search biological 
relevance was investigated within the possible identities. 
3.3 Results 
3.3.1 Effect of drug treatment on cell viability 
Initially several different chemotherapeutics relevant to osteosarcoma were 
chosen for treatment of 2D SAOS-2 cultures to observe their effect on cell viability 
using the resazurin assay. The resazurin assay consists or an in-cell reduction of 
resazurin, a REDOX indicator. This is then converted to resarufin which is 
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detectable using fluorescence. The cell activity, measured by increase in the 
fluorescent signal can be directly correlated to cell viability in most cell culture 
cases. It should be noted that this is not always the case and, ideally, a cell activity 
assay such as this one should be combined with a growth assay, such as cell 
counting or spheroid growth analysis. The cells were treated with a range of 
concentrations of doxorubicin, paclitaxel, vinblastine and a combination treatment 
of doxorubicin and paclitaxel. Doxorubicin had the most effect on cell viability of 
all the chemotherapeutics (Figure 3.3). Doxorubicin treatment displayed a dose-
dependent and time-dependent decrease in cell viability. Cell viability was 
reduced at 36 hrs treatment compared to 12 hrs (p< 0.0001). A significant 
reduction in viability can be observed between 0nM and 3200nM treatments at 
12 hrs (p< 0.0001) and at 400nM at 36 hrs (p< 0.0001). The IC50 of the 
doxorubicin and paclitaxel combination treatment (IC50= 0.9µM) is lower than 
doxorubicin alone (IC50= 1.09µM), however is most likely due to an additive 
effect rather than synergistic action as observed by the Excess Over Bliss values 
(<15%) (Table 3.2). Vinblastine treatment led to a significant drop in cell viability 
after 24 hrs of treatment at as low as 5nM (p= 0.0077). Vinblastine treatment was 
performed for a longer treatment period to observe longer term treatment effects 
of the chemotherapeutic on the SAOS-2 cultures. However, the overall effect at 
72 hours was not significantly different from the effect at 24 hours of treatment 
(p= 0.2826). A similar effect was observed with paclitaxel treatment. The cell 
viability remained at a similar value between 12 and 36 hours of treatment (p= 
0.2272). 
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Table 3.2 Excess over bliss values for the combination chemotherapy of 
paclitaxel and doxorubicin on SAOS-2 cells cultured in 2D. Values <0= 
antagonistic, 0= additive, >0= synergistic (n=3). 
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Figure 3.3 Percentage of cell viability compared to untreated control and a non-
linear transform plot displaying amount of drug required to reduce cell viability by 
50% (IC50). For each treatment condition the IC50 and R2 values are displayed. 
The treatments were performed on 2D cultured SAOS-2 cells. a) Doxorubicin 
treatment b) Paclitaxel treatment c) Doxorubicin and paclitaxel combination 
treatment of the corresponding concentrations to individual treatment combined 
(doxorubicin concentrations shown on scale) d) Vinblastine treatment. All 
experiments performed at n=3. 
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The 3D cell culture model results differed considerably to the 2D model (Figure 
3.4). Doxorubicin was selected to pursue in further studies since its effect was 
the most profound in 2D cell cultures. In 3D culture there was a small but 
significant increase in cell viability between 0 and 4µM spheroid aggregates at 0 
hrs treatment (p= 0.0101), possibly due to an immediate drug effect on cell 
viability. There was no significant change in the cell viability observed at treatment 
times of up to 48 hours at concentrations of up to 4µM, which is nearly five times 
the concentration of the IC50 in 2D cell cultures (Figure 3.3). 
 
 
Figure 3.4 Percentage of 3D cell culture viability compared to untreated control 
and a non-linear transform plot displaying amount of drug required to reduce cell 
viability by 50% (IC50). 3D cell culture results show no significant effect on cell 
viability by doxorubicin at concentrations used after 48 hours treatment (n=2).  
3.3.2 Detection of doxorubicin 
3.3.2.1 Fluorescence microscopy detection of doxorubicin 
As doxorubicin was found to be the most effective therapeutic treatment in 2D 
and not significantly effective in the 3D spheroid aggregate model it was important 
to determine whether the drug had fully penetrated the mass by the end of the 
48-hour treatment period. After 6 hours, doxorubicin could be observed within all 
areas of the spheroid aggregate, indicating that it has diffused through the whole 
~600m mass (Figure 3.5). 
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Figure 3.5 Fluorescence imaging (Hoechst (blue)/doxorubicin (red)) indicating 
full doxorubicin infiltration into spheroid aggregates. Scale bar = 500m. 
3.3.2.2 Optimisation of matrices for detection of doxorubicin 
Commonly utilised matrices in MALDI analyses, such as α-CHCA, do not always 
achieve the highest signals for a molecule of interest. Doxorubicin is a molecule 
which does ionise during the MALDI process but, due to close interfering lipid 
peaks in biological samples, is very difficult to detect at lower concentrations 
using conventional matrices. Thus a binary matrix combination of α-CHCA and 
DHB was tested for improved detection of doxorubicin. Mixtures of 20/20 (Final 
concentration α-CHCA= 15mg/mL, DHB= 5mg/mL) and  7/20 (final concentration 
α-CHCA=5.25mg/mL, DHB=5mg/mL) were used in order to determine if these 
were an improvement to the sole use of α-CHCA as a matrix. NEDC was also 
tested in negative mode in order to investigate whether doxorubicin detection 
produced a better limit of detection in negative mode. The lowest LOD (1.644µM) 
and LOQ (4.981µM) was achieved using the α-CHCA:DHB 7/20 matrix (Figure 
3.6 and Table 3.3). This was not necessarily due to the signal to matrix peak ratio 
as this matrix did not produce the highest signal when normalised to a matrix 
peak (Figure 3.6). Interestingly, 5mg/mL α-CHCA which presented with the 
highest peak:matrix ratio resulted in the poorest LOD (18.5µM) and LOQ 
(56.1µM) (Figure 3.6 and Table 3.3). This is due to the way the limits are 
calculated. If the data values are less consistent and higher overall, the standard 
deviation will rise and therefore so will the LOD and LOQ values. 
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Figure 3.6 Detection and quantification limits of doxorubicin using MALDI-MS 
profiling in positive and negative mode. The signal was normalised by matrix peak 
and the data point distribution at lower concentrations is shown. Goodness of fit 
are displayed as R2 values (n=3).  
 
Table 3.3 Comparison of matrices showing the limit of detection (LOD) and limit 
of quantification (LOQ) using each matrix. 
3.3.2.3 Detection of doxorubicin using cell plug arrays 
Cell plug arrays were made to aid quantification of doxorubicin inside the spheroid 
aggregates. This was made by mixing SAOS-2 cells with doxorubicin standard 
and spiking these cells into a gelatin block. These could then be sectioned 
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alongside the sample of interest and used as an internal standard array to 
determine the concentration of doxorubicin within the sample. 
Detection of doxorubicin within the cell plug arrays was not successful in positive 
mode by Q-TOF MS due to a close, interfering lipid peak. Other instrument types 
(FT-ICR) and negative mode were used to visualise the drug. Putative 
doxorubicin could be observed in negative mode showing a promising increase 
in signal with increase in doxorubicin concentration, however the TOF determined 
signal was not sufficient for absolute determination (Figure 3.7). Here a signal 
corresponding to the m/z of ATP was chosen not necessarily as a qualitative 
observation but simply to demonstrate that signal within the cell array was, in 
general, consistent throughout and this is not the effect seen for the Doxorubicin 
abundance. 
 
Figure 3.7 Negative mode MALDI-MSI of a cell plug doxorubicin array (0-4µM) 
and a 4µM treated spheroid aggregate. a) Distribution of ATP throughout the 
array to demonstrate even distribution of cells, b) Intensity of doxorubicin 
throughout the array (0-4M doxorubicin), c) Intensity of doxorubicin inside a 4µM 
treated spheroid aggregate. 
Treated spheroids were also compared using an FT-ICR instrument, which is 
known to obtain higher mass resolution and higher sensitivity data. Using this 
instrument the doxorubicin peak was well separated from any interfering peaks 
and could be easily identified (Figure 3.8). An increased doxorubicin signal could 
be observed with increased treatment concentration, whereas the signal for ADP 
is undetectable in 4µM treated spheroid aggregates (Figure 3.9). As before, the 
ADP signal was used to show that there isn’t an overall increase with treatment 
within the model. Due to instability of the phosphate groups of ATP and ADP 
b) c) b) Dox. 
0 
0.031 0.063 
0.125 
0.25 0.5 
1 2 4 
a) ATP c) Dox. spheroid 
0 
0.031 0.063 
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during the desorption ionisation process levels of these molecules cannot be 
easily determined as you cannot be sure whether the molecule observed was 
fragmented. ADP and ATP peaks were used as references within this chapter as 
their structures could be confirmed using MS/MS. 
 
 
Figure 3.8 Positive mode MALDI-MSI a) Q-TOF of an average spectrum and b) 
FT-ICR-MS of a single spectrum of spheroid aggregates treated with 
doxorubicin (4µM).  
 
Figure 3.9 Negative mode MALDI-MSI (FT-ICR-MS) of spheroid aggregates 
treated with different concentrations of doxorubicin (0, 0.8, 4µM). Red signal 
represents ADP and the green signal represents doxorubicin. 
3.3.2.4 Defining spheroid aggregate doxorubicin response using 
MSI 
In order to define the metabolomic and lipidomic spheroid aggregate response to 
doxorubicin, treated and untreated 48-hour spheroid aggregate sections were 
Dox 
Dox 
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imaged in negative mode. The whole spheroid region was selected and average 
spectra were extracted for comparison between treatment groups. Comparison 
was performed using PCA-DA, a PCA which takes into account the group the 
samples belong to and finds the principal components which separate these 
groups. The control and treatment groups were well separated and several ionic 
species were separated out in the loading plot, in particular for the high treatment 
group (Figure 3.10). 
The in-software t-test was used as a screening method and the top 50 significant 
variances were selected from the data. After removing high possibility isotope 
peaks, 42 species were left. Using the Kruskal-Wallis test of significance, several 
ionic species were found to be significantly higher with treatment such as m/z 
335.0617 (p<0.005) and some were higher in control samples m/z 765.5488 
(p<0.005) (Figure 3.11). The most significantly differing ionic species are 
displayed in figure 3.11 as determined by both statistical approaches used and 
remaining significant peaks are provided in the supplementary information 
(Appendix chapter 3 figures 1-9). Due to low abundance of these peaks, small 
sample size and interference of isobaric species, MS/MS analysis was not 
conclusive.  
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Figure 3.10 PCA-DA loading plots show a) a clear separation of treatment groups on the score chart and b) the weighting chart of all the 
ionic peaks. The significantly differing peaks of interest are found around the edges of the cluster and similar peaks are clustered around 
the middle. Principal component 1 = 51.4%, principal component 2 = 48.6% (n=3).
a) b) 
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Figure 3.11 Comparison of normalised signal intensity of ionic peaks between 
control, 0.8 and 4 µM treatments. The species shown are the most significantly 
higher/lower between treatment groups as determined by both an in-software t-
test and ANOVA (p<0.05) (n=3). 
3.3.2.4.1 Linear mixed effects analysis 
As well as the PCA-DA method discussed previously, a linear mixed effects 
model was also used to define the best statistical analysis method for this data. 
The resulting 18 ionic species and the corresponding F-values (overall 
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significance) are listed in Table 3.4. The data is also displayed in scatter graph 
form, sorted into random effects (batch and culture) and fixed effects (dose) in 
Appendix chapter 3 figures 10 and 11. The random effects were determined to 
not have a significance on the fixed effect variance. The data was displayed this 
way to show the high variability present and highlight the necessity for the three 
separate experiments with three biological and three technical replicates in this 
study in order to obtain significant data. The individual p-values of differences 
between treatment groups are given in appendix chapter 3 table 1. For the ionic 
species which were only discovered using the ANOVA method the individual p-
values can only be found in appendix chapter 3 table 1 and not in appendix 
chapter 3 figures 1-9. 
 
Table 3.4 A list of doxorubicin treatment dose dependant significantly differing 
ionic species produced using an ANOVA test. Significance is represented by an 
F-value for which the significance threshold was 1x10-5. 10 highlighted species 
(in pink) also appeared as significant in the in-software statistical test. 
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Ten ionic species (highlighted in Table 3.4) were detected as significant in both 
statistical tests (Figure 3.12), which may be indicative of the strong significance 
of these ionic species in drug response.  
  
Figure 3.12 Venn diagram representing the difference between the statistical 
tests used. 10 of the ionic species ‘hits’ were matched between the two methods. 
The less stringent in-software test identified 32 unique ionic species and the 
mixed effects ANOVA identified 8 unique ionic species. 
3.4 Discussion 
The aim of this chapter was to determine the effect of chemotherapeutics on 2D 
and 3D models of osteosarcoma using mass spectrometry imaging. The dose 
response of SAOS-2 osteosarcoma monolayer cells to a small panel of 
chemotherapeutics was determined and doxorubicin was selected as a candidate 
for testing in 3D cell culture due to its effectiveness in 2D viability experiments. 
The metabolomic and lipidomic differences between the different treatment 
groups were then analysed using MALDI-MSI, including doxorubicin itself, in 
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order to identify novel molecules involved in drug response. Significantly differing 
ionic species were identified using DA-PCA and significance of these confirmed 
using an in-software statistical method as well as a more stringent mixed effects 
ANOVA model. 
3.4.1 Effect of treatment on viability of 2D cell cultured 
SAOS-2 cells 
Treatment of 2D SAOS-2 cells with paclitaxel, vinblastine, doxorubicin and a 
combination treatment of doxorubicin and paclitaxel all resulted in a decrease in 
cell viability. Paclitaxel induced a viability drop of nearly 50% compared to control 
at 10nM concentration, which did not increase significantly with higher 
concentrations of therapeutic. Because of this drop and a lack of further dose 
dependant response the IC50 could not be determined. This may be a result of 
the drugs mechanism of action, as paclitaxel blocks cells in the G2/M phase of 
the cell cycle which leads to an inability to form a mitotic apparatus (Horwitz, 
1994). A further decrease in viability was seen at longer treatment times as this 
may allow more cells to enter the susceptible phase of the cell cycle (Straubinger, 
1996). Vinblastine had a more significant effect on SAOS-2 cell viability. 
Vinblastine treatment showed a dose-dependent response, although this was not 
fully effective on all the cell viability within the culture. Even at longer treatment 
times (up to 72 hours) an unaffected cell population remained, either due to slow 
proliferation or cell cycle arrest. In the cases where there still remains a 
population of active cells after treatment the level of apoptosis should be 
assessed. The absence of a significant decrease in cell viability may also be due 
to osteosarcoma drug resistance mechanisms, such as overexpression of ATP-
binding cassette (ABC) drug transporters which cause decreased drug uptake 
and increased drug efflux (Li et al., 2016). To overcome these mechanisms  
research has been dedicated to the use of combination therapy to prevent drug 
resistance. The potential of combination therapy was demonstrated by Yang et 
al. who used a combination of a Pgp inhibitor  NSC23925 and paclitaxel treatment 
on osteosarcoma cell lines aided in preserving their chemotherapeutic sensitivity 
(Yang et al., 2014). 
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doxorubicin treatment reduced cell viability in 2D cultures with an IC50 of 1.09µM. 
The IC50 obtained with a combination treatment of paclitaxel and doxorubicin was 
lower (IC50= 0.9µM) however this was not shown to be significantly higher than 
single dose experiments by Excess Over Bliss calculations, as the combined 
effect is not significantly higher (>15% cut-off value is commonly used) than the 
sum of the two treatments. As doxorubicin presented the largest dose dependent 
response out of the drug panel it was chosen for further testing on the 3D SAOS-
2 model.  
3.4.2 Effect of doxorubicin on 3D cell culture 
A large difference in effect was observed in the 3D cell culture model compared 
to the 2D cell response. At a longer treatment time of 48 hours, compared to 36 
hours, and nearly 4 times higher concentration (4uM compared to IC50 of 1.09µM) 
the cell viability was not significantly decreased in the 3D cell culture model. This 
difference could be due to the barrier-like environment of the spheroid structures 
preventing direct access of the drug to all cells within the culture. However, 
fluorescence microscopy and MSI results confirm that the drug penetrated the 
whole aggregate by the end of the 48-hour treatment period. Difference in 
response between 2D and 3D cell cultures could also be due to a decrease in 
proliferation or an increased expression of drug resistance mechanisms, such as  
ABC drug transporters. As doxorubicin-induced DNA damage predominantly 
occurs in the G2 phase of the cell-cycle reduction in cell proliferation is an 
important factor to increased resistance. A spheroid structure will consist of 
proliferating and quiescent regions which reduces the percentage of proliferating 
cells at a set time and reduces the number of cells entering the G2 phase of the 
cell cycle. An increase in resistance to doxorubicin in 3D cell cultures was also 
observed by Rimann et al. who observed higher resistance to treatment by the 
slower growing osteosarcoma HOS cell line (Rimann et al., 2014). They also only 
observed a response to doxorubicin in the 3D model for chondroblastic 
osteosarcoma samples, which suggests changes in drug resistance mechanisms. 
ABC transporter-mediated drug efflux has been demonstrated as a relevant 
mechanism in doxorubicin resistance and inhibition of this mechanism lead to 
reduction in resistance (Fanelli et al., 2016). There are several novel therapeutic 
treatments in development based on this knowledge including ABCB1 inhibitors, 
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protein kinase inhibitors, use of doxorubicin derivatives and nanodrug delivery 
systems (Hattinger et al., 2017). The reduction in response could also be due to 
a change in drug inactivation pathways. For example, in osteosarcoma cell lines, 
xenografts and patients  a higher expression of glutathione S-transferase P1 
(GSTP1) was correlated to a poorer response. Additionally, inhibition of this 
enzyme in combination with treatment improved outcome (Pasello et al., 2008; 
Bruheim et al., 2004).  
An increase in doxorubicin resistance within 3D cell culture compared to 2D is 
consistent with literature for the SAOS-2 cell line and other cell lines (Rimann et 
al., 2014; Arai et al., 2013), though the difference is more marked in this study. 
The IC50 values determined for 2D and 3D cultures of SAOS-2 cells vary as 
different treatment times, assay types and 3D cell culture methods have been 
used, but all observe an increase in resistance to doxorubicin in 3D cell cultures. 
Rimann and colleagues determined the 2D IC50 value for SAOS-2 of 0.12µM and 
3D value of 0.3µM after 72 hour treatment (Rimann et al., 2014). Baek and 
colleagues showed a 2D IC50 value of 0.1241µM and 3D value of 0.341µM after 
24hrs of treatment with no further decrease in cell viability with longer treatments 
(Baek et al., 2016). The Arai research group showed a 2D IC50 value of 0.19mM 
and 3D value of 0.47mM after 48 hours of treatment (Arai et al., 2013). As all of 
these groups used different spheroid production techniques and different ways to 
treat and compare groups it is quite difficult to correlate the data. The lack of 
standardized and consistent 3D culturing systems thus far is a factor which 
affects reproducibility and reliability of drug screening (Verjans et al., 2018). 
 
Table 3.5 A summary of comparisons between 2D and 3D cultured SAOS-2 cell 
viability response to Doxorubicin. 
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3.4.3 Detection of doxorubicin by MALDI-MSI  
The detection and quantification of doxorubicin and its metabolites by LC-MS in 
several biological matrices has been validated previously (Mazzucchelli et al., 
2017). However, MALDI-MS imaging capabilities to detect and quantify 
doxorubicin at lower concentrations (<25µM) are not as efficient due to lack of 
the LC separation modality. Detection is currently only possible at higher 
concentrations (~30µM) or with a high mass resolution instrument due to 
interference of abundant surrounding lipid peaks. Doxorubicin is a fluorescent 
molecule, therefore its distribution is commonly monitored using fluorescent 
imaging. However, there are well-known limitations associated with this method, 
such as variation in the fluorescent signal due to DNA, histone binding and its 
location in cell membranes, cytoplasm and nucleoplasm. It is often measured at 
early timepoints for this reason (Mohan & Rapoport, 2010).  The potential benefit 
of mass spectrometry imaging is that the doxorubicin molecule itself is monitored 
and may be more accurate at detecting and quantifying doxorubicin but also that 
it can distinguish the drug and its metabolites, as has been demonstrated recently 
by the Hummon group (Lukowski et al., 2017). However, a limit of detection (LOD) 
was not published for this method and the concentration used (30µM) was not 
necessarily treatment relevant. Doxorubicin treatment of osteosarcoma patients 
ranges from 40-60mg/m2 which translates to a Cmax (maximum plasma 
concentration) of 3,660ng/ml which is equal to 6.73 M/L (Liston & Davis, 2017). 
Considering that not all of the drug within patient serum will reach the 
osteosarcoma, the assumed concentration value would be much lower than 
30M. In fact little is published about the achievable LOD of doxorubicin, though 
the technical challenges have been noted (Baluya et al., 2017). Use of a novel 
binary matrix in this chapter to observe doxorubicin by MALDI-MS led to a large 
improvement, of more than 10-fold, in LOD and LOQ, compared to the 
conventionally used 5mg/mL α-CHCA matrix (Table 3.3). A combination of α-
CHCA and DHB has previously been used to improve performance for peptide 
glycan analysis. However, to our knowledge, nothing has been published on the 
use of the matrix combination on small molecules or its optimisation for an 
imaging modality (Laštovičková et al., 2009; Laugesen & Roepstorff, 2003).  
However, even with the improved sensitivity, the limit of detection was slightly 
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higher than the predetermined IC50 of doxorubicin treatment in this study (1.64µM 
compared to 1.09µM) and the limit of quantification is higher than the highest 
treatment concentration used for 3D cell cultures in this study. However, the lower 
LOD will aid in future detection of the drug within models where higher 
concentrations of doxorubicin are used.  
The LOD and LOQ of doxorubicin would also be improved by using a higher mass 
resolution instrument. The approach is demonstrated by using an FT-ICR 
instrument, where doxorubicin is identified more easily within the 4M and 0.8M 
treated spheroid aggregates (Figure 3.9).  
3.4.4 Detection of the metabolomic and lipidomic 
doxorubicin response in SAOS-2 spheroid aggregates by 
MALDI-MSI 
The metabolomic and lipidomic response of spheroid aggregates was analysed 
using a PCA-DA method, which separated the most significantly differing 
components between the three treatment groups (0, 0.8, 4M) which were 
analysed using MALDI-MSI. Several masses were significantly up/down 
regulated and 10 of those were significant in both statistical analyses used. 
Interestingly ADP was found to be depleted to a level below detection in the 4µM 
doxorubicin treated samples (Figure 3.9). This reduction due to drug treatment is 
expected for ATP, however the fate of ADP during treatment of cancer is not as 
well described. Although this was not reported in the literature, it was shown in 
the spheroid aggregate imaging experiments where a dose dependant ADP 
concentration was observed even though the cell viability remained stable. The 
resazurin assay used to monitor cell viability in this study was based on reduction 
of resazurin by the electron transport system therefore arguably is less affected 
by the reduction in phosphate or irreversible binding of ADP. The reduction in 
signal observed could be due to apoptosis dependent changes of the glycolytic 
pathway (Pradelli et al., 2014). Samples would require activated caspase-3 
staining after treatment to specifically observe differences in apoptotic cell count 
rather than total cell viability. Reduction of ADP could be due to increased 
Poly(ADP-ribose) Polymerase-1 (PARP) expression. PARP is activated by DNA 
damage and PARP inhibitors combined with chemotherapeutics have shown a 
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significant effect in several osteosarcoma cell lines, therefore expression and 
activation of this should be investigated within the 3D model (Engert et al., 2017). 
Reduction could also be due to a classic drug resistance response involving efflux 
of doxorubicin by ABC transporters. These efflux pumps require a constant 
supply of ATP which reduces the overall levels of the drug within the cell and 
decreases it’s energy dependent activity (Tacar et al., 2013; Gottesman et al., 
2002). On the other hand, there may be a more simple instrument related 
explanation. During the desorption ionisation process of MALDI phosphate group 
containing molecules may lose these groups and display reduced masses. As a 
reduction in ATP with treatment is expected it could be that a reduction in ATP 
signal would also reduce apparent ADP signal. 
Several unknown ionic species were found to be significantly up/down-regulated 
with Doxorubicin treatment. These were putatively identified using database 
searching. Ionic species m/z 335.0617 was putatively identified in the Human 
Metabolome Database as S-nitrosoglutathione (GSNO) (15ppm), an endogenous 
nitric oxide (NO) carrier which plays a critical role in redox based NO signalling. 
This molecule has been shown to induce increased expression of stress 
response genes and proteins, such as hypoxia-inducible factor 1 (HIF-1) and  
nuclear factor-κB (NF-κB) and has been implicated as a contributor in various 
disease states (Broniowska et al., 2013; Gaston, 2003). Ionic species m/z 
364.0735 was identified as 2-S-glutathionyl acetate M-H (23ppm) which was 
recognised as a product of CYP2E1 metabolism and GSH conjugation of drugs 
such as 1,1-Dichloroethylene Epoxide and Vinylidene Chloride (Forkert, 1999; 
Liebler et al., 1985). CYP2E1 is a drug metabolising enzyme with a broad 
substrate selectivity and a preference for low molecular weight substrates, 
therefore it is possible that it may also be involved in the breakdown pathway of 
Doxorubicin in osteosarcoma (Harrelson et al., 2007). This may be an indicator 
of differential expression of cytochrome P450 enzymes in osteosarcoma as a 
chemoresistance response. Differential expression in P450 enzymes was 
previously reported in rhabdomyosarcoma where expression of CYP2E1, 
amongst other enzymes was expressed significantly higher in tumour tissue 
(Molina-Ortiz et al., 2014). Another putative identification of potential interest to 
the study of osteosarcoma drug resistance was m/z 378.0869 which was 
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identified as S-Lactoylglutathione (28ppm). S-Lactoylglutathione is a known 
product of the Glyoxalase I (GLO1) enzyme. Elevated expression of GLO1 is 
significantly associated with many different cancer types, such as squamous cell 
carcinoma, gastric, high-grade breast, pancreatic, sarcoma, bladder and renal 
cancers. Additionally, high expression has been specifically associated with local 
invasion, metastasis, growth and progression (Zou et al., 2015). A highly 
significant increase in ionic species m/z 396.0996 was also found. This was 
putatively identified as S-Adenosyl-4-methylthio-2-oxobutanoate (3ppm) which 
may be a factor in a modified methionine salvage pathway from 5’-
methylthioadenosine (MTA) which could be of interest in cancer cases as a 
regulator of apoptosis and proliferation (Albers, 2009). Putative lipid 
identifications were also retrieved from the LipidMaps database for ionic species 
m/z 714.5375, identified as PE(O-35:2) (0.0068Da); m/z 758.4969, identified as 
PS(34:2) (0.0009Da); m/z 765.5488, identified as PA(41:4) (0.0048Da); m/z 
791.5778, identified as PG(37:0) (0.0030Da); and m/z 858.8311, identified as 1-
O-behenoyl-Cer(d34:1) (0.0027Da). Although the lipid identifications listed are 
not directly associated with any known osteosarcoma pathways, they are worth 
investigating as possible markers of drug response. Furthermore, many of the 
significantly differing small molecules were not identified in the database 
searches and further investigation into the identities of these should be done, as 
these could be novel or unique markers for osteosarcoma drug response. 
Unfortunately, due to the small sample area (~1mm) and difficulty in obtaining 
MS/MS signal from these low abundance molecules due to interference from 
isobaric species, their identities were not confirmed. This issue could be 
circumvented by running LC-MS of pooled spheroid aggregate sections in order 
to increase detection of the peaks of interest and improve MS/MS signal, as 
reported previously (Acland et al., 2018). Alternative methods could also be used 
to preserve some of the spatial localisation. For example, the Hummon group 
developed a method utilising serial trypsinisation to strip layers of cells from a 
spheroid and subsequent collection and extraction for LC-MS analysis (Feist et 
al., 2017). Another alternative would be to use laser capture microdissection to 
dissect the spheroid aggregate regions and collect them for LC-MS analysis, 
which can be done after using the sample for imaging, as has been recently 
 
 
121 
demonstrated (Marialaura Dilillo et al., 2017). Or methods such as Liquid 
Extraction Surface Analysis Mass Spectrometry (LESA-MS) could be used, as 
these have a higher extraction efficiency, though the spatial resolution (~1mm) of 
the analysis may not be sufficient (Eikel et al., 2011). 
3.5 Concluding remarks 
In summary, a panel of 4 drugs was assessed on the SAOS-2 osteosarcoma cell 
line and doxorubicin was selected for further testing. A large difference in cell 
viability was observed between the 2D and 3D models of the tumour. Analysis of 
doxorubicin imaging inside a spheroid aggregate model of osteosarcoma was 
improved from a published concentration of 30M to an LOD of 1.644µM. The 
optimised sample preparation method could also be applied to tissue and in-
solution in future experiments, as required. Quantification of the drug within the 
3D cell culture sample set was not successful due to the limit of quantification 
remaining above the concentration range used. An untargeted MALDI-MSI 
analysis of treated spheroid aggregates was performed where a significant 
difference in the small molecule composition was observed between untreated 
and treated osteosarcoma spheroid aggregates as well as differences between 
treatment concentrations. These changes were observed despite no significant 
decrease in overall cell viability in the treated 3D model. Biologically significant 
putative identities, such as GSNO, 2-S-glutathionyl acetate and S-
Lactoylglutathione, were assigned to several ionic species. The significantly 
varying species could not be identified using MS/MS due to sample size and 
interfering isobaric species. Therefore, the samples should be analysed 
additionally using a different method, such as LC-MS, to confirm the identities of 
the species of interest. 
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Chapter 4: Peptide and protein 
MS analysis of cancer 
spheroids and development of 
QMSI   
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4.1 Introduction 
Conventional osteosarcoma (OS), the major subtype of OS, consists of complex 
karyotypes with the presence of multiple chromosomal abnormalities (Martin et 
al., 2012; Hoogerwerf et al., 1994). This atypically high level of chromosomal 
instability is thought to cause intra and inter-tumour heterogeneity, which 
complicates diagnosis and treatment (Kovac et al., 2015). It has a broad spectrum 
of morphology and is currently sub-classified into 8 different histological subtypes. 
Additionally, osteosarcoma, primary or secondary, also has a broad 
immunoprofile which lacks diagnostic specificity (Fletcher et al., 2013). A lack of 
specific diagnostic markers and full understanding of the molecular changes 
involved in the tumour subtypes in combination with the rarity of the disease 
contribute to difficulty in diagnosis and treatment of osteosarcoma (Zhong et al., 
2017; Kong & Hansen, 2009). 
4.1.1 MSI of cancer heterogeneity 
Mass spectrometry imaging is one of the analysis methods applied to enable the 
study of cancer heterogeneity (Bateman & Conrads, 2018). The technique is well 
suited for the analysis of heterogeneous samples as it can be used for untargeted, 
multiplex analysis of tissue or cell-based models and preserves spatial 
localisation of the molecules of interest. Therefore, within a single imaging 
experiment several molecular species can be visualised in order to elucidate 
differing areas of the sample (Balluff et al., 2017). MSI has recently been used 
for discovery of high-grade sarcoma protein biomarkers (Lou et al., 2016). Lou 
and colleagues additionally focused specifically on the identification of survival 
associated markers for high-grade OS, leiomyosarcoma (LMS), 
myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS) and 
found several proteins associated with poor and good responses to treatment 
within different sarcoma types (Lou et al., 2016). 
4.1.2 Quantification of proteins and peptides 
Subsequent quantification of proteins and peptides within a tissue or culture 
model improve the analysis further. The current methods to do so are either tissue 
homogenisation dependent (e.g. LC-MS, western blot), which remove spatial 
information, or are limited in the amount of proteins that can be analysed in a 
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single experiment (e.g. IHC). MALDI-MS imaging is a multiplex method which is 
also able to preserve spatial information. A novel technique using this method 
produced a recombinant ‘IMS-TAG’ protein which could be trypsinised into 
several standard proteotypic peptides in order to validate the presence of specific 
proteins within tissue (Cole et al., 2013).  Using this method a recombinant 
standard protein, made up of proteotypic (protein specific) peptide standards, 
could be trypsinised and prepared alongside the sample. Then appropriate 
isotopically labelled standards would be homogenously distributed across the 
sample and used as matched external standards for absolute quantification 
purposes. The standard would potentially be representative of the tissue as it 
would go through the same sample preparation process. This is similar to the 
QconCAT protein technique which has been adapted for quantification of 
peptides within cancer samples (Goddard et al., 2016; Chen et al., 2014; Beynon 
et al., 2005). Development of a way to quantify proteins using MSI would aid 
investigations of the effect of treatment. Use of isotopically labelled standards 
may mitigate many of the heterogeneity, extraction, and suppression effects 
commonly encountered in MALDI MSI experiments. With the development of this 
technique, endogenous protein and biotherapeutics could be quantified within a 
culture model or tissue and the intensities localised to specific regions within the 
sample, providing accurate region-specific quantitative information. 
4.1.3 Proteomic analysis of 3D osteosarcoma models 
3D cell culture models of sarcoma have been shown to have different protein 
expression patterns compared to monolayers. These were largely found to 
correspond to a change toward a more stressful environment containing nutrient 
deficient and oxygen depleted areas as well as a decrease in proliferation 
(Gebhard et al., 2018). However, it was determined that certain acutely localised 
protein species may have been 'buried' within the highly abundant peaks, as the 
whole spheroid was homogenised. MSI could be used to analyse proteins and 
peptides within osteosarcoma tissue and cell culture models in order to determine 
treatment dependent over/under expression. In the case of MSI, spatial 
distribution data would be preserved and species which are only present in a 
specific area of interest within the model may be easier to detect. This would aid 
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in the discovery of novel inhibitors of chemo-resistance due to increased 
understanding of sites of action and the mechanisms of resistance. 
4.1.4 Chapter aims 
To gain further knowledge of osteosarcoma and find solutions to chemo-
resistance, spheroid aggregate peptide and protein changes in response to 
treatment should be observed. The aims of this chapter were to develop methods 
for the peptide analysis of the osteosarcoma spheroid aggregate model. 
Doxorubicin-treated osteosarcoma spheroid aggregates were analysed using 
MALDI-MSI and several putative peptides were identified. Proteotypic peptide 
standard arrays were produced using the osteosarcoma cell line SAOS-2 and the 
functionality and reproducibility of these were assessed for future MALDI-MSI 
peptide quantification experiments. These could potentially enable quantification 
of multiple peptides within a sample whilst maintaining spatial distribution 
information. 
  
 
 
126 
4.2 Materials and Methods 
4.2.1 Materials 
Peptide standards for heat shock protein 70 (VTHAVVTVPAYFNDAQR), heat 
shock protein 90 (GVVDSEDLPLNISR) and actin (AVFPSIVGRPR) and their 13C, 
14N labelled versions were purchased from Cambridge Research Biochemicals 
(Billingham, UK). A custom SpikeMix mixture of peptide standards (Appendix 
chapter 4 table 1) and a SpikeMix 1000 labelled peptide mixture (Appendix 
chapter 4 table 2) were purchased from JPT Peptide Technologies (Berlin, 
Germany). 
4.2.1.1 Production of 3 peptide standard 
Peptide standards were dissolved in 1:4 ACN:0.1M ammonium bicarbonate 
solution in order to produce a solution of a mixture of the three containing 
180pmol/µL of each peptide in solution. This standard mix was then used in the 
3 peptide cell plug array (Section 4.2.3). The same stock mixture was produced 
with the three labelled standards for spraying on top of the sample. 
4.2.2 Cell culture 
Initial cell culture conditions were performed as stated in section 2.3.2. Once 
confluent, SAOS-2 cells were trypsinised then used for cell plug array production. 
SAOS-2 spheroid aggregates were cultured according to the method in section 
2.2.3. These were treated and harvested as stated in chapter 2 with the addition 
of a PBS wash step before embedding. 
4.2.3 Production of peptide arrays 
As described in Chapter 3, gelatin blocks were made by pouring 20% (w/v in 
dH2O) gelatin into ice cube moulds, setting the moulds in the fridge for at least 4 
hours and transferring to -80oC for freezing overnight and storage. Each block 
was transferred from -80oC to a -30oC cryostat and the top of the block was cut 
to produce an even surface. Nine holes were then drilled into the frozen block at 
a drill diameter of 2.5mm and depth of 10mm using a pillar drill. The block was 
placed back into -80oC storage before the loading process. During the cell loading 
process the cell plug was mounted in a cryostat set to -30oC. 
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SAOS-2 cells were cultured in monolayer as in section 2.3.2 until confluent. Then 
they were trypsinised, counted, centrifuged and washed with 1:4 ACN:0.1M 
ammonium bicarbonate solution and the supernatant removed fully. The number 
of cells required to make a full cell plug array was ≥70,000,000 cells (6 hole array), 
≥10,500,000 cells (9 hole array). A range of peptide mix concentrations were 
produced in 1:4 ACN:0.1M Ammonium bicarbonate solution (3 peptide array- 0, 
1.5, 6, 15, 30, 45, 60, 90, 180 pmol/µL) (120 peptide array- 0, 1.5, 15, 30, 60, 90 
pmol/µL). The cells were mixed with peptide standards 2:1 cell: peptide v:v. In 
order to pipette the viscous cells the pipette tip was cut off. Immediately after 
mixing cells with standard the mixture was deposited inside a cell plug hole. Once 
all the cell:peptide mixtures were deposited inside the cell plug this was stored in 
a sealed container in -80oC. The resultant peptide concentrations after mixing 
were diluted by a factor of 3 (3 peptide array- 0, 0.5, 2, 5, 10, 15, 20, 30, 60 
pmol/µL) (120 peptide array- 0, 0.5, 5, 10, 20, 30 pmol/µL). 
 
Figure 4.1 Peptide array block schematic. Blocks were made from frozen 20% 
(w:v) gelatin and 2.5mm diameter, 10mm depth holes were filled with a cell and 
peptide standard mixture (2:1 (v:v)). All final concentrations stated were at 
pmol/L. The control cell plug was offset in order to aid coordination. 
4.2.4 MSI of peptide arrays 
4.2.4.1 Sample preparation 
The sample preparation for the spheroid aggregates was identical to Chapter 
2.2.4.2. Sectioning of the cell plug array and spheroids was performed as 
described in section 2.2.4.1, however optimal sections were achieved with the 
cell plug array when this was sectioned transferred directly from -80oC. 
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All sample sections were taken straight after cryosectioning or from -80oC storage 
and immediately placed in a vacuum desiccator for ~15 minutes prior to wash 
steps. The sections were then washed 1min in 70% EtOH, 1min in 100% EtOH, 
dipped 10 times in dH20, 1min in 70% EtOH and 1min in 100% EtOH. 
Labelled peptide standards were applied to sections using the SunCollect™ 
automated sprayer. The 3 peptide Q-TOF test array was coated with the 
corresponding labelled peptide mix (15pmol/µL, 1 layer) to produce a 0.75 
pmol/mm2 layer on top of the section. The 3 peptide standard arrays were coated 
with labelled peptide mix (0.94 pmol/µL, 2 layers) to produce a 92.6 (± 0.9) 
fmol/mm2 layer on top of the sample. Due to a limited amount of the 1000 labelled 
peptide mixture (16.67 fmol/µL, 6 layers) the 120 peptide arrays were coated with 
a 2.48 (± 0.031) fmol/mm2 layer which was not high enough to detect, therefore 
these samples could not be normalised using the labelled standards. All peptides 
were sprayed with the following settings- speed x: low 7, speed y: medium 1, Z 
position: 30. 
Following the standard application, trypsin (20ng/µL, dH2O) was applied using 
the SunCollect™ automated sprayer (15 layers, 10µL/min) (speed x: low 7, speed 
y: medium 1, Z position: 40) to produce approximately 3.35 µg/cm2. Following 
overnight incubation at 37oC in a saturated environment (50% MeOH), matrix was 
applied to the section. The initial Q-TOF test 3 peptide array section was not 
trypsinised as the 3 peptides did not require trypsinisation in order to be seen on 
the spectrum. Three concentrations (20, 30 and 60 pmol/µL) of the labelled 
peptide mix were also spotted (1µL) on the initial Q-TOF test slide before matrix 
application. 
The matrix was applied to the sample section using the SunCollect™ automated 
sprayer. For Q-TOF experiments α-CHCA (5mg/mL, 70:30 ACN:0.1% TFA) was 
used. Five layers of matrix were applied at 3.5 μL/min for the first layer and 3 
μL/min for the remaining four layers. For the FT-ICR experiments DHB (25mg/mL, 
50% ACN, 0.1% TFA) was used as a matrix. Three layers of DHB matrix were 
applied (at 10, 35 and 35 µL/min) (speed x: low 7, speed y: medium 1, Z position: 
25). 
4.2.4.2 Quadrupole-Time-of-flight MSI of 3 peptide array 
 
 
129 
For an initial evaluation of the array, a modified MALDI-Q-TOF; Q-Star Pulsar-i™ 
(Applied Biosystems/MDS Sciex, Concord Ontario, Canada) was used, as it is a 
high throughput instrument useful for preliminary testing. These modifications 
have been reported elsewhere (Trim et al., 2010). Data was acquired in positive 
mode using an NdYVO4 laser (Elforlight “SPOT”, Daventry, UK). Images of 
150μm pixel size were acquired. Data was acquired over an m/z range of 700-
2000. 
4.2.4.3 Fourier-transform ion cyclotron resonance MSI of 3 and 
120 peptide arrays 
MALDI-FTICR-MSI of arrays was performed on a 9.4T SolariX XR mass 
spectrometer (Bruker Daltonics, Germany) in positive-ion mode, using 150 laser 
shots per spot and 75 μm pixel size. This instrument was used for the peptide 
quantification specifically because of its high resolving power (>100,000). Data 
was acquired in a m/z range from 700 to 2000 Da. Data acquisition was 
performed using FtmsControl (Bruker Daltonics, Germany), and visualizations 
were obtained from flexImaging 4.0 (Bruker Daltonics, Germany). 
4.2.4.4 Data Analysis 
After conversion of images to imzML format using FlexImaging 4.0 (Bruker 
Daltonics, Germany) MSIQuant software was used in order to visualise data and 
to extract average ROI signal for each of the spiked peptide standard areas. 
Different normalisation methods were used in order to analyse reproducibility (no 
normalisation, root mean square, label and combined). The data was visualised 
and linear regression was performed using GraphPad Prism v7 software 
(GraphPad Software, USA). The R2 values were exported and the graphs were 
analysed visually to determine best fit. The LOD and LOQ were determined as 
described previously in chapter 3 (Section 3.2.4). 
4.2.5 MSI of spheroid aggregates 
4.2.5.1 Sample preparation 
A 48 hour 4 µM doxorubicin treated spheroid aggregate was sectioned as in 
Chapter 2 at 10µm, making sure to sample a section in the middle region of the 
spheroid aggregate. The same H+E comparison was used for this section as in 
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chapter 2 as a serial section was used. The trypsin and matrix deposition protocol 
used was identical to Section 4.2.4.1. 48-hour 0, 0.8 and 4uM spheroid 
aggregates, with trypsin spotted (0.5µL) rather than sprayed, were also imaged. 
4.2.5.2 MALDI-MSI of peptides 
Imaging of spheroid aggregates was executed using a Synapt G2. Images of 
60μm pixel size were acquired. Data were acquired over an m/z range of 700–
2,000 in positive mode analysis. The ion mobility function was used in order to 
improve separation of peaks. Data acquisition and analysis was performed using 
MassLynx v4.1 (Waters, UK) and High Definition Imaging (HDI) Software (Waters, 
UK). 
4.2.5.3 Data processing 
For the spotted trypsin samples regions of interest (ROIs) containing whole 
spheroid aggregates were selected in HDI and exported as average spectra into 
MassLynx software. They were then exported as .txt files and peaks were 
selected using Mmass v5 open source software (Strohalm et al., 2010). Peptide 
predictions were based on using the Mascot server. Up to two missed cleavages 
were allowed and methionine oxidation was set as a variable modification. 
Peptide assignments were made with a tolerance of 100ppm. As MS/MS was not 
performed the identities of these are still putative. 
4.3 Results 
4.3.1 MSI of abundant peptides within osteosarcoma 
spheroid aggregates 
A trypsin digest of a spheroid aggregate was performed in order to observe 
protein intra-heterogeneity within the mass. The tryptic digest produced many 
proteotypic peptide peaks which were then used for putative protein 
identifications within the MASCOT database. Two peptide peaks in particular 
were localised within specific areas of the spheroid aggregate (Figure 4.2). 
Peptide species m/z 1032 was localised within the inner necrotic region of the 
spheroid aggregate and was putatively identified as Histone H3.1. Peptide 
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species m/z 1117 was localised within the perinecrotic region and was putatively 
identified as Hypoxia- Inducible Factor 1-alpha (HIF-1α).  
 
Figure 4.2 MSI Histone H3.1 (red) and HIF-1α (green) peptide signals m/z 1032 
and 1117 respectively. Histone H3.1 signal is highest within the inner necrotic 
region of the spheroid aggregate and HIF-1α signal is highest in the perinecrotic 
region. H+E scale bar = 500m. 
Trypsin digestion of spheroid aggregate samples produced peptide molecular 
images for each treatment group. For each treatment group an average spectrum 
was used for a database search of the peptide species within. The first 4 protein 
hits within the database search of the most abundant peaks in each treatment 
group were collected (Table 4.1). These should not be compared between groups 
as they are just the most abundant peaks in each sample. A larger response 
comparison experiment should be performed in future in order to establish clear, 
significant differences due to treatment. 
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Table 4.1 MASCOT server derived protein identifications for three doxorubicin 
treatment groups (0, 0.8, 4µM). The identifications are for the four most abundant 
peptide peaks and no significance should be drawn for differences between drug 
responses in this case. 
4.3.2 Peptide quantification 
Further experiments were conducted towards quantification of peptides and 
proteins within the spheroid aggregates. Achieving protein quantification whilst 
maintaining spatial information will enable the accurate abundance determination 
of biopharmaceuticals and endogenous molecules. 
4.3.2.1 Use of Q-TOF MSI for quantification of a 3-peptide mix 
Initially, a three-peptide array was produced consisting of proteotypic peptides for 
Actin, HSP 70 and HSP 90 (Section 4.2.1). This array was covered with a 
homogenous layer of the corresponding labelled peptides and analysed using 
MALDI-MSI (Figure 4.3). Unlabelled peptide species signals were concentration 
dependant as expected. As the peptides were observed at low concentration 
levels and the signals were not seen to plateau, the assumption was made that 
during analysis none of the peptides were ‘saturated’ and that a linear relationship 
could be observed. The sprayed labelled standard signal was relatively 
homogenous throughout the sample, although some ‘hot spots’ of higher signal 
were present. Standard graphs were produced for each peptide H+ peak as well 
as their Na+ peak for both non- normalised data and internal standard normalised 
(Figure 4.4). Overall, the use of internal standard in this case lead to a poorer 
fitting regression. The best fit for the internal standard samples was dependent 
on the initial signal intensity of the peptide standard. For example, the HSP 70 
proteotypic peak was the least abundant (R2=0.4717), which showed a best fit 
value well below the chosen cut-off (R2=0.8), and the Actin peak was the most 
abundant (R2= 0.8426). Only the HSP 90 Na+ species had an observed 
improvement with internal standard normalisation (R2= 0.852 to 0.885). This was 
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also the only case with an improved LOD (From 28.46 pmol/µg to 24.62 pmol/µg) 
and LOQ (From 86.24 pmol/µg to 74.60 pmol/µg) but the values were still lower 
than the H+ peak (LOD= 24.54 pmol/µg, LOQ= 74.36 pmol/µg) (Table 4.2). 
Overall, the LOD and LOQ values were at the higher end of the standard array 
(>14 pmol/µg). The initial array additionally had three additional spots of the 
labelled standard mix on the right side of the array to observe the difference in 
signal between the array and standard spotting on glass as well as to observe 
any non-specific signal and saturation (Figure 4.3). These spots can be seen in 
the labelled peptide images as areas of higher signal, demonstrating the matrix 
suppression effects on the standards. The Na+ species for actin and HSP 90 
showed some non-specific, labelled peptide related signal in the spotted areas. 
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Figure 4.3 MSI of 3 peptide array of HSP-70, HSP-90 and actin peptide H+ and 
Na+ species as well as their labelled counterparts. A concentration dependent 
gradient can be observed for the embedded peptides with a consistent signal for 
the labelled peptides. Three spots on the right hand side of the images consist of 
the labelled peptide mix on the glass slide as control. 
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Figure 4.4 Three peptide mix (actin, HSP-90, HSP-70) standard graphs of pilot 
experiment. No normalisation results and label standard normalisation are shown. 
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Table 4.2 Three peptide mix (actin, HSP-70, HSP-90) LOD and LOQ values for 
pilot experiment. No normalisation results and label standard normalisation are 
shown. 
 
4.3.2.2 Use of FT-ICR-MSI for quantification of a 3 peptide mix 
array 
The 3-peptide standard array was then analysed using FT-ICR-MSI in triplicate. 
The overall intensities for all three peptides were increased compared to the Q-
TOF analysis along with the best fit values of the non-normalised data (average 
R2= 0.8963). Similarly to the previous analysis, the internal standard 
normalisation did not have a global improvement on the best fit values. For this 
experiment, the data was also normalised using root mean square (RMS) which 
did not have a significant overall increase in best fit. In the cases which arose 
with best fit values below the cut-off (R2= 0.8), a further investigation into the 
signal variation and a repeat experiment should be performed in order to identify 
the reason for the poor fit. If poor fit is consistent, then the peptide may be 
considered a poor candidate for quantification using this method as it would not 
meet the criteria. 
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Figure 4.5 Three peptide mix (HSP70, actin, HSP90) standard graphs for 3 
separate standard array FT-ICR-MSI experiments (labelled 1, 2, 3 in figure). 
Different types of normalisation - no normalisation, RMS, label and combined 
normalisation and an expanded view of the no normalisation lower concentration 
data is shown (n=3). 
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Table 4.3 Three peptide mix (actin, HSP-70, HSP-90) LOD and LOQ values for 
FT-ICR-MSI experiment. No normalisation, RMS normalised and label standard 
normalised results are shown. 
4.3.2.3 Use of FT-ICR-MSI for quantification of a 120 peptide mix 
array 
The 120-peptide standard array was analysed using FT-ICR-MSI in duplicate. 
Out of the 120 peptides present within the array, 25 were detected and all 
presented a concentration dependent trend (Figure 4.6 and Appendix chapter 4 
figures 1-3). Due to the low concentration of the internal standard applied, internal 
standard normalisation was not successful. The best fit values for the majority of 
the proteotypic peptides were above an acceptable value (R2>0.8). 
 
 
 
139 
 
Figure 4.6 120 peptide mix standard graphs for 2 separate standard array FT-
ICR-MSI experiments (labelled 1 and 2 in figure). No normalisation and RMS 
normalisation is shown (n=2). 
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Table 4.4 120 peptide mix LOD and LOQ values of FT-ICR-MSI experiment. A 
total of 25 proteotypic peptides were detected. No normalisation and RMS normalised 
results are shown. 
4.4 Discussion 
The aim of the chapter was to develop a method for the proteomic MSI of and 
quantification of proteins within spheroid aggregates of sarcoma. Several putative 
proteotypic peptides were identified in a concentration and location dependent 
manner. A novel method for protein quantification was further developed for use 
within the 3D model. The quantification method could potentially quantify as many 
as 25 proteotypic peptides within the sample in a single experiment. As this has 
not previously been reported for any amount of proteotypic peptides within an 
imaging experiment, it is a substantial amount which could be further increased 
with optimisation. 
4.4.1 Assessment of osteosarcoma spheroid aggregate 
peptide composition using MALDI-MSI 
A peptide species corresponding to histone H3.1 was located within the necrotic 
inner region of the spheroid aggregate. Histone H3.1 is a well-characterised core 
component of nucleosomes and is present at high levels in all cells within the 
model (Luger et al., 1997). However, it is also well known that histone proteins 
are released during cell death and elevated levels are often observed in the 
serum of cancer patients, due to presence of necrotic regions, which contain both 
necrotic and apoptotic cells (Holdenrieder et al., 2008). Release of the histone 
protein H3 from chromatin may increase the abundance of the corresponding 
peptide species as it may be more readily ionisable and has potential for use as 
a necrotic region marker within the model. Observation of a HIF-1α proteotypic 
peptide within the peri-necrotic region of the spheroid aggregate indicates the 
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presence of hypoxia within the model. HIF1 is rapidly degraded via the VHL-
mediated ubiquitin protease pathway under normoxic conditions (Greijer & van 
der Wall, 2004). However, under hypoxic conditions the degradation of HIF1 is 
decreased which leads to an accumulation of the protein. The presence of a large 
hypoxic region could be a driver of the doxorubicin drug resistance observed in 
the 3D model compared to 2D. Previous work has found a large association 
between hypoxia in osteosarcoma cell line and cytotoxic drug resistance, 
however they found this effect to be independent of HIF-1 (Adamski et al., 2013). 
Of the other putative proteins identified within the spheroid aggregates a few have 
potential associations with osteosarcoma. For example, SEMA6A (Semaphorin 
6A) is a member of the Semaphorin family, the members of which are identified 
as modifiers controlling tumour growth, angiogenesis and metastatic progression, 
and are abnormally expressed in several cancers (Rehman & Tamagnone, 2013). 
High levels of this protein were found in a study using the SAOS-2 cell line (Salah 
et al., 2015). Sacsin molecular chaperone (SACS) was also putatively identified 
as abundant in the high treatment sample. SACS is a chaperone protein which is 
thought to regulate HSP70 and HSP90, which are families of proteins responsible 
for cellular stress responses and are overexpressed in most tumours (Ménade et 
al., 2018; Murphy, 2013; Parfitt et al., 2009). It could be a potential marker of the 
osteosarcoma drug response and should be confirmed using MS/MS and an 
additional method such as IHC. 
The results derived from these preliminary experiments demonstrate the potential 
of using MSI on these treatments to extract useful information. There is further 
optimisation required in sample preparation and analysis in order to observe more 
proteotypic peptides and to enable tandem MS analysis for confirmation of 
species. The peptides discovered in the database search were based on the most 
abundant peaks within each sample and therefore cannot be classed as specific 
for that drug response. To completely reveal the proteomic drug response in this 
model several technical and biological repeats are required as well as a global 
multivariate comparison analysis of the data, as was performed in Chapter 3 with 
small molecules. The biological relevance of the protein species found during the 
untargeted imaging experiment should be further studied to discover proteomic 
markers of drug response. 
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4.4.2 Novel array method demonstrates quantification of up 
to 25 proteotypic peptides using MALDI-MSI 
All imaged cell plug arrays produced concentration dependent standard graphs 
with a majority of acceptable best fit values. The acceptable best fit cut-off value 
(measured as R2) was selected to be >0.8. This is lower than the typical cut-off 
value used of >0.95, which lowers the acceptable predictability power, however 
the margin of error for a proof-of-concept experiment is acceptable at the lower 
cut-off value. In future, with optimisation, this method may be able to achieve a 
higher predictive power and the R2 value cut-off can be raised to >0.95. The 
internal standard normalisation was not successful in improving best fit. This may 
be because further optimisation is needed of the labelled peptide concentration 
and application (Mirzaei et al., 2008). The way of applying a standard during an 
MSI experiment greatly alters it’s signal and must be optimised and validated 
(Chumbley et al., 2016). Out of 120 cancer related proteotypic peptides within the 
standard mix, 25 were identified by FT-ICR-MSI. The variability between separate 
experiments in the 120 peptide mix cases was lower than in the 3 peptide array 
experiments. This could be because the 120 peptide array peptides are only 
released once trypsinised and therefore are more stable throughout the sample 
preparation process in a folded protein form.  As well as stability, incomplete 
trypsinisation could be a factor for variation, which should be considered in future 
experiments (Mirzaei et al., 2008). As the quantification of proteotypic peptides 
has not been reported previously to be able to quantify 25 peptides in a single 
imaging experiment is a notable achievement. However, the method should be 
further optimised in the future in order to get a higher signal from the detected 
peptides and to increase the overall number of detected peptides. The 1000 
peptide labelled standard which was sprayed on top of the sample may be 
supressing overall signal coming from the sample and therefore decreasing the 
number of detectable peptides. The largest number of ionisable proteotypic 
peptides within a single experiment should be determined in future experiments, 
as 120 peptides, combined with corresponding labelled peptide application, may 
lead to overall ion suppression and loss of detection capability. By optimising the 
peptide standard amount and concentrations the number of peptides detected 
will be increased. Additionally, a more in-depth study of the visualised peptides 
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should be performed in order to see if there were structural reasons as to why 
these were detected as opposed to others. In general, some structures will be 
more readily ionisable than others and concentrations may need to be adjust 
accordingly in future mixed peptide standard arrays. 
In future experiments it may be useful to first normalise the peptide array 
determined concentration by the 0 pmol/µg control value. In some detected 
proteotypic peptide cases, such as F-actin-capping protein, subunit beta and 
Keratin type I cytoskeletal 14, the basal amount of peptide within the array is 
already quite high (>1000 a.u.) and in these cases accurate quantification of 
levels within a sample using the array would not be possible as the data would 
be skewed by the endogenous levels within the cells in the array. This may be an 
explanation of the poor best fit values these peptides are displaying. If the 
endogenous peptide concentration is already high, combining this with the 
standard will saturate the analysis. Checking the control values within the array 
can be used as a quality control step, however this issue may lead to an inability 
to quantify certain proteins in this manner. This is an issue that would also apply 
to on tissue spotting or mimetic tissue arrays of standards like the ones currently 
being used for MSI drug quantification (Groseclose & Castellino, 2013). However, 
in this case 2D cultured cells are used to produce the array and a 3D model is 
the sample to be quantified. The expression changes which occur due to cell 
culture method are expected to lead to an increase in the concentration of 
proteins of interest within the 3D culture model compared to the 2D cultured cells 
as the expression should be more similar to in vivo. This may aid the 
quantification process without having to alter the array and reduce its 
representability. This issue would however only occur when quantifying 
endogenous protein, rather than biopharmaceuticals, as these are not 
endogenously present within tissue or cell culture-based models. The technology 
developed could potentially be used with specifically selected proteotypic peptide 
arrays designed to assess levels of typical proteins of interest. The array model 
could also be expanded to quantification in other tissue types by changing the 
cell type within the array cores. 
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4.5 Concluding remarks 
To conclude, a method for the proteomic MALDI-MS imaging of spheroid 
aggregates was developed. Several putative proteotypic peptides were identified 
in a concentration and location dependent manner and this method can be further 
optimised and used for a large-scale drug response comparison study. This 
method will require further optimisation to achieve a greater abundance of 
proteotypic peptides per sample and can be used to observe proteomic inter- and 
intra-spheroid aggregate differences. Additionally, a novel cell plug array method 
for protein QMSI was further developed for use within the 3D model. The 
quantification method identified 25 proteotypic peptides in a single imaging 
experiment and has the potential to include a higher number of peptides with 
further optimisation. This method, after further validation, could be used in the 
future for absolute quantification of proteotypic peptides within tissues and 
alternative models using MALDI-MSI. 
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Chapter 5: Optimisation of 3D 
liver cell culture and MS 
analysis 
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5.1 Introduction 
5.1.1 The study of drug hepatoxicity 
An integral part of the drug discovery process is the testing of drug toxicity. It is 
vital to determine the absorption, distribution, metabolism and excretion (ADME) 
properties of a drug of interest and to determine its potential adverse outcome 
pathways (AOPs) before moving onto clinical trials (Figure 1.3). In recent years, 
animal models have undergone a substantial amount of criticism in the field, due 
to their inability to accurately and consistently predict human response to drugs 
and disease (Greek & Menache, 2013). Due to the limits of animal based models, 
such as inter-species variability, low throughput and experimental cost, scientists 
have been looking at alternative models for use in the drug development workflow. 
Among other organs, the liver is crucial when toxicity is concerned, as it is 
responsible for the metabolism of drugs and toxins. In fact hepatoxicity, in 
particular acute liver toxicity often termed drug-induced liver injury (DILI), has 
been the most common cause of safety-related withdrawal and non-approval of 
drugs by the FDA (Chen et al., 2011; Wysowski & Swartz, 2005; Temple, 2001).  
DILI has proven very difficult to predict with pre-clinical models and animal testing 
(Fontana et al., 2014). Consequently, research has focused on the development 
of functional 3D in vitro models for the testing of drug hepatotoxicity (Andersson, 
2017; Godoy et al., 2013). A cheap, simple way to predict DILI would be to use 
hepatoma cell lines, however several of these are known to have very little liver-
specific metabolic function compared to human hepatocytes (Andersson et al., 
2012). 3D cell culture has been recently utilized as a way of improving hepatoma 
cell line liver-specific metabolic activity (Takahashi et al., 2015).   
Acetaminophen (APAP) is one of the most widely used drugs with a well 
characterised biotransformation process (McGill et al., 2012). When consumed 
at a dose which exceeds recommended levels, patients experience acute liver 
toxicity due to the presence of a reactive intermediate metabolite, N‐acetyl‐p‐
benzoquinone imine (NAPQI), which depletes glutathione, an important 
antioxidant responsible for neutralising reactive molecules and modifies cellular 
proteins (McGill & Jaeschke, 2013). In the case of acetaminophen known altered 
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metabolic conditions can alter the hepatoxicity of the drug, therefore it is a useful 
drug to use for the validation of adverse outcome pathway analysis. 
5.1.2 Adverse outcome pathway analysis 
Whilst optimization of representative 3D cell cultures has advanced greatly there 
is still comparably little progress made with regard to analysis methods which can 
routinely be used in research and industry (End et al., 2017; Rimann & Graf-
Hausner, 2012). There are many mechanisms that are thought to cause DILI, for 
example formation of reactive metabolites, oxidative stress mitochondrial 
dysfunction or inhibition of bile salt excretion (Yuan & Kaplowitz, 2013). Ideally, 
an untargeted technique is required to elucidate these mechanisms. MSI, 
specifically Matrix-assisted laser desorption ionisation mass spectrometric 
imaging (MALDI-MSI) is an analytical technique with the ability to detect label-
free analytes with limited a priori knowledge and perform de novo discoveries, 
which allows it to be used in untargeted studies of biological samples (Day & 
Palubeckaite, 2017; Aichler & Walch, 2015). Several studies using MSI have 
focused on the analysis of drug distribution and endogenous molecule analysis 
in treated tissue such as intestine, tumour and skin (Nilsson et al., 2017; Giordano 
et al., 2016; Mitchell et al., 2015). 
5.1.3 pNIPAM-Laponite hydrogel 
In the following study, a 3D hydrogel-based model was developed. Hydrogels are 
3D cross-linked, highly hydrated polymer networks (Tibbitt & Anseth, 2009). 
These scaffolds are well suited to 3D cell culture as they are highly porous, 
biocompatible structures. A previously reported synthetic composite poly-N-
Isopropylacrylamide (pNIPAM)- Laponite® hydrogel was used for the 
experiments in this chapter (Figure 5.1) . The hydrogel design is based on the 
irreversible polymerisation of NIPAM using a thermal initiator, AIBN, which 
enables free radical polymerisation of pNIPAM chains anchored on Laponite® 
platelets (L-pNIPAM hydrogel), this forms a freely flowing solution when held 
above the lower critical solution temperature (LCST) of 32°C (Figure 5.1). Cells 
can be incorporated in the liquid L-pNIPAM hydrogel and due to the thermal 
transition of pNIPAM upon cooling below the LCST, the pNIPAM chains extend 
resulting in an entanglement of polymer chains and Laponite® platelets resulting 
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in a solidified hydrogel which is non reversible (Figure 5.1). This hydrogel has 
been shown to be biocompatible and suitable for differentiation of mesenchymal 
stem cells (MSCs) into nucleus pulposus (NP) and osteoblast-like cells for tissue 
engineering purposes (Thorpe et al., 2016a; Thorpe et al., 2016b). The pNIPAM- 
Laponite® hydrogel has additionally been used to produce a model of small 
intestinal epithelium using Caco-2 and HT29-MTX cells (Dosh et al., 2017). The 
hydrogel is biocompatible, non-biodegradable and can be made very consistently 
and in large amounts if needed (Thorpe et al., 2018).  
 
Figure 5.1 pNIPAM-Laponite® hydrogel gelation. The temperature dependent 
gelation process of polyNIPAM and Laponite gels is shown where cells can be 
suspended within liquid hydrogel at >32oC and the gel can polymerise at room 
temperature with cells suspended inside and used for cell culture. 
 
The variant hydrogel used in this study polymerises irreversibly once below its 
lower critical solution temperature (LCST) of 32oC which means cells can be 
incorporated before or after gelation. An addition of 2% of hyaluronic acid (HA), 
producing a 0.4% HA/pNIPAM hydrogel, was investigated to determine if 
including this extracellular matrix component improved hepatic function. 
Incorporation of HA has been shown previously to maintain hepatic function in 
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cultures (Kim & Rajagopalan, 2010). The HepG2 hepatocellular carcinoma cell 
line was used in this model. Using a cell line is a good starting point in order to 
test whether the model would be suitable for culture of primary liver derived cells 
and have an effect on hepatocyte-like function of the cells. The HepG2 cell line 
is well established and simple to culture although its hepatocyte-like function is 
low in 2D cultures, thus this study determined if this 3D culture system could 
restore hepatocyte function. This model was tested for its potential to be 
developed for drug toxicity studies, the ability of the culture model to maintain 
viable, active cells over longer time periods (up to 4 weeks) was assessed. In 
order to characterise alterations in the hepatic phenotype during 3D culture, 
levels of albumin and alkaline phosphatase (ALP) were assessed. Albumin is a 
well known hepatic differentiation marker, shown to be expressed even at very 
early stages of differentiation (Cascio & Zaret, 1991). This makes it a very useful 
molecule for monitoring in different culture conditions, particularly because it is 
secreted by the cells. Alkaline phosphatase is present in many mammalian 
tissues and is especially abundant in hepatic tissue (Sharma et al., 2014). It is a 
useful additional marker of hepatocyte differentiation and increases in ALP levels 
are associated with liver toxicity, and thus can be useful measure of potential 
toxicity. 
5.1.4 Chapter Aims 
The main aims of this chapter were to optimise the long-term culture of HepG2 
cells within a pNIPAM or 0.4%HA/pNIPAM hydrogel, determine the hepatocyte 
activity change with culture method, and to assess whether the MSI methods 
developed previously can be used to analyse small molecules within these 
polymeric structures. The cells were cultured in hydrogel with and without HA and 
the cell activity over culture time was monitored. Hepatic differentiation was 
monitored in the cultures with the use of albumin ELISA and ALP IHC. The 
cultures were then treated with differing concentrations of the hepatotoxic drug 
acetaminophen (0-10mM) and imaged using MALDI-MS imaging, in order to 
determine whether mass spectrometry can be used for metabolomics and 
lipidomic analysis of the 3D constructs. 
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5.2 Materials and Methods  
5.2.1 Preparation of the hydrogel  
A synthetic composite hydrogel (L-pNIPAM), produced in-house by Essa 
Abdusalam, was either used as received or 2% HA was added to a final 
concentration of 0.4% HA (v/v) according to previously established protocols 
(Boyes et al., 2012, 2013). Briefly, L-pNIPAM was prepared by vigorous stirring 
of 0.1g Laponite® (BYK Additives Ltd, Cheshire, UK) in 9ml water for 24h at RT. 
0.009g of Azobisisobutyronitrile (AIBN) (Sigma, Poole UK), and 0.9g NIPAM 
(Sigma, Poole UK) were added to the suspension and stirred for 1h. After passing 
the suspension through a 5-8µm pore filter paper, polymerisation was initiated by 
heating to 80oC and the reagents were allowed to react for 24h without stirring in 
a covered glass vial. A solution of 2% (w/v) HA in H2O (Sigma, Poole UK) was 
made by refrigerating HA in deionised water for 48 hours, with vigorous stirring 
every 8 hours. This was added (1:4 v/v, HA:hydrogel) to the pNIPAM hydrogel to 
make 0.4% HA/L-pNIPAM and sonicated to thoroughly mix. Both hydrogel 
solutions were kept at 60oC until use when they were cooled down to 38-39oC for 
cell suspension. Further cooling of the polymeric suspension below the LCST 
(32oC) resulted in rapid gelation into a solid hydrogel. 
5.2.2 2D cell culture 
HepG2 cells (hepatocellular carcinoma) were obtained from ATCC and cultured 
in DMEM supplemented with 10% FBS, 10 U/ml penicillin and 10 μg/mL 
streptomycin (Thermo Scientific, USA). The cell line was maintained in a 
humidified atmosphere containing 5% CO2 at 37oC. The cells were cultured until 
they reached approximately 80% confluency before transfer to 3D culture. Once 
confluent, the cell lines were passaged by trypsinisation, subsequent 
centrifugation, resuspension in fresh medium and seeded in new flasks or used 
for 3D experiments. Once in culture, cells were used within a 15 passage window.  
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5.2.3 3D cell culture 
The prepared hydrogels were cooled down to 38-39oC for use and cells were 
suspended in either L-pNIPAM or 0.04% HA/L-pNIPAM hydrogel. The gelation 
was induced by cooling below 32oC. To determine cell viability over time cells 
were seeded at 1, 2, 4 and 8 million cells/mL of hydrogel in 12-well plates, with 
300µL of hydrogel in each well, and cultured for up to 21 days. Following which, 
assays were performed with a cell density of 2x106/mL hydrogel. Further 
comparison was made between different seeding methods. HepG2 cells were 
seeded both on top of the hydrogel (layered) and suspended within the hydrogel. 
The benefits of dynamic culture were additionally considered as these were found 
to improve culture of other cell types within the hydrogel (Dosh et al., 2017). 
Layered cultures were achieved by adding the cell suspension on top of the 
hydrogel after gelation. This suspension was left on top of the hydrogel for 30 
minutes to enable cell attachment and media added. The dynamic cultured cells 
were cultured under static conditions for 24 hours prior to transfer to dynamic 
culture on an orbital shaker at 30 rpm. Acellular hydrogel controls were also 
produced for determination of hydrogel background signal and all samples were 
harvested in triplicate at each timepoint.  
5.2.4 Cell activity/viability assay 
To assess cell viability during prolonged culture a Resazurin assay was used. 
Resazurin (Sigma, Poole UK) stock was made at 3mg/mL in DMEM culture media. 
The stock was filter sterilised using a 0.2µm filter and stored in a light protected 
container. Resazurin (200µL of 0.3mg/mL) was added to each well and incubated 
for 1.5 hours at 37oC and protected from light. The fluorescence was recorded 
using a 530 nm excitation / 590 nm emission filter set using a CLARIOstar® plate 
reader (BMG LABTECH, Germany). After reading the plates, the cultures were 
washed twice with culture medium and cultured further until the last remaining 
time point. Resazurin has been shown to be relatively non-toxic with short 
incubation times and subsequent washes and therefore can be used for 
continuous studies (Riss et al., 2004) which meant that the same cell population 
could be monitored over time. 
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5.2.5 Histological staining 
After culture, samples were fast-frozen using liquid nitrogen and stored at -80oC. 
Sample sections were cut using the Leica 1850 UV cryostat (Leica Biosystems, 
UK), set to -30oC, at a 10μm thickness, thaw mounted on a positively charged X-
tra® adhesive slide (Leica Biosystems, UK). Haematoxylin and Eosin staining 
was used to compare static, dynamic, suspended and layered cultures. The 
method used is described previously (Section 2.2.5.1) with the exception of an 
increased dehydration time of 10 minutes for each IMS wash before clearing and 
mounting the sections. 
5.2.6 Cytospins of monolayer control cells 
HepG2 cultured cells were centrifuged (2,000 rpm, 2mins) and suspended in PBS 
to a cell density of 1,000 cell/µl. Two hundred microliters of cell suspension was 
cytospun by centrifugation at 1,000 rpm for 5 mins (Shandon cytospin 3, Thermo 
Scientific, Loughborough, UK). Slides were then air-dried and stored at -80°C in 
air-tight containers until required for immunohistochemical investigation. 
5.2.7 Immunohistochemistry 
Sample sections were cut using the Leica 1850 UV cryostat (Leica Biosystems, 
UK), set to -30oC, at a 10 μm thickness, thaw mounted on a positively charged 
X-tra® adhesive slide (Leica Biosystems, UK). Immunohistochemistry was 
performed to observe alkaline phosphatase levels, representing hepatic activity, 
within suspended static and dynamic hydrogel culture samples using an 
unlabelled anti-human ALP antibody (1:200, rabbit polyclonal) (Clone # 
ab108337 , Abcam, Cambridge, UK) and biotinylated goat anti-rabbit IgG (Clone 
# ab207995 , Abcam, Cambridge, UK). Cytospun HepG2 slides were used as a 
time zero control. Sample sections were fixed in acetone (-20oC) for 5 minutes 
and immersed in Tris-Buffered Saline (TBS: 20mM Tris, 150mM NaCl, pH 7.5) 
for 5 minutes in triplicate. Endogenous peroxidases were blocked for 30 minutes 
by immersing slides into 3% w/v hydrogen peroxide (Sigma-Aldrich, Poole UK) in 
IMS. Sections were washed once in dH2O and twice for 5 minutes in TBS. 
Sections were washed three times in TBS and placed in humidified slide boxes. 
Non-specific protein interactions were blocked and secondary antibody-host 
interactions were neutralised by the application of 200µL 1% BSA in 75% v/v TBS 
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and 25% v/v normal goat serum (Abcam, Cambridge, UK) and incubated for 2 
hours at room temperature. Blocking solution was tapped off and excess wiped 
from around the tissues, before 200µL of anti-human ALP primary antibody 
(1:200 dilution) was then applied. Antibody dilutions were performed in 1% w/v 
BSA in TBS and sections incubated overnight at 4oC. Sections were washed 
three times in TBS before 200µL of goat anti-rabbit biotinylated secondary 
antibody (1:500 dilution) was applied for 30 minutes at room temperature. 
Antibody dilutions were performed in 1% w/v BSA in TBS. Sections were washed 
in TBS for 5 minutes in triplicate before 2 drops of horseradish peroxidase (HRP) 
streptavidin-biotin complex (Vector Laboratories, Peterborough, UK) was applied 
for 30 minutes at room temperature. Sections were washed three times in TBS 
for 5 minutes prior to application of 200µL 0.08% v/v hydrogen peroxide in 
0.65mg/mL 3, 3 -diaminobenzidine tetrahydrochloride (DAB) (Sigma-Aldrich, 
Poole, UK) in TBS per section for 20 minutes. Sections were washed in dH2O for 
5 minutes prior to incubation in haematoxylin for 1 minute and blued under 
running tap water for 5 minutes. Sections were then immersed in 99% (v/v) IMS 
for 10 minutes followed by immersion in SubX for 5 minutes. Finally, sections 
were mounted using 2 drops of Pertex per slide and coverslips applied. A 
negative control in which rabbit IgG (Abcam, Cambridge, UK) replaced the 
primary antibody at an equal IgG concentration was previously tested on a 
hydrogel sample by Rasha Dosh in order to confirm absence of non specific 
binding (Dosh et al., 2017). 
5.2.7.1 Microscopy and Image capture 
Sections were visualised on an Olympus BX60 microscope. Images were 
captured using a QImaging Micropublisher 5.0 RTV camera and Capture-Pro8 
software. The IHC slides were assessed by visual assessment of five 
representative images from each sample and an intensity grade between 0-3 was 
assigned based on density of stain. Where grade 0 is no staining and grade 3 
representing the most intense staining (Figure 5.2). Five representative images 
were graded by two independent graders (IP and CLM) and averaged. 
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Figure 5.2 Example images of grade 1, 2 and 3 level ALP immunostaining 
intensity. Grade 0 would be given for no positive staining, however there were 
no samples marked at grade 0. 
5.2.8 Albumin ELISA 
During the 4 weeks of HepG2 cell culture within hydrogels, culture media was 
collected at 0, 2, 4, 7 and 14 days for both L-pNIPAM and 0.4% HA/L-pNIPAM 
cultures. The media was used in an enzyme linked immunosorbent assay 
(ELISA) for quantification of human albumin (Cat #ab179887, Abcam, Cambridge, 
UK) as per the manufacturer's instructions. Briefly, human albumin serially diluted 
standards of 200, 100, 50, 25, 12.5, 6.25, 3.125, 0 ng/mL were produced. To the 
wells of a 96 well plate, 50µL of standards and samples in triplicate along with 
50µL blue conjugate and 50µL antibody was added. The plate was incubated at 
room temperature for 2 hours on an orbital shaker (500rpm). Following incubation, 
wells were washed 3 times with wash buffer. Excess wash buffer was tapped off 
and 200µL of p-Nitrophenyl Phosphate (pNpp) substrate solution was added to 
every well. Following incubation for 1 hour at room temperature without shaking, 
50µL of stop solution was added to every well. The ELISA assay absorbance was 
read immediately using a CLARIOstar® plate reader (BMG LABTECH, Germany) 
at a wavelength of 450 nm. Wavelength correction was performed by subtraction 
of readings at 570 nm from those at 450 nm to correct for optical imperfections of 
the 96-well plate.  
5.2.8.1 Data processing and statistical analysis 
For ELISA data, a standard curve was generated by plotting the standard 
concentrations against the corresponding mean absorbance (at 450nm). A line 
of best fit was determined on GraphPad Prism v7 software (GraphPad Software, 
USA) by linear regression analysis. The unknown sample concentrations were 
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determined from the standard curve and combined over day measurements in 
order to calculate cumulative Albumin concentrations. 
The ELISA data was identified as non-parametric by the Shapiro-Wilk test of 
normality. Therefore, the Kruskal-Wallis test was used to determine if there were 
any significant differences between the cultures and between time points. This 
analysis was combined with the Conover-Iman post-hoc test when a significant 
difference was observed between treatment groups. Statistical analysis was 
performed using StatsDirect software (StatsDirectLtd, UK). 
5.2.9 Mass Spectrometric Imaging of HepG2 cells in 
hydrogel 
5.2.9.1 Sample preparation 
HepG2 L-pNIPAM samples were treated, in triplicate, with 0, 0.5, 2.5 mM 
acetaminophen for a total of 48 hours, replacing the drug media every 24 hours. 
At the end of the treatment the samples were fast-frozen and stored at -80oC. 
Sample sections were cut using the Leica 1850 UV cryostat (Leica Biosystems, 
UK), set to -30oC, at a 10 μm thickness, thaw mounted on a positively charged 
X-tra® adhesive slide (Leica Biosystems, UK). The samples were then stored at 
-80oC in an air tight container or used for MSI immediately. 
5.2.9.2 Matrix deposition 
All sections (10m) were taken straight after cryosectioning or from -80oC storage 
and immediately placed in a vacuum desiccator for ~15 minutes prior to matrix 
application. X-tra® slide mounted sections were used for Synapt G2 analysis. 
Imaging was performed in positive mode, therefore the binary matrix α-CHCA: 
DHB (20/7) was prepared as a matrix solution (Section 3.2.4). The matrix was 
applied to the sample section using the SunCollect™ automated sprayer. Five 
layers of matrix were applied at 10μL/min (speed x: low 7, speed y: medium 1, Z 
position: 35). 
5.2.9.3 Mass Spectrometric Imaging 
Several images of the APAP treated HepG2 hydrogels were obtained using a 
Synapt G2 due to its high sensitivity and moderate resolving power (~10,000 in 
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sensitivity mode). Images of 60μm pixel size were acquired over an m/z range of 
50-1,200 in positive mode. The ion mobility function was used in order to improve 
separation of peaks. Images generated using the Synapt G2 were processed 
using the Waters High Definition Imaging (HDI v 1.4) software package. The 
images were all TIC normalised. 
5.3 Results 
5.3.1 Characterisation of HepG2 3D model 
The ability of the hydrogel to maintain cell viability over longer culture periods was 
assessed using the Resazurin cell viability assay. The cell viability of HepG2 cells 
in hydrogel was maintained for up to 21 days in culture with no significant 
changes at an initial seeding density of 2x106 cells/mL (Figure 5.3). Other cell 
densities were tested, however these displayed a higher variance (Appendix 
chapter 5 figures 1-3). Overall, 0.4% v/v HA/L-pNIPAM culture viability, as 
determined by resazurin conversion, was significantly higher than that of L-
pNIPAM cultures (p= 0.016) indicating either increased cell proliferation or 
viability due to the inclusion of HA in the culture. The 0.4% v/v HA/L-pNIPAM 
cultures displayed a higher overall cell viability, however showed a higher 
standard deviation which may be problematic for future standardisation. 
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Figure 5.3 Cell viability of HepG2 cells cultured in a hydrogel scaffold. Two types 
of hydrogel were used; L-pNIPAM and 0.4% v/v HA/L-pNIPAM. The cells were 
seeded at a density of 2x106 cells/mL (n=3).  
 
An increase in cumulative albumin concentration was observed over 14 days in 
culture (Figure 5.4). A significant difference between the HA containing and pure 
hydrogel cultures was observed (p= 0.0001). This indicates that the  cultures 
without the presence of HA in the gel either produced more albumin or it was 
more likely to be sequestered within these gels due to the presence of HA. The 
levels of albumin were significantly higher in the supernatant of both hydrogel 
compositions, when cells were included, compared to their acellular counterparts 
(p< 0.0001). The albumin concentration increased significantly between days 0-
4 of culture in the 0.4% v/v HA/L-pNIPAM cultures (p= 0.0319) and in the L-
pNIPAM cultures (p= 0.0021). After the 4 day point the albumin levels reached a 
plateau of 40ng/mL in HA hydrogel and 123ng/mL in HA free hydrogels. 
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Figure 5.4 Cumulative albumin concentration in the culture media of HepG2 
hydrogel cultures (n=2).  
 
The ability of the cells to form larger structures and proliferate in different culture 
conditions within the hydrogel was assessed by H&E staining (Figure 5.5). 
Layered culture conditions, both static and dynamic, led to cell growth on top of 
the hydrogel without any migration into the gel. The cells continued to proliferate 
at a standard monolayer culture rate and, once at a certain size, cell masses 
visibly detached from the surface of the hydrogel into the media (data not shown). 
The suspended cultures began as single cell suspensions within the hydrogel 
which, over the period of 4 weeks, migrated towards each other primarily at the 
edge of the hydrogel to form solid masses within. Suspended static and dynamic 
cultures both formed solid masses at 4 weeks and were histologically identical.  
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Figure 5.5 H&E staining of static and dynamic HepG2 cultures suspended within  
and layered on top of hydrogel. Cultures were kept up to 4 weeks. Scale bar = 
200m. 
 
To evaluate hepatic activity Alkaline Phosphatase was monitored within the 
suspended static and dynamic cultures by IHC (Figure 5.6). Compared to the 
cytospin 2D control both static and dynamic cultures expressed a higher level of 
Alkaline Phosphatase indicating recovered hepatic function.  
 
 
Figure 5.6 IHC of ALP in static 4 wk HepG2 cultures suspended within L-pNIPAM 
hydrogel. A) Cytospun HepG2 cell control, B) Static suspended HepG2 hydrogel 
culture C) Dynamic suspended HepG2 hydrogel culture. The image shows an 
increase in ALP expression in 3D cultures. 
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Figure 5.7 Grading intensity of ALP IHC between static and dynamic condition 
suspended 0% HA/L-pNIPAM hydrogel cultures compared to a control 2D 
cytospin. Grades are from 0-3 indicating no staining at 0 and very intense staining 
at 3. One biological repeat and 3 technical repeats were performed. 
 
5.3.2 Mass spectrometry imaging of HepG2 model  
Positive mode imaging of hydrogel HepG2 cultures revealed many cell related 
signals, such as m/z 184.0726 (phosphocholine) and ionic species m/z  723.4959, 
754.5381, 782.5694 and 808.5851 putatively identified as phospholipid species 
PA and PC (Figure 5.8 and Appendix chapter 5 figures 4-13). The signal for 
phosphocholine was used as a cell location marker in order to correlate signals 
with cell mass locations. Signals of these ionic species were upregulated within 
the 0.5 and 2.5mM APAP treated samples compared to the untreated control 
indicating an altered lipid expression as a result of treatment. 
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Figure 5.8 MSI of untreated, 0.5 and 2.5mM APAP-treated HepG2 hydrogel 
cultures corresponding to ionic signals m/z 184.0726 (phosphocholine, top) m/z 
723.4902 (bottom). The red arrows are pointing at the one of the cell locations 
within the gel marked by the increased signal. 
  
0 0.5 2.5 
0 0.5 2.5 
 
 
163 
5.4 Discussion 
In this chapter, an in vitro three-dimensional liver toxicity model has been 
developed using a nanocomposite hydrogel as a scaffold and its compatibility 
with the MSI technique MALDI-MSI was assessed. The HepG2 cell line retained 
its cell viability during growth in both 0.4% v/v HA/L-pNIPAM and pure hydrogel 
for up to 21 days and formed large cell masses after 4 weeks of culture. Hepatic 
differentiation of 0.4% v/v HA/L-pNIPAM cultures should be assessed further in 
the future, as addition of HA may either be beneficial or hinder differentiation 
inside the hydrogel construct. The method developed can be used to analyse 
small molecules and lipids to observe adverse outcome pathways related to DILI. 
5.4.1 Characterisation of HepG2 hydrogel cultures 
HepG2 3D culture hepatic function was assessed by quantifying the amount of 
albumin excreted into the cell media. Albumin is produced solely by hepatocytes 
and is subsequently used as a measure of hepatic function (Ebrahimkhani et al., 
2014). Albumin is responsible for the transport of insoluble endogenous e.g. 
bilirubin or fatty acids and exogenous e.g. drugs or nutrients substances. In fact, 
in albumin-drug binding causes increases in drug solubility but reduces toxicity 
and increases drug half-life, therefore is an important component of an in vitro 
toxicity model (Yamasaki et al., 2013). Within the HepG2 hydrogel culture media, 
the Albumin concentration increases significantly within two days of culture in 
both L-pNIPAM and 0.4% v/v HA/L-pNIPAM sample sets, compared to acellular 
control samples at low background production levels. However, the release is 
decreased considerably after four days of culture in hydrogel. This could be due 
to increased or altered protein and glycan deposition during culture in hydrogel 
and subsequent increased sequestering of the albumin within the gel. 
Hepatocytes are responsible for production of several more extracellular proteins, 
namely clotting factors and - and -globulins, and protein glycosylation is a 
common post-translational modification, which could be restored in HepG2 3D 
cultures (Wiśniewski et al., 2016). The ECM is known to sequester many 
biomolecules, principally growth factors, as part of its regulatory function (Tibbitt 
& Anseth, 2009) As the albumin is sequestered, it might no longer diffuse out of 
the hydrogel and into the media where it can be detected. This may also be an 
explanation for the lower signal observed in the HA hydrogels. A further 
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investigation of albumin levels inside the hydrogel is required in order to elucidate 
this further by proteomic MSI or IHC of sample sections.  
The levels of alkaline phosphatase expressed within the hydrogel cultures 
compared to 2D cultures were increased. Levels of ALP are a sign of restored 
hepatic function and increases in the levels could be later monitored after 
treatment in order to confirm DILI occurrence (Hussaini & Farrington, 2007). 
Overall, the increased levels of albumin and ALP in the 3D cell cultures, which 
can be continually cultured for up to 4 weeks, indicate that the HepG2 cells have 
altered certain hepatocyte characteristics compared to 2D culture. Further 
indicators of increased activity could be studied, such as altered levels of P450 
proteins as well as the altered sensitivity of the model to known therapeutics 
compared to the 2D equivalent.     
Although 3D culture was shown to improve the HepG2 cell line hepatic function 
to an extent, higher functionality models have been developed in recent years 
(Otieno et al., 2018). The production of a pre-clinical model which could capture 
liver processes such as inflammation, infection and oxidative stress as well as 
the genotype associated pre-disposition towards DILI is challenging (Mosedale & 
Watkins, 2017). In order to represent all these processes the model would have 
to contain a high amount of genetic variation, representative of the general patient 
pool, as well as contain stromal cell types in order to be inclusive of indirect effects 
associated with supporting cell types. Use of 3D cell culture has enabled longer 
culture of active primary hepatocytes. By growing hepatocytes in spheroid form, 
Bell and colleagues managed to create a co-culture compatible system which 
lasted for at least 5 weeks, which makes it suitable for long-term toxicological 
studies (Bell et al., 2016). This model was shown to be much more representative 
of in vivo than the HepaRG cell line and stem cell derived hepatocytes (Bell et al., 
2017). Another recent study compared 2D sandwich cultures of primary human 
hepatocytes (PHHs) to 3D spheroid cultures of the same cells in order to observe 
differences in their phenotype maintenance (Bell et al., 2018). They found that 
even in sandwich cultures there were certain aspects of hepatocyte 
dedifferentiation, which were not prevented and would lead to a lower capacity to 
detoxify reactive metabolic intermediates. In contrast, the 3D PHH spheroid 
cultures maintained high levels of ADME specific proteins and metabolic activity, 
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as demonstrated by their higher sensitivity to APAP and other drugs which lead 
to production of highly toxic intermediates by active CYP proteins (Bell et al., 
2018). Some groups have been working towards cell sources which are more 
widely available than limited primary human hepatocytes. A functional 
vascularized and human liver model was developed, based on the use of 
reprogrammed human induced pluripotent stem cells (iPSCs) (Takebe et al., 
2013). The model was able to rescue drug-induced lethal liver failure when 
transplanted, perform liver-specific functions, including human specific drug 
metabolism. The in vitro created iPSC liver buds resembled in vivo liver buds in 
their gene and protein expression (Takebe et al., 2013). These functions would 
enable the retrieval of more accurate adverse outcome pathway data, though the 
model may need simplification for this application as opposed to tissue 
engineering. In order to improve 3D models of liver further, the combination of 
organoid technology and microfluidic models has been suggested. Both types of 
model have challenges, such as structural fidelity and environmental control, 
which could be overcome by combination/synergistic engineering (Takebe et al., 
2017). 
5.4.2 MSI of HepG2 hydrogel cultures 
The phosphocholine signal in the mass spectrometry images was used as a cell 
location marker. Phosphocholine is with a fragment of phosphatidylcholine, a 
major component of the cell membrane, therefore this was deemed suitable to 
detect cell locations in positive mode imaging (Jansen et al., 2001). It may be 
particularly high within hepatocellular carcinoma cells as an increased expression 
of Choline Kinase α, which catalyses the conversion of choline to phosphocholine, 
was recently observed in tumour compared to normal tissues (Lin et al., 2017). 
Several ionic species were observed specifically localised within the cell masses 
in the hydrogel. Several of those were upregulated in treated samples which may 
be an indication of phospholipidosis, which is characterised by an accumulation 
of phospholipids within drug-affected hepatocytes (Begriche et al., 2011). To our 
knowledge this chapter presents the first instance of MSI of a liver toxicity model 
as well as the first instance of MSI of a 3D model based on a polymeric scaffold. 
Further identification and multivariate analysis would be required in order to 
elucidate significant small molecule and lipid differences between the different 
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treatment groups. The functional model could then be used for the study of 
unknown adverse outcome pathways in order to determine the molecular 
initiating events and toxicity pathways through the biochemical cell response to a 
drug. 
5.5 Concluding remarks 
Long-term culture of the HepG2 cell line was shown to improve the hepatic cell 
activity and increase the similarity of the cell line to in vivo in the elucidation of 
adverse outcome pathways. This synthetic polymer-based scaffold model was 
analysed using MSI for the first time in order to establish a method for evaluating 
AOPs. In the future, the technique can be useful in determining, in an untargeted 
fashion, the metabolomic changes occurring within 3D cell culture models. 
Additionally, proteomic MSI could be used to confirm differentiation and 
maintenance of the cell phenotype.   
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Chapter 6: Conclusions and 
future work 
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6.1 Conclusions and future work 
6.1.1 3D model of osteosarcoma: Optimisation and MSI analysis 
The most common application of 3D cell culture has been within the cancer field. 
Models such as this are particularly useful in cases of rare cancers where there 
is limited knowledge about origin, function and treatment options due to lack of 
affected people and therefore experience.  In chapter 2, a 3D cell culture model 
of osteosarcoma was developed in order to better represent and study the 
disease. Because very little is known about osteosarcoma and access to patient 
samples is limited, even in designated hospitals, cell line derived 3D cell culture 
models are potentially a suitable alternative to study the disease.  
The use of untargeted MSI was demonstrated in this chapter as a tool for the 
elucidation of unknown molecular disease mechanisms. Untargeted techniques, 
such as MSI, could aid in the discovery of potentially important pathways related 
to osteosarcoma formation, propagation and drug resistance, which can be 
achieved without prior knowledge, which for rare tumours such as osteosarcoma 
is currently lacking. The spheroid aggregate model designed in this chapter is a 
unique two-step culture model with the aim of producing a large mass which is 
representative of many of the tumour environments encountered but still 
maintaining some visible clonal differences, in order to better study the 
heterogeneity present within osteosarcoma. The spheroid aggregates are 
>500m which produces a mass containing proliferating, apoptotic and necrotic 
regions due to diffusion distances within. These are representative of these cell 
states within an osteosarcoma tumour. Additionally, due to the heterogeneity 
observed within cell lines which is then expanded by culturing each of these cells 
into a colony, heterogeneity can be more easily studied.  As the aggregates are 
made up of individual clonal spheroids they are uniquely capable of representing 
tumour heterogeneity whilst still maintaining larger regions of clonality which are 
easier to analyse and interpret than single cell heterogenous regions. Potentially 
a clonal spheroid within the spheroid aggregate may have a completely different 
reaction to a pharmaceutical than another clone within the same mass, which will 
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be easier to observe in a large clonal population than a single cell due to an 
increase in signal and area of regions of interest. This model is presently 
exclusive in these capabilities as all other 3D cell culture tumour models entail 
either MCTS or clonal spheroid methods.  
This thesis additionally contains the first report of MSI of a mesenchymal tumour 
cell model. The clonal differences within a spheroid aggregate could be observed 
using MSI of endogenous metabolites and could be used in the future to 
determine different interactions within a single tumour due to heterogeneity. 
Observation of intra-aggregate differences would provide information on 
endogenous molecular heterogeneity and specific clonal behaviour. Intra-
aggregate analysis could be taken further using a mass spectrometer capable of 
high spatial resolution imaging. Using higher spatial resolution would provide a 
clearer molecular map of the spheroid aggregate model and would better pinpoint 
certain active pathways within the proliferative, apoptotic or necrotic regions. In 
future, the model developed in this thesis has the potential for co-culture. As the 
method used involves two separate culture stages a second cell type could be 
introduced at the second stage, which would then be integrated into the 
aggregate mass. This may be potentially useful as a study of angiogenesis by 
the addition of an endothelial cell population, such as HUVECs, as an improved 
model, as was recently reported (Chaddad et al., 2017). For future studies it 
would be useful to characterise the model further by studying potential 
mineralisation and altered expression of osteogenic markers such as SATB2, 
alkaline phosphatase and osteocalcin as well as expression of type I collagen 
(Evola et al., 2017; Machado et al., 2016). 
6.1.2 3D model of osteosarcoma: Therapeutic treatment analysis 
Chapter 3 focuses on use of the osteosarcoma model developed in chapter 2 for 
improved analysis of osteosarcoma drug response. The treatment options for 
osteosarcoma are lacking due to lack of research and tumour aggressiveness. 
3D cell culture models, like the one developed in chapter 2, could demonstrate a 
more representative tumour response to chemotherapeutics, leading to less false 
positive results moving onto further stages of drug development and making the 
process more cost and time efficient. The higher time efficiency would potentially 
lead to more successful drug candidates in a shorter time period. The difference 
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in drug responses was demonstrated in chapter 3 where the SAOS-2 cell line 
proved to be completely resistant to doxorubicin in 3D cell culture when treated 
with a 4-fold higher doxorubicin concentration than the IC50 observed in the 2D 
cell culture. This may largely be due to the difference in cell proliferation and lack 
of penetration into the mass, however expression changes may also be 
contributing to resistance. Doxorubicin resistance is common in high-grade 
osteosarcoma patients mainly due to ABC transporter mediated drug efflux, 
therefore it may be interesting in the future to check for its increased expression 
(Hattinger et al., 2017). For the first time, potential molecular biomarkers of drug 
response were determined by PCA-DA of MSI data obtained from a large treated 
spheroid aggregate cohort. The significantly differing species were calculated 
using two separate statistical methods and 10 highly differing species were 
detected using both tests, which may be indicative of the strong significance of 
these ionic species in drug response. Disease relevant putative assignments 
were given to some of the ionic species however additional analysis is required 
in order to confirm the identities of these molecules of interest by MS/MS. This 
had proved difficult due to the spheroid aggregate small size, which impeded 
MS/MS analysis, and spectral complexity, which made molecular identification 
more difficult. Instrumentation capable of smaller raster sizes and higher mass 
resolution may aid in solving these complications. Once identified, further study 
of the role these molecules play in drug resistance can be established.   
6.1.3 3D model of osteosarcoma: Proteotypic peptide detection 
by MSI 
Proteins are important targets when studying a rare disease, such as 
osteosarcoma. In oncology, the use of biomarkers is for therapeutic monitoring, 
potential prediction of severity and relapse (prognostic), and for earlier stage 
cancer detection so bone-targeted treatment can be started at an earlier stage 
(diagnostic). All the mentioned types of biomarker have been explored for 
osteosarcoma (Evola et al., 2017). Despite the number of possible markers found, 
only the marker SATB2 is commonly used as a diagnostic marker of 
osteosarcoma tissue in the clinic, due to its high percentage positivity in OS 
compared to other markers (Machado et al., 2016). Currently, this biomarker is 
being used as an additional diagnostic step in disputable cases after the main 
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diagnostic strategy involving identification of malignant osteoid matrix formation 
and use of clinical and radiological data. The untargeted proteomic analysis of a 
3D osteosarcoma model may provide useful information in the form of biomarkers 
and drugable targets therefore focus was also directed towards novel peptide 
imaging within the osteosarcoma model. Chapter 4 demonstrated the adaptation 
of the analysis for proteotypic peptides within the osteosarcoma model developed 
in chapter 2. The analysis of tryptic peptide species was achieved within the 
spheroid aggregate. In future, the sample preparation requires further 
optimisation in order to observe a larger number of proteotypic species within the 
model. This would be improved with a 3D cell culture specific, optimised digestion 
step and optimisation of the instrumentation available. Once the analysis is fully 
optimised, a full cohort of treatment groups should be run, similarly to chapter 3, 
in order to identify significantly differing species.  
6.1.4 3D model of osteosarcoma: QMSI 
The quantification of peptides and proteins using MSI is currently under 
development, as it would prove very useful primarily in the biopharmaceutical and 
cancer biology fields. Quantification of multiple peptides/proteins within a single 
experiment has been heavily developed using other mass spectrometry-based 
methods, primarily LC-MS. However, these methods do not preserve topological 
information within the sample. The ability to accurately quantify a peptide/protein 
within a specific location of a tissue or a 3D cell culture model would increase the 
amount of information about a biopharmaceutical or biomarker of interest and 
improve knowledge of disease or treatment. In chapter 4, a method was 
developed for more accurate MSI quantification of up to 25 proteotypic peptides 
within a single mass spectrometry imaging experiment, which, to our knowledge, 
has never before been demonstrated. A cell plug construct was created, 
containing multiple peptide standards mixed with intact osteosarcoma cells in 
order to better represent proteotypic peptide signatures within an osteosarcoma 
culture sample. In future, this quantification method will be used to quantify 
proteotypic species within the 3D osteosarcoma culture model. Its applicability to 
osteosarcoma tissue will additionally be tested. The values should be confirmed 
using an accepted quantitative method such as LC-MS, western blot, ELISA or 
IHC. Of the four validation methods mentioned only IHC would maintain spatial 
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information of the molecule of interest. A suitable example of where this would be 
useful can be found in chapter 5 where accumulated albumin concentration in the 
cell medium plateaued at day 4 of culture using an ELISA method. In this case 
the method used may not have detected albumin which could be sequestered 
inside the scaffold. Additionally, three of the methods are antibody detection 
based and therefore higher-cost and lower throughput than MS-based methods. 
LC-MS is a MS-based validated method for protein quantification, which benefits 
from multiplex capabilities, however requires homogenisation of the sample. If 
QMSI was validated for the purpose of multiple protein quantification within one 
experiment it would quickly become the method of choice due to its multiplex 
capabilities and efficiency. This thesis describes the first steps taken towards the 
creation and validation of peptide QMSI methods. 
6.1.5 3D model of liver: Adaptability of methods to a different 3D 
model 
The pharmaceutical industry has struggled with high failure rates for drugs and 
low productivity within their R&D sector for many years (Smietana et al., 2015). 
Another common application of 3D cell culture is its use in toxicity testing of 
promising pharmaceuticals in order to reduce risk of failure at later stages of 
testing. The use of hepatic and cardiac 3D cell culture models in toxicity testing 
was recognised in AstraZeneca’s revised strategy as part of improving safety 
assessment by identifying early preclinical safety signals (Morgan et al., 2018). 
In this setting the 3D cell culture and MSI methods developed would have a 
potential to save a significant amount of costs within the drug discovery field. This 
may be particularly important as analyses show that the majority of ongoing 
projects are pursuing novel mechanism therapeutics, which haven’t had high 
success rates in the past compared to rigorously validated mechanisms (Shih et 
al., 2017). Mass spectrometry would be a suitable tool for the definition of AOPs 
for pharmaceuticals of interest to acquire knowledge of the mechanisms involved. 
The aim of Chapter 5 was to demonstrate the applicability of the protocols 
developed in the previous chapters to a completely different 3D cell culture model, 
testing the robustness of the methods. The liver model was developed using a 
synthetic scaffold, in which the cell population was cultured long term. 
Complications may sometimes arise with the analysis of polymeric scaffolds. For 
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example, the pNIPAM based scaffold used in this chapter is auto-fluorescent at 
certain wavelengths, thus interfering with any fluorescent imaging techniques. 
Additionally, some synthetically derived polymeric scaffolds would impede certain 
metabolite, lipid or protein extraction protocols as they are hard to break down 
and extract from and, if broken down, may present with polymer contamination. 
In chapter 5 the MSI of small molecules within HepG2 cells within a synthetic 
hydrogel was demonstrated. Additionally, in order to analyse small molecules in 
their original state the sample preparation must be as fast and simple as possible. 
The method developed is the first of its kind, capable of detecting small molecule 
species within the synthetic scaffold. The sample preparation protocol developed 
for MSI of the samples was minimal in terms of interference and time period of 
sample collection. There was no sample interference to the analysis observed, 
therefore this protocol would be potentially suitable for definition of AOPs within 
the drug discovery workflow. Additionally, this protocol could be applied in future 
to analysis of other polymeric hydrogel samples. Further testing of the model 
would be required with an improved cell source consisting of an even higher 
functional activity, such as primary hepatocytes. MSI analysis could also be used 
for protein and glycan investigation of the cultures. This would be particularly 
useful in the confirmation of hepatocyte differentiation as hepatocytes are 
responsible for production of ECM components and display restored protein 
glycosylation (Wiśniewski et al., 2016). 
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6.2 Closing Remarks 
Further development of MSI is required to improve suitability to the alternative 
models available, so that the combined approach can successfully provide the 
information required in disease characterisation and treatment. The work within 
this thesis represents considerable method development towards this cause. 
Within this thesis, MSI has been shown to be capable of providing spatio-
molecular information in tumour spheroids, and in vitro liver constructs. Due to a 
considerable interest and scientific effort there are many more designed 
alternative disease models available which would benefit from the information 
MSI could provide and the methods developed in this thesis have the robust 
potential to apply to many more types of alternative model. 
Published data strongly suggests that MSI will develop into a valuable tool for 
biomedical research and wider clinical applications. The technique will 
complement pre-existing biomedical techniques such as immunohistochemistry 
in both research and in-vitro diagnostics. The use of alternative disease models 
in combination with MSI within research and industry environments will produce 
workflows capable of higher capability, lower cost, higher throughput and 
improved ethical impact. The use of these models in combination with suitable 
methodology will contribute towards the replacement and reduction of the use of 
animals in research and industry.  
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Appendices 
 
 
Appendix chapter 3 figure 1 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 2 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 3 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 4 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 5 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 6 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 7 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 8 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
 
 
223 
 
Appendix chapter 3 figure 9 Ionic species significantly varying between 
doxorubicin treated spheroid aggregates. The data was extracted from PCA-DA 
analysis, tested using the Kruskal-Wallis test of significance or using ANOVA. 
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Appendix chapter 3 figure 10 Nine of 18 significantly differing species discovered 
using PCA-DA and defined using a linear mixed effects model. The graphs show 
the variability due to random and fixed effects. 
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Appendix chapter 3 figure 11 Nine of 18 significantly differing species discovered 
using PCA-DA and defined using a linear mixed effects model (2). The graphs 
show the variability due to random and fixed effects. 
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Appendix chapter 3 table 1 18 significantly differing species discovered using 
PCA-DA and defined using a linear mixed effects model. P-values for each 
comparison are given next to each peak.  
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Appendix chapter 4 figure 1 120 peptide mix standard graphs for 2 separate 
standard array experiments. No normalisation and RMS normalisation is shown.
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Appendix chapter 4 figure 2 120 peptide mix standard graphs for 2 separate 
standard array experiments (2). No normalisation and RMS normalisation is 
shown. 
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Appendix chapter 4 figure 3 120 peptide mix standard graphs for 2 separate 
standard array experiments (3). No normalisation and RMS normalisation is 
shown. 
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Peptide Sequence C-term MW (average) Description (Human) 
GVGASGSFR R 836.89234 Histone H1.0 
VGENADSQIK K 1060.11602 Histone H1.0 
TFEDIPLEEPEVK K 1545.68532 Vascular endothelial growth factor receptor 2 
GAFGQVIEADAFGIDK K 1637.78728 Vascular endothelial growth factor receptor 2 
DITSDTSGDFR R 1213.20834 Annexin A1 
GPAGPQGPR R 835.90758 Collagen alpha-1(I) chain 
SIAFPSIGSGR R 1091.21772 Core histone macro-H2A.1 
ADHGEPIGR R 950.99498 Heat shock protein HSP 90-beta 
ISSSSFSR R 869.91896 Keratin, type II cytoskeletal 8 
WSLLQQQK K 1030.1777 Keratin, type II cytoskeletal 8 
LINQPLPDLK K 1150.36774 Microtubule-associated protein 2 
TDAPLNIR R 899.00324 Heat shock protein 75 kDa, mitochondrial 
NPDDITNEEYGEFYK K 1833.85798 Heat shock protein HSP 90-alpha 
ALLFIPR R 829.04082 Heat shock protein HSP 90-beta 
LLDEEEATDNDLR R 1532.56244 Programmed cell death 6-interacting protein 
AQLLQPTLEINPR R 1492.71872 Heat shock protein 75 kDa, mitochondrial 
GVVGLPGQR R 882.01908 Collagen alpha-1(I) chain 
VAQLEAQZQEPZK K 1560.7513 Fibrinogen gamma chain 
LALASLGYEK K 1064.23214 Programmed cell death 6-interacting protein 
DYETATLSEIK K 1269.35442 Alpha-actinin-1 
LAILGIHNEVSK K 1293.5116 Alpha-actinin-1 
VEVLAGDLR R 971.10896 Contactin-2 
DNZZILDER R 1194.2961 Fibrinogen gamma chain 
DQVANSAFVER R 1235.30328 Heat shock protein HSP 90-alpha 
EFSITDVVPYPISLR R 1735.97334 Heat shock 70 kDa protein 4 
VGLQVVAVK K 912.12788 60 kDa heat shock protein, mitochondrial 
AGGIETIANEYSDR R 1495.54712 Heat shock 70 kDa protein 4 
SQIHDIVLVGGSTR R 1481.65302 Heat shock cognate 71 kDa protein 
VEEEIVTLR R 1087.22418 Tumor protein D54 
FVVQNVSAQK K 1119.27088 Heat shock protein 105 kDa 
GGSASVWSER R 1035.06834 Aldehyde dehydrogenase family 16 member A1 
YQGLZPPVPR R 1186.38322 Angiotensin-converting enzyme 
IGPLGLSPK K 881.07078 60S ribosomal protein L12 
HELLSLASSNHLGK K 1505.67442 Eukaryotic translation initiation factor 3 subunit H 
ILYLTPEQEK K 1233.40998 Eukaryotic peptide chain release factor subunit 1 
YLEESNFVHR R 1293.38396 Tyrosine-protein kinase SYK 
LFPDVLFPADSEHNK K 1728.89788 Mitogen-activated protein kinase 8 
SNFGYNIPLK K 1152.29904 Proteasome subunit alpha type-3 
LTTFQALQHPWVTGK K 1726.97142 Calcium/calmodulin-dependent protein kinase type IV 
FQFPSHVTDVSEEAK K 1720.83282 Serine/threonine-protein kinase MRCK beta 
LSVEIWDWDR R 1318.43318 Protein kinase C alpha type 
FLEEFITPIVK K 1335.58628 DNA topoisomerase 2-alpha 
TLEVEIEPGVR R 1241.39068 DnaJ homolog subfamily B member 11 
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GTEELYAIK K 1023.13716 Protein kinase C alpha type 
GFFLLVEGGR R 1094.26296 Alkaline phosphatase, tissue-nonspecific isozyme 
DGIVLGADTR R 1016.10652 Proteasome subunit beta type-7 
AEDGSVIDYELIDQDAR R 1908.9694 Annexin A2 
LEVEANNAFDQYR R 1568.64244 F-actin-capping protein subunit beta 
ITNSLTVLZSEK K 1364.56474 Eukaryotic translation initiation factor 3 subunit J 
AASAHAIGTVK K 1025.15964 cAMP-dependent protein kinase type II-beta regulatory subunit 
EAFTVIDQNR R 1192.27854 Myosin regulatory light chain 2, skeletal muscle isoform 
SVGIVTTTR R 933.06098 Alkaline phosphatase, tissue-nonspecific isozyme 
ISVYYNEATGGK K 1301.40112 Tubulin beta chain 
TIVLQEIIGK K 1113.34758 Activin receptor type-1B 
LGGEVSZLVAGTK K 1290.4862 Electron transfer flavoprotein subunit alpha, mitochondrial 
QVLGLGVNGK K 984.15078 MAP kinase-activated protein kinase 3 
SAAQAAAQTNSNAAGK K 1460.50638 Plasminogen activator inhibitor 1 RNA-binding protein 
DAFVAIVQSVK K 1176.36196 Annexin A6 
TVLVSEGIVTPR R 1270.47496 Low-density lipoprotein receptor-related protein 2 
ELWFSDDPNVTK K 1450.5478 Apoptosis-inducing factor 1, mitochondrial 
IPVGPETLGR R 1038.19816 ATP synthase subunit beta, mitochondrial 
LADDLYR R 864.9422 Attractin 
GPFPQELVR R 1042.1884 Cadherin-2 
FGFLQEFSK K 1102.2386 Contactin-2 
STTPDITGYR R 1110.1747 Fibronectin 
LWDLTTGTTTR R 1264.38426 Guanine nucleotide-binding protein subunit beta-2-like 1 
NLPLPPPPPPR R 1194.42514 Heterogeneous nuclear ribonucleoprotein K 
ALELDSNLYR R 1193.30636 Myosin-9 
LLTSGYLQR R 1050.20886 Ubiquitin thioesterase OTUB1 
TPENFPZK K 992.1065 Plasminogen 
ETLPAEQDLTTK K 1345.45214 Proteasome subunit alpha type-1 
DLPVSEQQER R 1200.25594 26S proteasome non-ATPase regulatory subunit 13 
NSLTFPDDNDISK K 1465.51784 Rho-associated protein kinase 1 
ITQSEFDR R 995.04424 Endophilin-B1 
LHLDYIGPZK K 1215.42114 SPARC 
ALDLDSSZK K 1008.10436 Stress-induced-phosphoprotein 1 
ALASQLQDSLK K 1173.31672 Vinculin 
AENYWWR R 1024.08854 Activated CDC42 kinase 1 
LSDPANWLK K 1043.17316 Cadherin-2 
FSVSPVVR R 890.03778 Elongation factor 2 
VQQTVQDLFGR R 1290.42484 Stress-70 protein, mitochondrial 
LLEYTPTAR R 1063.20432 Glycogen synthase kinase-3 beta 
ALLSAPWYLNR R 1303.50796 Beta-hexosaminidase subunit alpha 
DAEEWFFTK K 1172.24232 Keratin, type I cytoskeletal 14 
ITQYLDAGGIPR R 1303.46336 Calcium/calmodulin-dependent protein kinase type II subunit alpha 
ALTSELANAR R 1045.14774 Moesin 
LENLEQYSR R 1151.22662 Neuronal pentraxin-1 
ILEFFGLK K 966.1735 Protein disulfide-isomerase 
VYLSEZK K 898.03502 Plasminogen 
LPLVTPHTQZR R 1321.54814 26S protease regulatory subunit 4 
DYLHYIR R 979.08944 40S ribosomal protein S11 
FGISSVPTK K 935.0751 SAP domain-containing ribonucleoprotein 
VSTEVDAR R 875.92354 Transaldolase 
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GYAPESVLER R 1120.21258 tRNA pseudouridine synthase A, mitochondrial 
LLQTLPQLR R 1081.30902 E3 ubiquitin-protein ligase UBR4 
DPLADLNIK K 998.131 Clathrin coat assembly protein AP180 
YVEZSALTQK K 1198.34602 Cell division control protein 42 homolog 
LVFSNVNLK K 1033.2214 DNA damage-binding protein 1 
LQSQLLSIEK K 1158.34514 Dynamin-1 
SADZSVEEEPWK K 1436.49976 Excitatory amino acid transporter 2 
ELEASEELDTIZPK K 1633.77228 Glutaredoxin-3 
DAGQISGLNVLR R 1242.38204 Stress-70 protein, mitochondrial 
EPGZGZZSVZAR R 1412.5959 Insulin-like growth factor-binding protein 2 
ENIWDGVTTK K 1162.24926 Protein kinase C beta type 
EVZQLLPFLVR R 1373.66246 Neurochondrin 
DQLVLGR R 799.91524 Platelet-derived growth factor receptor beta 
LAYINPDLALEEK K 1488.68036 Stress-induced-phosphoprotein 1 
IIALDGDTK K 945.06838 Transketolase 
DTQLQQIVDK K 1187.30024 Calcineurin subunit B type 1 
NSQGEEVAQR R 1117.12758 Lamin-B1 
ELIFQETAR R 1106.22906 Mitogen-activated protein kinase 3 
TIVLQESIGK K 1087.26724 TGF-beta receptor type-1 
QENGASVILR R 1086.19966 Elongation factor 1-delta 
ISZTIANR R 934.07218 Fibronectin 
TPFLLVGTQIDLR R 1472.72732 Cell division control protein 42 homolog 
LLGYVATLK K 977.1979 Cold shock domain-containing protein E1 
ALFAISZLVR R 1149.40612 Hsp70-binding protein 1 
GEFTIETEGK K 1110.1714 Glycine--tRNA ligase 
DNPGVVTZLDEAR R 1445.55464 Ubiquitin-like modifier-activating enzyme 1 
IEAAZFATIK K 1123.32248 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 
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Sequence Sequence (mod) Monoisot. 
Mass 
Description 
GGSASVWSER GGSASVWSEX 1044.48638 Aldehyde dehydrogenase family 16 member A1 
YQGLCPPVPR YQGLZPPVPX 1195.60472 Angiotensin-converting enzyme 
IGYSSPQTLADQSSK IGYSSPQTLADQSSB 1588.78241 Long-chain-fatty-acid--CoA ligase 3 
IGYSSPLTLSDQSSK IGYSSPLTLSDQSSB 1589.80281 Long-chain-fatty-acid--CoA ligase 4 
ALQSNHFELSLR ALQSNHFELSLX 1423.74472 Agrin 
HSFFSGVNWQDVYDK HSFFSGVNWQDVYDB 1835.83583 RAC-gamma serine/threonine-protein kinase 
INPDHIGFYR INPDHIGFYX 1240.62281 Glutamyl aminopeptidase 
LTFDEYR LTFDEYX 952.45296 Annexin A3 
NAGFTPQER NAGFTPQEX 1028.49147 DNA-(apurinic or apyrimidinic site) lyase 
STYPPSGPTYR STYPPSGPTYX 1234.58577 Acid ceramidase 
IADFGWSVHAPSLR IADFGWSVHAPSLX 1564.80255 Aurora kinase B 
LSDSYSNTLPVR LSDSYSNTLPVX 1360.68621 Brain-specific angiogenesis inhibitor 1-associated protein 2 
FGFPAFSGISR FGFPAFSGISX 1194.60609 Biliverdin reductase A 
SNAQGIDLNR SNAQGIDLNX 1096.55005 Carboxypeptidase E 
DNEDFQESNR DNEDFQESNX 1262.50389 Ceruloplasmin 
ELQDLALQGAK ELQDLALQGAB 1192.65428 Chromogranin-A 
AALSSFQK AALSSFQB 858.46906 COP9 signalosome complex subunit 2 
ISNYGWDQSDK ISNYGWDQSDB 1319.58734 Calcyclin-binding protein 
DLTPEHLPLLR DLTPEHLPLLX 1312.73783 m7GpppX diphosphatase 
EFTAQNLGK EFTAQNLGB 1014.52255 Eukaryotic translation initiation factor 3 subunit H 
DDFTEFGK DDFTEFGB 965.42216 Eukaryotic translation initiation factor 3 subunit J 
IDIPSFDWPIAPFPR IDIPSFDWPIAPFPX 1779.92232 4-aminobutyrate aminotransferase, mitochondrial 
YIQHTYR YIQHTYX 989.49584 Rho GDP-dissociation inhibitor 1 
NQQIFLR NQQIFLX 927.51657 Growth factor receptor-bound protein 2 
GVGASGSFR GVGASGSFX 846.42232 Histone H1.0 
FGLFTPGSR FGLFTPGSX 990.51622 Coproporphyrinogen-III oxidase, mitochondrial 
HSGPNSADSANDGFVR HSGPNSADSANDGFVX 1639.72141 Heterogeneous nuclear ribonucleoprotein F 
LGDGLFLQCCR LGDGLFLQZZX 1347.63028 Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial 
TEAESWYQTK TEAESWYQTB 1249.57063 Keratin, type II cytoskeletal 5 
YEELQQTAGR YEELQQTAGX 1203.57593 Keratin, type II cytoskeletal 5 
HLSSGDLLR HLSSGDLLX 1006.5435 GTP:AMP phosphotransferase AK3, mitochondrial 
TSLPWQGLK TSLPWQGLB 1036.57967 Casein kinase I isoform alpha 
LQEFNAR LQEFNAX 886.45363 Calcium/calmodulin-dependent protein kinase type IV 
GFCLPPHCSR GFZLPPHZSX 1239.55164 Creatine kinase B-type 
SGYFDER SGYFDEX 882.37471 Creatine kinase U-type, mitochondrial 
LGSGPDGEPTIR LGSGPDGEPTIX 1207.60721 Protein kinase C gamma type 
ASSSLGLQDFDLLR ASSSLGLQDFDLLX 1530.79172 Protein kinase C iota type 
ISQGLGLQDFDLIR ISQGLGLQDFDLIX 1583.85465 Protein kinase C zeta type 
TEEGPTLSYGR TEEGPTLSYGX 1218.57559 Matrin-3 
TDFGIFR TDFGIFX 864.43691 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial 
HIGYDDSSK HIGYDDSSB 1028.46543 S-adenosylmethionine synthase isoform type-2 
LPLPEPWR LPLPEPWX 1016.56825 UPF0160 protein MYG1, mitochondrial 
ELLPEIR ELLPEIX 878.51007 Nuclear autoantigenic sperm protein 
LVEPGSPAEK LVEPGSPAEB 1033.5535 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 
VDNDENEHQLSLR VDNDENEHQLSLX 1577.73092 Nucleophosmin 
LTLEDSGTYECR LTLEDSGTYEZX 1452.64302 Neuroplastin 
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VAQLPLSLK VAQLPLSLB 975.6208 Neuronal pentraxin receptor 
LLLPLFR LLLPLFX 880.57736 N-terminal Xaa-Pro-Lys N-methyltransferase 1 
DFSLEQLR DFSLEQLX 1016.51662 Membrane-associated progesterone receptor component 2 
ELCGTPGYLAPEILK ELZGTPGYLAPEILB 1667.86836 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform 
FGIDDQDFQNSLTR FGIDDQDFQNSLTX 1664.76697 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 
SAPLPNDSQAR SAPLPNDSQAX 1164.57626 Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha 
LFTNFHR LFTNFHX 943.49035 Phosphatidylinositol transfer protein alpha isoform 
CPLQDFLR ZPLQDFLX 1057.52541 Lysosomal acid phosphatase 
FPLGPCPR FPLGPZPX 952.48281 Lysosomal acid phosphatase 
ELSELSLLSLYGIHK ELSELSLLSLYGIHB 1708.94906 Prostatic acid phosphatase 
APLDIPIPDPPPK APLDIPIPDPPPB 1376.77946 Proteasome activator complex subunit 2 
SLEPDTFQGLER SLEPDTFQGLEX 1400.68111 Reticulon-4 receptor-like 2 
IGPLGLSPK IGPLGLSPB 888.55238 60S ribosomal protein L12 
YSLDPENPTK YSLDPENPTB 1170.56481 60S ribosomal protein L17 
LLADQAEAR LLADQAEAX 995.52751 60S ribosomal protein L19 
LSYNTASNK LSYNTASNB 1004.50183 60S ribosomal protein L34 
LDELYGTWR LDELYGTWX 1161.56938 60S ribosomal protein L4 
ANPFGGASHAK ANPFGGASHAB 1063.52902 40S ribosomal protein S23 
SLQAQLQR SLQAQLQX 952.53295 Phosphatidylinositide phosphatase SAC1 
NFSDNQLQEGK NFSDNQLQEGB 1286.59824 Transgelin-2 
VGEFSGANK VGEFSGANB 915.45413 Thioredoxin 
SCHTGLGR SZHTGLGX 896.4162 Serotransferrin 
LPDGTSLTQTFR LPDGTSLTQTFX 1344.69129 UBX domain-containing protein 1 
AFHPFIAGPYNR AFHPFIAGPYNX 1398.7072 Vigilin 
ASLYPCPETPQER ASLYPZPETPQEX 1556.71685 V-type proton ATPase 116 kDa subunit a isoform 1 
AGQAVDDFIEK AGQAVDDFIEB 1199.59134 6-phosphogluconate dehydrogenase, decarboxylating 
LCFFYNK LZFFYNB 998.47752 Afamin 
ALANSLACQGK ALANSLAZQGB 1139.58483 Fructose-bisphosphate aldolase A 
SEIDLLDIR SEIDLLDIX 1082.58469 Annexin A3 
NHLLHVFDEYK NHLLHVFDEYB 1421.71828 Annexin A4 
VAPPGLTQIPQIQK VAPPGLTQIPQIQB 1496.88059 Sodium/potassium-transporting ATPase subunit beta-1 
HEQNIDCGGGYVK HEQNIDZGGGYVB 1483.66051 Calreticulin 
EETPGTEWEK EETPGTEWEB 1212.53898 Clathrin light chain B 
VTEQEWR VTEQEWX 956.45911 Clathrin light chain B 
VAHQLQALR VAHQLQALX 1044.60677 Chromogranin-A 
DFLPLYFGWFLTK DFLPLYFGWFLTB 1653.86862 2',3'-cyclic-nucleotide 3'-phosphodiesterase 
YNTPGFSGCLSGVR YNTPGFSGZLSGVX 1523.70662 Contactin-associated protein 1 
LFTAESLIGLK LFTAESLIGLB 1198.70525 Coatomer subunit delta 
VTQVDGNSPVR VTQVDGNSPVX 1180.60756 Coatomer subunit delta 
FIPCSPFSDYVYK FIPZSPFSDYVYB 1629.76285 Dihydropyrimidinase-related protein 3 
SAADLISQAR SAADLISQAX 1040.54898 Dihydropyrimidinase-related protein 3 
VTNLSEDTR VTNLSEDTX 1043.51227 Eukaryotic translation initiation factor 3 subunit G 
HELLSLASSNHLGK HELLSLASSNHLGB 1512.81397 Eukaryotic translation initiation factor 3 subunit H 
ILYLTPEQEK ILYLTPEQEB 1240.67944 Eukaryotic peptide chain release factor subunit 1 
VGENADSQIK VGENADSQIB 1067.53384 Histone H1.0 
GQLEQITGK GQLEQITGB 980.5382 Heterochromatin protein 1-binding protein 3 
NVTLNPDPNEIK NVTLNPDPNEIB 1360.70778 Isopentenyl-diphosphate Delta-isomerase 1 
EVSFDVELPK EVSFDVELPB 1169.60593 Inter-alpha-trypsin inhibitor heavy chain H3 
IGLIQGNR IGLIQGNX 879.51656 6-phosphofructokinase, muscle type 
TVGIDDLTGEPLIQR TVGIDDLTGEPLIQX 1635.87069 GTP:AMP phosphotransferase AK3, mitochondrial 
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ILQGGVGIPHIR ILQGGVGIPHIX 1268.75923 Casein kinase I isoform alpha 
YLEESNFVHR YLEESNFVHX 1302.62321 Tyrosine-protein kinase SYK 
YHEEFEK YHEEFEB 988.43815 LIM and SH3 domain protein 1 
SADTLWGIQK SADTLWGIQB 1125.59096 L-lactate dehydrogenase A chain 
LTTVPTQAFEYLSK LTTVPTQAFEYLSB 1604.85411 Leucine-rich repeat-containing protein 4B 
VLNHPNIVK VLNHPNIVB 1040.6222 Serine/threonine-protein kinase MARK2 
NSIASCADEQPHIGNYR NSIASZADEQPHIGNYX 1940.86743 MAP/microtubule affinity-regulating kinase 3 
DLGSELVR DLGSELVX 897.4795 Hepatocyte growth factor receptor 
FVIGGPQGDAGLTGR FVIGGPQGDAGLTGX 1453.75526 S-adenosylmethionine synthase isoform type-2 
LFPDVLFPADSEHNK LFPDVLFPADSEHNB 1735.86605 Mitogen-activated protein kinase 8 
HAFFEGLNWENIR HAFFEGLNWENIX 1641.79272 Serine/threonine-protein kinase MRCK beta 
EGLEETLR EGLEETLX 955.48498 Neurofilament light polypeptide 
FACHSASLTVR FAZHSASLTVX 1257.61635 Non-POU domain-containing octamer-binding protein 
TGTSCALDCGAGIGR TGTSZALDZGAGIGX 1504.66376 N-terminal Xaa-Pro-Lys N-methyltransferase 1 
VEGGTPLFTLR VEGGTPLFTLX 1198.65852 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial 
IQDLIDDK IQDLIDDB 966.51131 Pachytene checkpoint protein 2 homolog 
GFLLWYSGR GFLLWYSGX 1107.57407 Procollagen C-endopeptidase enhancer 1 
ALLPILQWHK ALLPILQWHB 1225.74264 [Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 1, 
mitochondrial 
SGGASHSELIHNLR SGGASHSELIHNLX 1486.75159 Protein-L-isoaspartate(D-aspartate) O-methyltransferase 
SNFGYNIPLK SNFGYNIPLB 1159.6117 Proteasome subunit alpha type-3 
DGSSGGVIR DGSSGGVIX 856.4278 Proteasome subunit beta type-6 
LFLQNNLIR LFLQNNLIX 1139.66904 Reticulon-4 receptor-like 2 
IDIDPEETVK IDIDPEETVB 1165.59576 UV excision repair protein RAD23 homolog B 
VELCSFSGYK VELZSFSGYB 1196.5627 60S ribosomal protein L24 
VFQFLNAK VFQFLNAB 973.54764 60S ribosomal protein L24 
NCSSFLIK NZSSFLIB 975.4939 60S ribosomal protein L28 
YNGLIHR YNGLIHX 881.4747 60S ribosomal protein L28 
TGSQGQCTQVR TGSQGQZTQVX 1230.56506 40S ribosomal protein S28 
DVTCDVHYENYR DVTZDVHYENYX 1579.66007 Septin-5 
IYEFPETDDEEENK IYEFPETDDEEENB 1764.74573 Septin-7 
TPPSEEDSAEAER TPPSEEDSAEAEX 1426.60873 Small glutamine-rich tetratricopeptide repeat-containing protein alpha 
VADISGDTQK VADISGDTQB 1040.52294 Staphylococcal nuclease domain-containing protein 1 
SIEQSIEQEEGLNR SIEQSIEQEEGLNX 1640.7881 Syntaxin-1A 
IADGYEQAAR IADGYEQAAX 1102.52824 T-complex protein 1 subunit epsilon 
LNWLSVDFNNWK LNWLSVDFNNWB 1542.77105 Prostaglandin E synthase 3 
VLDASWYSPGTR VLDASWYSPGTX 1360.66507 Thiosulfate sulfurtransferase 
DEFPLLTTK DEFPLLTTB 1070.57391 Thymidylate synthase 
TFEDIPLEEPEVK TFEDIPLEEPEVB 1552.77517 Vascular endothelial growth factor receptor 2 
DLLNHAFFQEETGVR DLLNHAFFQEETGVX 1784.87209 Serine/threonine-protein kinase WNK1 
EVYLSGSFNNWSK EVYLSGSFNNWSB 1537.72925 5'-AMP-activated protein kinase subunit beta-1 
LTLLAQQK LTLLAQQB 921.57386 Long-chain-fatty-acid--CoA ligase 4 
EGYSGVGLLSR EGYSGVGLLSX 1146.59084 DNA-(apurinic or apyrimidinic site) lyase 
YNPNVLPVQCTGK YNPNVLPVQZTGB 1496.75369 Sodium/potassium-transporting ATPase subunit beta-1 
ATLWYVPLSLK ATLWYVPLSLB 1297.75254 Cytosolic acyl coenzyme A thioester hydrolase 
IIQLIEGK IIQLIEGB 920.5786 3'(2'),5'-bisphosphate nucleotidase 1 
AEEDEILNR AEEDEILNX 1097.52282 Calnexin 
CVNTTLQIK ZVNTTLQIB 1083.58378 Adenylyl cyclase-associated protein 1 
YPLYVLK YPLYVLB 902.53568 Carboxypeptidase B2 
FTQISPVWLQLK FTQISPVWLQLB 1466.83767 Chitinase domain-containing protein 1 
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HVVFYPTLK HVVFYPTLB 1110.6317 Chitinase domain-containing protein 1 
AVLFCLSEDK AVLFZLSEDB 1188.59399 Cofilin-1 
HELQANCYEEVK HELQANZYEEVB 1526.69148 Cofilin-1 
HGVFLVR HGVFLVX 836.48961 Adapter molecule crk 
SINSILDYISTSK SINSILDYISTSB 1447.76497 COP9 signalosome complex subunit 2 
NVLCSACSGQGGK NVLZSAZSGQGGB 1344.60056 DnaJ homolog subfamily A member 2 
ELAEQLGLSTGEK ELAEQLGLSTGEB 1381.718 Eukaryotic translation initiation factor 3 subunit G 
NVLVSSNDCVK NVLVSSNDZVB 1241.61653 Focal adhesion kinase 1 
LLLAGYDDFNCNVWDAL
K 
LLLAGYDDFNZNVWDAL
B 
2134.02844 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 
SIQEIQELDK SIQEIQELDB 1209.63322 Rho GDP-dissociation inhibitor 1 
VAPSAVLGPNVSIGK VAPSAVLGPNVSIGB 1415.82273 Mannose-1-phosphate guanyltransferase alpha 
HDGAFLIR HDGAFLIX 937.5009 Growth factor receptor-bound protein 2 
TFDEIASGFR TFDEIASGFX 1151.54864 Solute carrier family 2, facilitated glucose transporter member 1 
VICAEEPYICK VIZAEEPYIZB 1388.65594 GMP synthase [glutamine-hydrolyzing] 
GLPWSCSADEVQR GLPWSZSADEVQX 1513.68588 Heterogeneous nuclear ribonucleoprotein H 
VDPEIQNVK VDPEIQNVB 1048.56441 Keratin, type II cytoskeletal 2 epidermal 
SEIDNVK SEIDNVB 811.41669 Keratin, type II cytoskeletal 1 
LTTFQALQHPWVTGK LTTFQALQHPWVTGB 1733.93442 Calcium/calmodulin-dependent protein kinase type IV 
VLTPELYAELR VLTPELYAELX 1312.7266 Creatine kinase B-type 
FEACNYPLELYER FEAZNYPLELYEX 1712.77436 Protein kinase C gamma type 
YAVTDDYQLSK YAVTDDYQLSB 1309.62814 MAP kinase-activated protein kinase 3 
LETLGIGQR LETLGIGQX 995.5639 Methionine adenosyltransferase 2 subunit beta 
FQFPSHVTDVSEEAK FQFPSHVTDVSEEAB 1727.82459 Serine/threonine-protein kinase MRCK beta 
DQGTYEDYVEGLR DQGTYEDYVEGLX 1553.68732 Myosin light polypeptide 6 
YAVLYQPLFDK YAVLYQPLFDB 1363.72672 Nucleosome assembly protein 1-like 1 
VGWIFTDLVSEDTR VGWIFTDLVSEDTX 1646.81793 Nuclear protein localization protein 4 homolog 
GPSSVEDIK GPSSVEDIB 938.48001 Nucleophosmin 
EFSPFGTITSAK EFSPFGTITSAB 1291.65395 Polyadenylate-binding protein 1 
GYGFVHFETQEAAER GYGFVHFETQEAAEX 1749.79859 Polyadenylate-binding protein 1 
DGLILTSR DGLILTSX 883.50024 Protein DJ-1 
FYGPAGPYGIFAGR FYGPAGPYGIFAGX 1481.73307 Membrane-associated progesterone receptor component 2 
IITEGASILR IITEGASILX 1081.63706 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 
GVNTFSPEGR GVNTFSPEGX 1072.51768 Proteasome subunit alpha type-5 
TTTGSYIANR TTTGSYIANX 1092.54391 Proteasome subunit beta type-6 
YSSPANLYVR YSSPANLYVX 1178.59594 Receptor-type tyrosine-protein phosphatase S 
TFAYTNHTVLPEALER TFAYTNHTVLPEALEX 1870.94526 Glycogen phosphorylase, liver form 
EILGTAQSVGCNVDGR EILGTAQSVGZNVDGX 1684.80778 60S ribosomal protein L12 
STESLQANVQR STESLQANVQX 1241.62395 60S ribosomal protein L13 
TIGISVDPR TIGISVDPX 966.53735 60S ribosomal protein L13 
NQSFCPTVNLDK NQSFZPTVNLDB 1429.67511 60S ribosomal protein L27a 
DETEFYLGK DETEFYLGB 1108.51679 60S ribosomal protein L35a 
AGNFYVPAEPK AGNFYVPAEPB 1199.6066 60S ribosomal protein L7 
IVEPYIAWGYPNLK IVEPYIAWGYPNLB 1669.8959 60S ribosomal protein L7 
HFYWYLTNEGIQYLR HFYWYLTNEGIQYLX 2011.98199 40S ribosomal protein S10 
TVQVEQSK TVQVEQSB 925.49601 Septin-7 
HSAILASPNPDEK HSAILASPNPDEB 1385.70302 Syntaxin-1A 
AVFDETYPDPVR AVFDETYPDPVX 1417.67529 Alanine--tRNA ligase, cytoplasmic 
ALYESEENCEVDPIK ALYESEENZEVDPIB 1802.81237 Ras/Rap GTPase-activating protein SynGAP 
ALTVPELTQQVFDAK ALTVPELTQQVFDAB 1666.90211 Tubulin beta chain 
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SEALGVGDVK SEALGVGDVB 981.5222 Testin 
SPQELLCGASLISDR SPQELLZGASLISDX 1654.82237 Prothrombin 
YGFYTHVFR YGFYTHVFX 1198.57989 Prothrombin 
TVSVLNGGFR TVSVLNGGFX 1058.5748 Thiosulfate sulfurtransferase 
TATPQQAQEVHEK TATPQQAQEVHEB 1473.73031 Triosephosphate isomerase 
DQYELLCLDNTR DQYELLZLDNTX 1548.71177 Serotransferrin 
LYVELHR LYVELHX 938.52131 UBX domain-containing protein 1 
DLNPDVNVFQR DLNPDVNVFQX 1325.66032 V-type proton ATPase 116 kDa subunit a isoform 1 
FYDSWESTVK FYDSWESTVB 1268.58046 Serine/threonine-protein kinase WNK1 
LLWTLESLVTGR LLWTLESLVTGX 1396.79535 Aldehyde dehydrogenase family 16 member A1 
GIVNEQFLLQR GIVNEQFLLQX 1325.73309 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
IAFLPFGYLVDQWR IAFLPFGYLVDQWX 1733.91685 Angiotensin-converting enzyme 
VGAPLVCCEIK VGAPLVZZEIB 1252.63989 Long-chain-fatty-acid--CoA ligase 3 
AAYFGIYDTAK AAYFGIYDTAB 1226.60627 ADP/ATP translocase 2 
FLVNLVK FLVNLVB 839.53601 Afamin 
GILAADESTGSIAK GILAADESTGSIAB 1339.70743 Fructose-bisphosphate aldolase A 
TQDVFTVIR TQDVFTVIX 1087.59012 Glutamyl aminopeptidase 
SEIDLLNIR SEIDLLNIX 1081.60068 Annexin A6 
ANACNSVIK ANAZNSVIB 983.49496 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
LVASAYSIAQK LVASAYSIAQB 1157.65356 3'(2'),5'-bisphosphate nucleotidase 1 
YSFTIELR YSFTIELX 1037.54211 Carboxypeptidase B2 
LTASAPGYLAITK LTASAPGYLAITB 1312.74818 Carboxypeptidase E 
DLYSGLIGPLIVCR DLYSGLIGPLIVZX 1584.85729 Ceruloplasmin 
WDYLTQVEK WDYLTQVEB 1188.59063 Calcyclin-binding protein 
LLLQLEATK LLLQLEATB 1035.64193 Dynactin subunit 2 
INCPVYITK INZPVYITB 1114.59361 Dihydropyrimidinase-related protein 1 
VAVFFGGLSIK VAVFFGGLSIB 1144.67355 Spliceosome RNA helicase DDX39B 
EAALGAGFSDK EAALGAGFSDB 1072.52801 Trifunctional enzyme subunit beta, mitochondrial 
VNQIGSVTESLQACK VNQIGSVTESLQAZB 1640.82831 Alpha-enolase 
TAIQAAGYPDK TAIQAAGYPDB 1141.58587 Beta-enolase 
VNQIGSVTESIQACK VNQIGSVTESIQAZB 1640.82831 Beta-enolase 
AVLHVALR AVLHVALX 887.55802 Glucose-6-phosphate isomerase 
AVILIGGPQK AVILIGGPQB 1002.63169 Mannose-1-phosphate guanyltransferase alpha 
VTILELFR VTILELFX 999.59922 Solute carrier family 2, facilitated glucose transporter member 1 
GIVEECCFR GIVEEZZFX 1178.50877 Insulin-like growth factor II 
VLVVHDGFEGLAK VLVVHDGFEGLAB 1390.76996 6-phosphofructokinase, muscle type 
NPDSQYGELIEK NPDSQYGELIEB 1399.67106 UMP-CMP kinase 
LSVEIWDWDR LSVEIWDWDX 1327.6436 Protein kinase C alpha type 
EFIWGVFGK EFIWGVFGB 1089.57384 Protein kinase C eta type 
SVVYQETNGETR SVVYQETNGETX 1391.65564 Phosphoribosyl pyrophosphate synthase-associated protein 1 
HLEILQLSK HLEILQLSB 1087.64808 Leucine-rich repeat-containing protein 4B 
ITPENLPQILLQLK ITPENLPQILLQLB 1626.97997 Matrin-3 
DLIGFGLQVAK DLIGFGLQVAB 1167.67428 Hepatocyte growth factor receptor 
VCGSNLLSICK VZGSNLLSIZB 1257.63007 Myelin proteolipid protein 
FFLCQVAGDAK FFLZQVAGDAB 1262.62087 Neural cell adhesion molecule 1 
FIVLSNNYLQIR FIVLSNNYLQIX 1488.83281 Neural cell adhesion molecule 1 
IDVAFVDR IDVAFVDX 943.50023 Pachytene checkpoint protein 2 homolog 
FNVYCFR FNVYZFX 1014.46209 Brevican core protein 
GVVFLYR GVVFLYX 862.49403 Brevican core protein 
LTAEQALQHPFFER LTAEQALQHPFFEX 1695.8608 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform 
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LEESVALR LEESVALX 925.5108 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform 
FVTLVFR FVTLVFX 890.52533 Prostatic acid phosphatase 
AVENSSTAIGIR AVENSSTAIGIX 1226.64942 Proteasome subunit alpha type-3 
ANINIEK ANINIEB 808.45341 Ras-related protein Rab-10 
DTLYEAVR DTLYEAVX 975.49007 60S ribosomal protein L10a 
IEGVYAR IEGVYAX 816.43691 60S ribosomal protein L35a 
FCIWTESAFR FZIWTESAFX 1325.6102 60S ribosomal protein L4 
DYLHLPPEIVPATLR DYLHLPPEIVPATLX 1742.95944 40S ribosomal protein S10 
LGEWVGLCK LGEWVGLZB 1068.55173 40S ribosomal protein S12 
VVGCSCVVVK VVGZSZVVVB 1113.57657 40S ribosomal protein S12 
IVVNLTGR IVVNLTGX 880.53696 40S ribosomal protein S15a 
NAWADNANACAK NAWADNANAZAB 1312.57097 Phosphatidylinositide phosphatase SAC1 
FLEEFITPIVK FLEEFITPIVB 1342.76276 DNA topoisomerase 2-alpha 
TLAVSGLGVVGR TLAVSGLGVVGX 1137.6745 DNA topoisomerase 2-alpha 
ITAFVVER ITAFVVEX 943.53662 Very long-chain specific acyl-CoA dehydrogenase, mitochondrial 
HDAVTDTIDIAPNQR HDAVTDTIDIAPNQX 1674.82006 Activin receptor type-1B 
AYGTGFVGCLR AYGTGFVGZLX 1209.58398 Agrin 
ANILYAWAR ANILYAWAX 1086.58497 Peptidyl-glycine alpha-amidating monooxygenase 
NNLVIFHR NNLVIFHX 1021.56966 Peptidyl-glycine alpha-amidating monooxygenase 
WYVVQTNYDR WYVVQTNYDX 1352.63887 Acid ceramidase 
IYLILEYAPR IYLILEYAPX 1259.71531 Aurora kinase B 
NLFIQVDYFPLTEQK NLFIQVDYFPLTEQB 1861.97053 Contactin-associated protein 1 
LLHEVQELTTEVEK LLHEVQELTTEVEB 1674.89194 Dynactin subunit 2 
AYALAFAER AYALAFAEX 1020.52678 Peroxisomal multifunctional enzyme type 2 
TLEVEIEPGVR TLEVEIEPGVX 1250.67456 DnaJ homolog subfamily B member 11 
NCPHIVVGTPGR NZPHIVVGTPGX 1315.66944 Spliceosome RNA helicase DDX39B 
LAAAFAVSR LAAAFAVSX 914.5213 Trifunctional enzyme subunit beta, mitochondrial 
VIGNGSFGVVYQAR VIGNGSFGVVYQAX 1475.77601 Glycogen synthase kinase-3 alpha 
GASGSFVVVQK GASGSFVVVQB 1085.59604 Heterochromatin protein 1-binding protein 3 
DIDILIVR DIDILIVX 965.57848 Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial 
AFSVFLFNTENK AFSVFLFNTENB 1423.7227 Isopentenyl-diphosphate Delta-isomerase 1 
GFSSGSAVVSGGSR GFSSGSAVVSGGSX 1263.60828 Keratin, type II cytoskeletal 2 epidermal 
GTEELYAIK GTEELYAIB 1030.54261 Protein kinase C alpha type 
IGEAVGLQPTR IGEAVGLQPTX 1149.63812 Protein kinase C eta type 
NVLLVTQHYAK NVLLVTQHYAB 1292.73321 Tyrosine-protein kinase SYK 
GFSVVADTPELQR GFSVVADTPELQX 1427.72839 LIM and SH3 domain protein 1 
VTLITENLGHPR VTLITENLGHPX 1358.75455 Low-density lipoprotein receptor-related protein 2 
AVLENNLGAAVLR AVLENNLGAAVLX 1348.77019 Methionine adenosyltransferase 2 subunit beta 
GLSATVTGGQK GLSATVTGGQB 1025.55966 Myelin proteolipid protein 
AGEVFIHK AGEVFIHB 907.50068 Non-POU domain-containing octamer-binding protein 
GIPEFWLTVFK GIPEFWLTVFB 1343.73688 Nucleosome assembly protein 1-like 1 
FVALENISCK FVALENISZB 1187.60998 Nuclear protein localization protein 4 homolog 
SDLYIGGVAK SDLYIGGVAB 1029.55859 Neurexin-1 
GLVVPVIR GLVVPVIX 861.56752 Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate 
dehydrogenase complex, mitochondrial 
VTVAGLAGK VTVAGLAGB 822.50543 Protein DJ-1 
YGSVTVWR YGSVTVWX 976.50058 Serine/threonine-protein phosphatase 4 catalytic subunit 
GFFLLVEGGR GFFLLVEGGX 1103.60027 Alkaline phosphatase, tissue-nonspecific isozyme 
NILQLHDLTTGALLK NILQLHDLTTGALLB 1656.96538 Prolyl endopeptidase 
DTNGSQFFITTVK DTNGSQFFITTVB 1464.734 Peptidyl-prolyl cis-trans isomerase B 
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VNLAELFK VNLAELFB 940.5473 Peroxiredoxin-5, mitochondrial 
FSNQETSVEIGESVR FSNQETSVEIGESVX 1690.80375 Ribose-phosphate pyrophosphokinase 2 
DGIVLGADTR DGIVLGADTX 1025.53807 Proteasome subunit beta type-7 
FHTITTSYYR FHTITTSYYX 1297.63306 Ras-related protein Rab-10 
ASVDELFAEIVR ASVDELFAEIVX 1357.71167 Ras-related protein Rap-2b 
LWTLVSEQTR LWTLVSEQTX 1241.66435 60S ribosomal protein L27a 
AFLIEEQK AFLIEEQB 984.53713 60S ribosomal protein L34 
FLDGIYVSEK FLDGIYVSEB 1177.61102 60S ribosomal protein L9 
LTNVAVVR LTNVAVVX 880.53696 Ribosome maturation protein SBDS 
GLLDVTCK GLLDVTZB 912.48299 S-phase kinase-associated protein 1 
SSHYDELLAAEAR SSHYDELLAAEAX 1470.69782 Staphylococcal nuclease domain-containing protein 1 
LVVVDFSATWCGPCK LVVVDFSATWZGPZB 1745.83602 Thioredoxin 
ASVITQVFHVPLEER ASVITQVFHVPLEEX 1733.93396 Vigilin 
TAFDEAIAELDTLNEESY
K 
TAFDEAIAELDTLNEESY
B 
2166.00954 14-3-3 protein beta/alpha 
SIDDEVVEQR SIDDEVVEQX 1198.5705 5'-AMP-activated protein kinase catalytic subunit alpha-2 
AEDGSVIDYELIDQDAR AEDGSVIDYELIDQDAX 1917.8831 Annexin A2 
NSVSQISVLSGGK NSVSQISVLSGGB 1282.69722 Actin-related protein 2/3 complex subunit 1B 
LEVEANNAFDQYR LEVEANNAFDQYX 1577.73494 F-actin-capping protein subunit beta 
STLNEIYFGK STLNEIYFGB 1178.60628 F-actin-capping protein subunit beta 
AGQVFLEELGNHK AGQVFLEELGNHB 1448.7503 2',3'-cyclic-nucleotide 3'-phosphodiesterase 
VSHYIINSLPNR VSHYIINSLPNX 1421.76546 Crk-like protein 
ITNSLTVLCSEK ITNSLTVLZSEB 1371.71591 Eukaryotic translation initiation factor 3 subunit J 
FAEIVNTLDK FAEIVNTLDB 1156.62192 Ephrin type-B receptor 1 
AQLSTILEEEK AQLSTILEEEB 1267.67508 Focal adhesion kinase 1 
EAEILEVLR EAEILEVLX 1080.60542 Coproporphyrinogen-III oxidase, mitochondrial 
AHQLWLSVEALK AHQLWLSVEALB 1401.78596 Mitochondrial inner membrane protein 
VVSQYHELVVQAR VVSQYHELVVQAX 1536.82878 Mitochondrial inner membrane protein 
TNAENEFVTIK TNAENEFVTIB 1272.64412 Keratin, type II cytoskeletal 1 
AASAHAIGTVK AASAHAIGTVB 1032.58072 cAMP-dependent protein kinase type II-beta regulatory subunit 
GQDIFIIQTIPR GQDIFIIQTIPX 1409.7906 Phosphoribosyl pyrophosphate synthase-associated protein 1 
EAFTVIDQNR EAFTVIDQNX 1201.59666 Myosin regulatory light chain 2, skeletal muscle isoform 
GADPEDVITGAFK GADPEDVITGAFB 1326.65466 Myosin regulatory light chain 2, skeletal muscle isoform 
ALVEEALAQR ALVEEALAQX 1108.61157 UPF0160 protein MYG1, mitochondrial 
HVLVTLGEK HVLVTLGEB 1002.59531 Myosin light polypeptide 6 
ITTQITAGAR ITTQITAGAX 1040.58537 Neurexin-1 
GCITIIGGGDTATCCAK GZITIIGGGDTATZZAB 1761.7939 Phosphoglycerate kinase 1 
EILVEESNVQR EILVEESNVQX 1324.6862 Serine/threonine-protein phosphatase 4 catalytic subunit 
SVGIVTTTR SVGIVTTTX 942.53736 Alkaline phosphatase, tissue-nonspecific isozyme 
FGPYYTEPVIAGLDPK FGPYYTEPVIAGLDPB 1773.90685 Proteasome subunit beta type-3 
IEDGNDFGVAIQEK IEDGNDFGVAIQEB 1541.74527 Proteasome activator complex subunit 2 
SAINEVVTR SAINEVVTX 997.54317 60S ribosomal protein L31 
DFNHINVELSLLGK DFNHINVELSLLGB 1605.86058 60S ribosomal protein L9 
EGDVLTLLESER EGDVLTLLESEX 1369.69642 40S ribosomal protein S28 
DIATIVADK DIATIVADB 952.53204 Ribosome maturation protein SBDS 
AIELNPANAVYFCNR AIELNPANAVYFZNX 1760.85434 Small glutamine-rich tetratricopeptide repeat-containing protein alpha 
ISVYYNEATGGK ISVYYNEATGGB 1308.64412 Tubulin beta chain 
VVLAYEPVWAIGTGK VVLAYEPVWAIGTGB 1609.89589 Triosephosphate isomerase 
GSLTFEPLTLVPIQTK GSLTFEPLTLVPIQTB 1750.99601 Xaa-Pro aminopeptidase 1 
TIVLQEIIGK TIVLQEIIGB 1120.69469 Activin receptor type-1B 
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EGDLITLLVPEAR EGDLITLLVPEAX 1434.79573 Brain-specific angiogenesis inhibitor 1-associated protein 2 
FGVVVVGVGR FGVVVVGVGX 997.59479 Biliverdin reductase A 
INSITVDNCK INSITVDNZB 1170.57942 Adenylyl cyclase-associated protein 1 
IGLVEALCGFQFTFK IGLVEALZGFQFTFB 1736.90508 DnaJ homolog subfamily A member 2 
LGGEVSCLVAGTK LGGEVSZLVAGTB 1297.67911 Electron transfer flavoprotein subunit alpha, mitochondrial 
SFLIWVNEEDHTR SFLIWVNEEDHTX 1654.79787 Creatine kinase U-type, mitochondrial 
LGIYTVLFER LGIYTVLFEX 1219.68401 Mitochondrial 2-oxoglutarate/malate carrier protein 
QVLGLGVNGK QVLGLGVNGB 991.59056 MAP kinase-activated protein kinase 3 
NIIGLLNVFTPQK NIIGLLNVFTPQB 1463.85913 Mitogen-activated protein kinase 8 
SGNVAELALK SGNVAELALB 1008.56949 Nuclear autoantigenic sperm protein 
IVTSEEVIIR IVTSEEVIIX 1167.67384 Neuroplastin 
SAAQAAAQTNSNAAGK SAAQAAAQTNSNAAGB 1467.71572 Plasminogen activator inhibitor 1 RNA-binding protein 
LNVEFALIHK LNVEFALIHB 1190.69027 Ribose-phosphate pyrophosphokinase 2 
SALTVQFVTGSFIEK SALTVQFVTGSFIEB 1633.88065 Ras-related protein Rap-2b 
HGYIGEFEIIDDHR HGYIGEFEIIDDHX 1709.80367 40S ribosomal protein S15a 
AALCHFIVDELNAK AALZHFIVDELNAB 1607.82208 Beta-soluble NSF attachment protein 
GAFGQVIEADAFGIDK GAFGQVIEADAFGIDB 1644.82384 Vascular endothelial growth factor receptor 2 
DFLAGGVAAAISK DFLAGGVAAAISB 1226.675 ADP/ATP translocase 2 
DAFVAIVQSVK DAFVAIVQSVB 1183.6692 Annexin A6 
DIVPGDIVEIAVGDK DIVPGDIVEIAVGDB 1546.83334 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 
GQTLVVQFTVK GQTLVVQFTVB 1226.71141 Calreticulin 
IDVVVNNAGILR IDVVVNNAGILX 1291.74873 Peroxisomal multifunctional enzyme type 2 
LSVLGAITSVQQR LSVLGAITSVQQX 1380.79642 Eukaryotic peptide chain release factor subunit 1 
ETEEILADVLK ETEEILADVLB 1266.67982 Eukaryotic translation initiation factor 6 
LWAYLTIEQLLEK LWAYLTIEQLLEB 1626.91122 Inter-alpha-trypsin inhibitor heavy chain H3 
TVLVSEGIVTPR TVLVSEGIVTPX 1279.7375 Low-density lipoprotein receptor-related protein 2 
LVEVNGENVEK LVEVNGENVEB 1236.64411 Na(+)/H(+) exchange regulatory cofactor NHE-RF1 
FIATLQYIVGR FIATLQYIVGX 1289.73711 Prolyl endopeptidase 
TGTTIAGVVYK TGTTIAGVVYB 1116.62701 Proteasome subunit beta type-7 
NPILWNVADVVIK NPILWNVADVVIB 1487.85912 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 
TGQEVVFVAEPDNK TGQEVVFVAEPDNB 1539.76601 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 2 
VANVSLLALYK VANVSLLALYB 1197.72124 40S ribosomal protein S23 
GVLEELLWFIK GVLEELLWFIB 1353.77874 Thymidylate synthase 
LQLLEPFDK LQLLEPFDB 1109.62119 Aconitate hydratase, mitochondrial 
TIPWLEDR TIPWLEDX 1038.53735 Alpha-actinin-4 
SASFNTDPYVR SASFNTDPYVX 1265.59158 Protein argonaute-2 
ELWFSDDPNVTK ELWFSDDPNVTB 1457.69179 Apoptosis-inducing factor 1, mitochondrial 
SATEQSGTGIR SATEQSGTGIX 1115.54463 Apoptosis-inducing factor 1, mitochondrial 
DITSDTSGDFR DITSDTSGDFX 1222.53412 Annexin A1 
TPAQFDADELR TPAQFDADELX 1271.60213 Annexin A1 
YGTDLSR YGTDLSX 820.39545 Sodium/potassium-transporting ATPase subunit alpha-1 
FDTDELNFPTEK FDTDELNFPTEB 1462.67072 Sodium/potassium-transporting ATPase subunit alpha-2 
SPDCTHDNPLETR SPDZTHDNPLETX 1550.66588 Sodium/potassium-transporting ATPase subunit alpha-3 
IDESSLTGESDQVR IDESSLTGESDQVX 1544.71935 Plasma membrane calcium-transporting ATPase 2 
IPVGPETLGR IPVGPETLGX 1047.59519 ATP synthase subunit beta, mitochondrial 
LADDLYR LADDLYX 874.44239 Attractin 
LTLTPWVGLR LTLTPWVGLX 1164.68943 Attractin 
FSDIQIR FSDIQIX 887.47403 C-1-tetrahydrofolate synthase, cytoplasmic 
GPFPQELVR GPFPQELVX 1051.56898 Cadherin-2 
NLDENGLDLLSK NLDENGLDLLSB 1337.69179 Cyclin-dependent kinase 1 
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VVPPLDEDGR VVPPLDEDGX 1105.56428 Cyclin-dependent kinase 2 
DLLQNLLK DLLQNLLB 963.58442 Cyclin-dependent kinase 5 
IGNCPFSQR IGNZPFSQX 1087.51083 Chloride intracellular channel protein 1 
NSNPALNDNLEK NSNPALNDNLEB 1335.651 Chloride intracellular channel protein 1 
IGDWLQER IGDWLQEX 1025.51695 Dual specificity protein kinase CLK3 
FGFLQEFSK FGFLQEFSB 1109.56368 Contactin-2 
GPAGPQGPR GPAGPQGPX 845.4383 Collagen alpha-1(I) chain 
FNDILGR FNDILGX 843.44781 Casein kinase II subunit alpha 
ALQDLGLR ALQDLGLX 894.51622 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 
NLYAGDYYR NLYAGDYYX 1143.52244 Epithelial discoidin domain-containing receptor 1 
LNLSQVR LNLSQVX 838.49002 ATP-dependent RNA helicase DDX1 
TGHSLLHTLYGR TGHSLLHTLYGX 1363.72359 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 
ISLQWLR ISLQWLX 924.54205 Dipeptidyl peptidase 4 
ELLGQGLLLR ELLGQGLLLX 1120.68434 Eukaryotic translation initiation factor 3 subunit C 
SYSSGGEDGYVR SYSSGGEDGYVX 1285.54502 Eukaryotic translation initiation factor 3 subunit I 
FDTQYPYGEK FDTQYPYGEB 1254.56481 Endoplasmic reticulum resident protein 29 
SGYLSSER SGYLSSEX 907.42748 Ezrin 
FDASFFGVHPK FDASFFGVHPB 1258.62258 Fatty acid synthase 
LSPDAIPGK LSPDAIPGB 904.51091 Fatty acid synthase 
IPSNPSHR IPSNPSHX 916.47543 EGF-containing fibulin-like extracellular matrix protein 1 
LNCEDIDECR LNZEDIDEZX 1332.53136 EGF-containing fibulin-like extracellular matrix protein 1 
STTPDITGYR STTPDITGYX 1119.54357 Fibronectin 
ALELDSNNEK ALELDSNNEB 1139.55497 Peptidyl-prolyl cis-trans isomerase FKBP4 
LSFQEFLK LSFQEFLB 1018.55787 Follistatin-related protein 1 
GTPQQIDYAR GTPQQIDYAX 1157.57045 Far upstream element-binding protein 1 
QLLSFGNPR QLLSFGNPX 1040.56424 Tyrosine-protein kinase Fyn 
LWDLTTGTTTR LWDLTTGTTTX 1273.65418 Guanine nucleotide-binding protein subunit beta-2-like 1 
QLICDPSYIPDR QLIZDPSYIPDX 1485.71612 Rab GDP dissociation inhibitor alpha 
SIAFPSIGSGR SIAFPSIGSGX 1100.58536 Core histone macro-H2A.1 
NLPLPPPPPPR NLPLPPPPPPX 1203.70032 Heterogeneous nuclear ribonucleoprotein K 
ADHGEPIGR ADHGEPIGX 960.46524 Heat shock protein HSP 90-beta 
LDGNQDLIR LDGNQDLIX 1052.54898 Isocitrate dehydrogenase [NADP], mitochondrial 
DEQLESLFQR DEQLESLFQX 1273.61779 Eukaryotic translation initiation factor 2 subunit 1 
ISSSSFSR ISSSSFSX 879.43257 Keratin, type II cytoskeletal 8 
WSLLQQQK WSLLQQQB 1037.57493 Keratin, type II cytoskeletal 8 
ITADQALK ITADQALB 866.49527 Calcium/calmodulin-dependent protein kinase type II subunit gamma 
SFGNPFEGSR SFGNPFEGSX 1106.50203 Calcium/calmodulin-dependent protein kinase kinase 2 
CSLNPEWNETFR ZSLNPEWNETFX 1561.68589 Protein kinase C beta type 
ANSLEPEPWFFK ANSLEPEPWFFB 1471.72269 Tyrosine-protein kinase Lck 
IDSLSAQLSQLQK IDSLSAQLSQLQB 1437.79185 Prelamin-A/C 
LQQLPADFGR LQQLPADFGX 1153.61191 Leucine-rich repeat-containing protein 59 
GSFSLSVR GSFSLSVX 861.45838 Tyrosine-protein kinase Lyn 
IYLSSAR IYLSSAX 818.45257 Mitogen-activated protein kinase kinase kinase 1 
EIQGLFDELR EIQGLFDELX 1228.6327 Mitogen-activated protein kinase kinase kinase 11 
LINQPLPDLK LINQPLPDLB 1157.68994 Microtubule-associated protein 2 
TPLYDLR TPLYDLX 886.47878 Protein MEMO1 
YSYYDESQGEIYR YSYYDESQGEIYX 1681.71355 Protein MEMO1 
NYLQSLPSK NYLQSLPSB 1056.56951 Mitogen-activated protein kinase 3 
ALELDSNLYR ALELDSNLYX 1202.61706 Myosin-9 
LDCPFFGSPIPTLR LDZPFFGSPIPTLX 1628.82599 Neurofascin 
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FQLTFPLR FQLTFPLX 1030.58391 Neuronal pentraxin-1 
ELTDEEAER ELTDEEAEX 1100.4861 Nuclear migration protein nudC 
LQELSAEER LQELSAEEX 1083.54356 Obg-like ATPase 1 
VPVPDER VPVPDEX 820.43182 Obg-like ATPase 1 
SSLNPILFR SSLNPILFX 1055.60029 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa 
subunit 
LLTSGYLQR LLTSGYLQX 1059.59521 Ubiquitin thioesterase OTUB1 
GLECSTLYR GLEZSTLYX 1107.52581 Phosphatidylinositol 3-kinase regulatory subunit alpha 
YGVSGYPTLK YGVSGYPTLB 1091.57425 Protein disulfide-isomerase A3 
FDVSGYPTIK FDVSGYPTIB 1133.58481 Protein disulfide-isomerase A4 
GYFFLDER GYFFLDEX 1055.49515 PDZ and LIM domain protein 4 
SQVEPADYK SQVEPADYB 1043.50148 Phosphatidylinositol transfer protein beta isoform 
TPENFPCK TPENFPZB 999.45751 Plasminogen 
FEDENFHYK FEDENFHYB 1235.53384 Peptidyl-prolyl cis-trans isomerase D 
ADEGISFR ADEGISFX 903.43255 Peroxiredoxin-1 
CTDDFNGAQCK ZTDDFNGAQZB 1322.51108 26S protease regulatory subunit 6A 
ETLPAEQDLTTK ETLPAEQDLTTB 1352.69146 Proteasome subunit alpha type-1 
TQIPTQR TQIPTQX 852.46929 Proteasome subunit alpha type-1 
LSEGFSIHTR LSEGFSIHTX 1155.59118 Proteasome subunit beta type-1 
DLPVSEQQER DLPVSEQQEX 1209.58649 26S proteasome non-ATPase regulatory subunit 13 
APLDIPVPDPVK APLDIPVPDPVB 1267.7267 Proteasome activator complex subunit 1 
NQGDFSLSVR NQGDFSLSVX 1131.5548 Tyrosine-protein phosphatase non-receptor type 6 
ACGNFGIPCELR AZGNFGIPZELX 1402.63609 Multifunctional protein ADE2 
LTSEPQPQR LTSEPQPQX 1064.54899 Ras-related protein Rab-14 
LALDYGIK LALDYGIB 899.52075 Ras-related protein Rab-8A 
NTLQLHR NTLQLHX 890.49617 60S ribosomal protein L15 
ECADLWPR EZADLWPX 1055.47337 60S ribosomal protein L23 
HGSLGFLPR HGSLGFLPX 992.5431 60S ribosomal protein L3 
YYPTEDVPR YYPTEDVPX 1148.53775 60S ribosomal protein L6 
NFGIGQDIQPK NFGIGQDIQPB 1223.63897 60S ribosomal protein L7a 
DIIHDPGR DIIHDPGX 931.47508 60S ribosomal protein L8 
GGNFGFGDSR GGNFGFGDSX 1022.44451 Heterogeneous nuclear ribonucleoproteins A2/B1 
NIDNFLSR NIDNFLSX 987.50131 Rho-associated protein kinase 1 
NSLTFPDDNDISK NSLTFPDDNDISB 1472.68744 Rho-associated protein kinase 1 
GLSQSALPYR GLSQSALPYX 1100.58537 40S ribosomal protein S13 
TPGPGAQSALR TPGPGAQSALX 1063.56496 40S ribosomal protein S14 
IPDWFLNR IPDWFLNX 1069.55842 40S ribosomal protein S18 
TTDGYLLR TTDGYLLX 947.49516 40S ribosomal protein S3a 
LNEQSPTR LNEQSPTX 953.48058 Vesicle-trafficking protein SEC22b 
ITQSEFDR ITQSEFDX 1004.48024 Endophilin-B1 
LHLDYIGPCK LHLDYIGPZB 1222.62596 SPARC 
LGESQTLQQFSR LGESQTLQQFSX 1402.70801 Spectrin alpha chain, non-erythrocytic 1 
DLEDLFYK DLEDLFYB 1049.51606 Serine/arginine-rich splicing factor 9 
ASSGLLYPLER ASSGLLYPLEX 1214.65344 FACT complex subunit SSRP1 
ALDLDSSCK ALDLDSSZB 1015.47355 Stress-induced-phosphoprotein 1 
VPQDGDFDFLK VPQDGDFDFLB 1287.62264 Serine/threonine-protein kinase 3 
DALSDLALHFLNK DALSDLALHFLNB 1463.78635 T-complex protein 1 subunit delta 
TEDFGLDVPAFR TEDFGLDVPAFX 1375.66472 Dual specificity testis-specific protein kinase 1 
GNLQEYLTR GNLQEYLTX 1102.56464 TGF-beta receptor type-2 
EELLDHLEK EELLDHLEB 1132.58553 Tropomodulin-1 
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VTQSDLYK VTQSDLYB 960.50076 Tumor protein D54 
TDAPLNIR TDAPLNIX 908.49549 Heat shock protein 75 kDa, mitochondrial 
ILGPAESDEFLAR ILGPAESDEFLAX 1426.73313 E3 ubiquitin-protein ligase UBR4 
GNLQNLER GNLQNLEX 952.49656 V-type proton ATPase subunit C 1 
ALASQLQDSLK ALASQLQDSLB 1180.65429 Vinculin 
ELALPGELTQSR ELALPGELTQSX 1322.70693 Vacuolar protein sorting-associated protein 26A 
HYTEHADGLCHK HYTEHADGLZHB 1474.65028 Tyrosine-protein kinase Yes 
LLLNPGNQR LLLNPGNQX 1033.59079 Tyrosine-protein kinase Yes 
HLIPAANTGESK HLIPAANTGESB 1244.66043 14-3-3 protein epsilon 
SVTEQGAELSNEER SVTEQGAELSNEEX 1557.7146 14-3-3 protein zeta/delta 
AENYWWR AENYWWX 1033.46453 Activated CDC42 kinase 1 
TLCVGPFPR TLZVGPFPX 1055.54614 Activated CDC42 kinase 1 
VQQLVPK VQQLVPB 818.51053 Alpha-actinin-4 
VLQPPSILYGGR VLQPPSILYGGX 1308.74292 Protein argonaute-2 
SDGSFIGYK SDGSFIGYB 980.46945 RAC-beta serine/threonine-protein kinase 
LDQGGAPLAGTNK LDQGGAPLAGTNB 1248.65534 Fructose-bisphosphate aldolase B 
LLSTDPVAAK LLSTDPVAAB 1021.58989 AP-1 complex subunit beta-1 
FLELLPK FLELLPB 866.53567 AP-2 complex subunit beta 
LGYLLFR LGYLLFX 890.52533 Beta-adrenergic receptor kinase 1 
NFPLTISER NFPLTISEX 1085.57447 Beta-adrenergic receptor kinase 1 
EFSIDVGYER EFSIDVGYEX 1223.56977 Actin-related protein 3 
YSYVCPDLVK YSYVZPDLVB 1250.60965 Actin-related protein 3 
ASHTAPQVLFSHR ASHTAPQVLFSHX 1459.75595 Actin-related protein 2/3 complex subunit 2 
VLSIGDGIAR VLSIGDGIAX 1009.57954 ATP synthase subunit alpha, mitochondrial 
LSDPANWLK LSDPANWLB 1050.55893 Cadherin-2 
IFDLIGLPPEDDWPR IFDLIGLPPEDDWPX 1791.90706 Cyclin-dependent kinase 4 
LEAFEHPNVVR LEAFEHPNVVX 1319.68613 Cyclin-dependent kinase 4 
APELLFGAR APELLFGAX 982.54751 Cyclin-dependent kinase 7 
LLVLDPAQR LLVLDPAQX 1033.61593 Cyclin-dependent kinase 9 
HSIEVPIPR HSIEVPIPX 1056.59553 Contactin-1 
ADQCYEDVR ADQZYEDVX 1164.4745 Coronin-1A 
NITLDDASAPR NITLDDASAPX 1181.59157 Cold shock domain-containing protein E1 
VSDFGLTK VSDFGLTB 873.46872 Tyrosine-protein kinase CSK 
ATTADGSSILDR ATTADGSSILDX 1215.59705 COP9 signalosome complex subunit 4 
AGAVNPTVK AGAVNPTVB 863.4956 Dipeptidyl peptidase 4 
SELDTIDSQHR SELDTIDSQHX 1309.61377 Excitatory amino acid transporter 2 
FSVSPVVR FSVSPVVX 899.51041 Elongation factor 2 
STLTDSLVCK STLTDSLVZB 1130.57327 Elongation factor 2 
LLLTPWVK LLLTPWVB 976.62007 Eukaryotic translation initiation factor 3 subunit A 
TLSFGSDLNYATR TLSFGSDLNYATX 1453.70767 Eukaryotic translation initiation factor 3 subunit A 
DAHNALLDIQSSGR DAHNALLDIQSSGX 1505.74617 Eukaryotic translation initiation factor 3 subunit C 
ESYPVFYLFR ESYPVFYLFX 1329.66328 Endoplasmic reticulum resident protein 29 
ALQLEEER ALQLEEEX 996.51153 Ezrin 
YIEDEDYYK YIEDEDYYB 1244.53284 Protein-tyrosine kinase 2-beta 
EVAAPDVGR EVAAPDVGX 922.47474 Flotillin-2 
IQVDYDGHCK IQVDYDGHZB 1241.55901 Follistatin-related protein 1 
DETNYGIPQR DETNYGIPQX 1201.56028 Guanine nucleotide-binding protein subunit beta-2-like 1 
YIETDPANR YIETDPANX 1087.51735 Gelsolin 
VQQTVQDLFGR VQQTVQDLFGX 1299.68106 Stress-70 protein, mitochondrial 
LLEYTPTAR LLEYTPTAX 1072.57922 Glycogen synthase kinase-3 beta 
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ALLSAPWYLNR ALLSAPWYLNX 1312.71671 Beta-hexosaminidase subunit alpha 
GLETFSQLVWK GLETFSQLVWB 1314.70632 Beta-hexosaminidase subunit alpha 
DLTEYLSR DLTEYLSX 1005.50064 Heterogeneous nuclear ribonucleoprotein D-like 
VIGGDDLSTLTGK VIGGDDLSTLTGB 1282.68597 Hypoxanthine-guanine phosphoribosyltransferase 
NPDDITNEEYGEFYK NPDDITNEEYGEFYB 1840.78827 Heat shock protein HSP 90-alpha 
ALLFIPR ALLFIPX 838.53041 Heat shock protein HSP 90-beta 
INLIAPPR INLIAPPX 902.55769 Eukaryotic translation initiation factor 2 subunit 1 
LAAFGQLHK LAAFGQLHB 991.56943 Interleukin enhancer-binding factor 3 
LSVEAPPK LSVEAPPB 847.48945 IST1 homolog 
DAEEWFFTK DAEEWFFTB 1179.53277 Keratin, type I cytoskeletal 14 
VVSTHEQVLR VVSTHEQVLX 1176.64903 Keratin, type I cytoskeletal 14 
ITQYLDAGGIPR ITQYLDAGGIPX 1312.70145 Calcium/calmodulin-dependent protein kinase type II subunit alpha 
FTDEYQLFEELGK FTDEYQLFEELGB 1625.77043 Calcium/calmodulin-dependent protein kinase type II subunit delta 
SLSAPGNLLTK SLSAPGNLLTB 1107.63791 Calcium/calmodulin-dependent protein kinase kinase 2 
CAFSIPNNCSGAR ZAFSIPNNZSGAX 1462.63208 Serine/threonine-protein kinase D2 
DLNSHNCLVR DLNSHNZLVX 1236.59087 LIM domain kinase 1 
DNPLDPVLAK DNPLDPVLAB 1088.5957 Leucine-rich repeat-containing protein 59 
LSNVAPPCILR LSNVAPPZILX 1248.68878 Microtubule-associated protein RP/EB family member 3 
ALTSELANAR ALTSELANAX 1054.56463 Moesin 
IPEQILGK IPEQILGB 904.5473 Dual specificity mitogen-activated protein kinase kinase 1 
LENLEQYSR LENLEQYSX 1160.57012 Neuronal pentraxin-1 
LFADAEEEQR LFADAEEEQX 1216.55993 Vesicle-fusing ATPase 
SPNELVDDLFK SPNELVDDLFB 1283.64886 NSFL1 cofactor p47 
VNVPGSQAQLK VNVPGSQAQLB 1147.64406 Nucleobindin-1 
GFGFVDFNSEEDAK GFGFVDFNSEEDAB 1568.68742 Nucleolin 
LQLEIDQK LQLEIDQB 993.5586 Nuclear migration protein nudC 
IEQLSPFPFDLLLK IEQLSPFPFDLLLB 1666.94251 2-oxoglutarate dehydrogenase, mitochondrial 
FANPFPAAVR FANPFPAAVX 1098.58496 Propionyl-CoA carboxylase beta chain, mitochondrial 
LLDEEEATDNDLR LLDEEEATDNDLX 1541.70844 Programmed cell death 6-interacting protein 
ILEFFGLK ILEFFGLB 973.57278 Protein disulfide-isomerase 
EISLLPDNLLR EISLLPDNLLX 1291.7375 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, 
mitochondrial 
LYAQYFQGDLK LYAQYFQGDLB 1352.68559 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, 
mitochondrial 
QFLDFGSSNACEK QFLDFGSSNAZEB 1509.66493 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, 
mitochondrial 
VDLGSEVYR VDLGSEVYX 1046.52718 PDZ and LIM domain protein 4 
HGESAWNLENR HGESAWNLENX 1321.60387 Phosphoglycerate mutase 1 
YGDLVDYLHR YGDLVDYLHX 1259.61739 Platelet-derived growth factor receptor beta 
VYLSECK VYLSEZB 905.4408 Plasminogen 
VFFDVDIGGER VFFDVDIGGEX 1262.61704 Peptidyl-prolyl cis-trans isomerase D 
YGNANAWR YGNANAWX 960.44413 Serine/threonine-protein phosphatase 6 catalytic subunit 
VSVADHSLHLSK VSVADHSLHLSB 1299.70263 Peroxiredoxin-4 
LPLVTPHTQCR LPLVTPHTQZX 1330.7055 26S protease regulatory subunit 4 
VDILDPALLR VDILDPALLX 1133.66835 26S protease regulatory subunit 6A 
VVGSEFVQK VVGSEFVQB 999.54803 26S protease regulatory subunit 6B 
SILYDER SILYDEX 904.45296 Proteasome subunit alpha type-2 
TTIFSPEGR TTIFSPEGX 1016.51662 Proteasome subunit alpha type-4 
FILNLPTFSVR FILNLPTFSVX 1315.75276 Proteasome subunit beta type-2 
DYLHYIR DYLHYIX 988.50058 40S ribosomal protein S11 
DVNQQEFVR DVNQQEFVX 1143.5548 40S ribosomal protein S19 
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AELNEFLTR AELNEFLTX 1101.56938 40S ribosomal protein S3 
AQCPIVER AQZPIVEX 981.49411 40S ribosomal protein S5 
DIPGLTDTTVPR DIPGLTDTTVPX 1293.68038 40S ribosomal protein S6 
VETFSGVYK VETFSGVYB 1036.53205 40S ribosomal protein S7 
IEDFLER IEDFLEX 930.4686 40S ribosomal protein S9 
FGISSVPTK FGISSVPTB 942.52657 SAP domain-containing ribonucleoprotein 
FGLNVSSISR FGLNVSSISX 1088.58537 SAP domain-containing ribonucleoprotein 
LAADAGTFLSR LAADAGTFLSX 1130.59592 Endophilin-B1 
LGEGSYGSVFK LGEGSYGSVFB 1150.57497 Serine/threonine-protein kinase 3 
IYGISFPDPK IYGISFPDPB 1143.60554 Threonine--tRNA ligase, cytoplasmic 
VSTEVDAR VSTEVDAX 885.44312 Transaldolase 
ILFQETR ILFQETX 915.50533 Serine/threonine-protein kinase TAO3 
HIAEDADR HIAEDADX 935.43361 Tropomyosin alpha-1 chain 
AQLLQPTLEINPR AQLLQPTLEINPX 1501.84918 Heat shock protein 75 kDa, mitochondrial 
GYAPESVLER GYAPESVLEX 1129.56429 tRNA pseudouridine synthase A, mitochondrial 
IFINLPR IFINLPX 881.53623 Thioredoxin-like protein 1 
LLQTLPQLR LLQTLPQLX 1090.67379 E3 ubiquitin-protein ligase UBR4 
VDALLSAQPK VDALLSAQPB 1048.60079 UDP-glucose:glycoprotein glucosyltransferase 1 
IGDLGHVTR IGDLGHVTX 976.53293 Wee1-like protein kinase 
DICNDVLSLLEK DIZNDVLSLLEB 1425.72646 14-3-3 protein zeta/delta 
EVFISGSFNNWSTK EVFISGSFNNWSTB 1622.78201 5'-AMP-activated protein kinase subunit beta-2 
LVVFDTSLQVK LVVFDTSLQVB 1255.72672 5'-AMP-activated protein kinase subunit gamma-1 
DLEDLQILIK DLEDLQILIB 1206.69508 Aconitate hydratase, mitochondrial 
DPLADLNIK DPLADLNIB 1005.55859 Clathrin coat assembly protein AP180 
ECHLNADTVSSK EZHLNADTVSSB 1367.62307 AP-2 complex subunit beta 
ELYLFDVLR ELYLFDVLX 1176.64181 Asparagine synthetase [glutamine-hydrolyzing] 
WINATDPSAR WINATDPSAX 1139.55988 Asparagine synthetase [glutamine-hydrolyzing] 
IVEIPFNSTNK IVEIPFNSTNB 1268.68559 Sodium/potassium-transporting ATPase subunit alpha-1 
GGQDNIPVLK GGQDNIPVLB 1047.58039 Sodium/potassium-transporting ATPase subunit alpha-3 
LDIDPETITWQR LDIDPETITWQX 1495.75461 C-1-tetrahydrofolate synthase, cytoplasmic 
VWSVASTVR VWSVASTVX 1013.55334 Cell adhesion molecule 4 
YVECSALTQK YVEZSALTQB 1205.58417 Cell division control protein 42 homolog 
VVPGYGHAVLR VVPGYGHAVLX 1176.66427 Citrate synthase, mitochondrial 
YLTNAYSR YLTNAYSX 996.49042 Chloride intracellular channel protein 4 
GVVGLPGQR GVVGLPGQX 891.51655 Collagen alpha-1(I) chain 
LPYSVVR LPYSVVX 842.48895 Complement C3 
DAGPLLISLK DAGPLLISLB 1033.62627 Coronin-1A 
LLYPPETGLFLVR LLYPPETGLFLVX 1526.87359 Tyrosine-protein kinase CSK 
VIDCLYTCK VIDZLYTZB 1178.55551 Calsyntenin-1 
LVFSNVNLK LVFSNVNLB 1040.61097 DNA damage-binding protein 1 
IIPGGAAAQDGR IIPGGAAAQDGX 1134.60206 Disks large homolog 4 
SLLQALNEVK SLLQALNEVB 1121.65356 Cytoplasmic dynein 1 heavy chain 1 
LQSQLLSIEK LQSQLLSIEB 1165.67978 Dynamin-1 
SADCSVEEEPWK SADZSVEEEPWB 1443.60674 Excitatory amino acid transporter 2 
LVPVGYGIR LVPVGYGIX 982.5839 Elongation factor 1-delta 
VLVPATDR VLVPATDX 879.50532 Eukaryotic translation initiation factor 3 subunit E 
NILVASPECVK NILVASPEZVB 1236.66274 Protein-tyrosine kinase 2-beta 
VAQLEAQCQEPCK VAQLEAQZQEPZB 1567.7214 Fibrinogen gamma chain 
IAQITGPPDR IAQITGPPDX 1076.58536 Far upstream element-binding protein 1 
IINDLLQSLR IINDLLQSLX 1193.70073 Far upstream element-binding protein 2 
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EVEPALELLEPIDQK EVEPALELLEPIDQB 1729.92289 Rab GDP dissociation inhibitor alpha 
ELEASEELDTICPK ELEASEELDTIZPB 1640.76944 Glutaredoxin-3 
YEISSVPTFLFFK YEISSVPTFLFFB 1584.83191 Glutaredoxin-3 
DAGQISGLNVLR DAGQISGLNVLX 1251.68105 Stress-70 protein, mitochondrial 
IILDLISESPIK IILDLISESPIB 1347.81044 Heterogeneous nuclear ribonucleoprotein K 
FESPEVAER FESPEVAEX 1072.50644 Heterogeneous nuclear ribonucleoprotein M 
FFADLLDYIK FFADLLDYIB 1251.66305 Hypoxanthine-guanine phosphoribosyltransferase 
EPGCGCCSVCAR EPGZGZZSVZAX 1421.51837 Insulin-like growth factor-binding protein 2 
GECWCVNPNTGK GEZWZVNPNTGB 1428.60056 Insulin-like growth factor-binding protein 2 
DIFQEIYDK DIFQEIYDB 1177.57464 Isocitrate dehydrogenase [NADP] cytoplasmic 
SEITELR SEITELX 856.45296 Keratin, type I cytoskeletal 10 
YLHDLGIVHR YLHDLGIVHX 1231.67009 Calcium/calmodulin-dependent protein kinase type 1 
VLAGQEYAAK VLAGQEYAAB 1056.56949 Calcium/calmodulin-dependent protein kinase type II subunit alpha 
IPTGQEYAAK IPTGQEYAAB 1084.56441 Calcium/calmodulin-dependent protein kinase type II subunit delta 
ENIWDGVTTK ENIWDGVTTB 1169.58079 Protein kinase C beta type 
CITLFQNNTTNR ZITLFQNNTTNX 1490.71754 Serine/threonine-protein kinase D2 
DILADVNHPFVVK DILADVNHPFVVB 1473.80708 Ribosomal protein S6 kinase alpha-1 
AANEVSSADVK AANEVSSADVB 1097.5444 Limbic system-associated membrane protein 
ITVQASPGLDR ITVQASPGLDX 1165.63304 Mitogen-activated protein kinase kinase kinase 11 
LIGTAVPQR LIGTAVPQX 963.57407 Microtubule-associated protein RP/EB family member 3 
LVGTPGAELLK LVGTPGAELLB 1104.66338 Mitogen-activated protein kinase 14 
EALLQASR EALLQASX 896.49549 Moesin 
EVCQLLPFLVR EVZQLLPFLVX 1382.76194 Neurochondrin 
SGQQIVGPPR SGQQIVGPPX 1047.57005 NSFL1 cofactor p47 
LSQETEALGR LSQETEALGX 1112.57011 Nucleobindin-1 
AYPFYWAWLPQAK AYPFYWAWLPQAB 1647.83291 Phosphatidylinositol 4-kinase type 2-alpha 
DTADGTFLVR DTADGTFLVX 1103.54864 Phosphatidylinositol 3-kinase regulatory subunit alpha 
GFVDDIIQPSSTR GFVDDIIQPSSTX 1443.72331 Propionyl-CoA carboxylase beta chain, mitochondrial 
VNLSAAQTLR VNLSAAQTLX 1081.61192 Programmed cell death protein 10 
LALASLGYEK LALASLGYEB 1071.60554 Programmed cell death 6-interacting protein 
GSFSEQGINEFLR GSFSEQGINEFLX 1492.71856 Protein disulfide-isomerase A6 
DQLVLGR DQLVLGX 809.46346 Platelet-derived growth factor receptor beta 
IGDFGLATK IGDFGLATB 928.51091 Serine/threonine-protein kinase PLK1 
TIAQDYGVLK TIAQDYGVLB 1114.61136 Peroxiredoxin-1 
LVQAFQYTDK LVQAFQYTDB 1219.63283 Peroxiredoxin-4 
AVANQTSATFLR AVANQTSATFLX 1287.68106 26S protease regulatory subunit 4 
EVVETPLLHPER EVVETPLLHPEX 1427.76477 26S protease regulatory subunit 7 
AVAHHTDCTFIR AVAHHTDZTFIX 1436.68582 26S protease regulatory subunit 8 
LLDSSTVTHLFK LLDSSTVTHLFB 1367.754 Proteasome subunit alpha type-6 
GPGLYYVDSEGNR GPGLYYVDSEGNX 1435.66071 Proteasome subunit beta type-5 
IVVLLQR IVVLLQX 849.56753 Proteasome activator complex subunit 1 
IIEVSGQK IIEVSGQB 880.51092 Ras-related protein Rab-14 
YDGIILPGK YDGIILPGB 982.55786 60S ribosomal protein L11 
FWYFVSQLK FWYFVSQLB 1224.64227 60S ribosomal protein L18a 
LDHYAIIK LDHYAIIB 979.5582 60S ribosomal protein L23a 
YCQVIR YZQVIX 847.42498 60S ribosomal protein L3 
YEITEQR YEITEQX 947.45878 60S ribosomal protein L6 
VPPAINQFTQALDR VPPAINQFTQALDX 1578.83934 60S ribosomal protein L7a 
AVDFAER AVDFAEX 816.40052 60S ribosomal protein L8 
TILPAAAQDVYYR TILPAAAQDVYYX 1489.78043 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit 1 
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LILIESR LILIESX 852.53081 40S ribosomal protein S13 
TLLVADPR TLLVADPX 893.52097 40S ribosomal protein S16 
VLNTNIDGR VLNTNIDGX 1010.53842 40S ribosomal protein S18 
VLQALEGLK VLQALEGLB 977.60006 40S ribosomal protein S19 
VCADLIR VZADLIX 855.45118 40S ribosomal protein S20 
AALQELLSK AALQELLSB 979.57933 40S ribosomal protein S25 
LITEDVQGK LITEDVQGB 1009.55351 40S ribosomal protein S3a 
GSSNSYAIK GSSNSYAIB 933.46471 40S ribosomal protein S5 
LIEVDDER LIEVDDEX 997.49554 40S ribosomal protein S6 
LDYILGLK LDYILGLB 941.5677 40S ribosomal protein S9 
AVLLAGPPGTGK AVLLAGPPGTGB 1087.64806 RuvB-like 1 
GEALSALDSK GEALSALDSB 997.51712 Vesicle-trafficking protein SEC22b 
TQIQSVEPYTK TQIQSVEPYTB 1300.67543 Signal transducer and activator of transcription 3 
VVENLQDDFDFNYK VVENLQDDFDFNYB 1752.80861 Signal transducer and activator of transcription 3 
LAYINPDLALEEK LAYINPDLALEEB 1495.80133 Stress-induced-phosphoprotein 1 
GEEILSGAQR GEEILSGAQX 1068.54389 Aspartate--tRNA ligase, cytoplasmic 
TVYSVFGFSFK TVYSVFGFSFB 1288.65831 Threonine--tRNA ligase, cytoplasmic 
LASAAYPDPSK LASAAYPDPSB 1126.57497 Tyrosine--tRNA ligase, cytoplasmic 
ADVQSIIGLQR ADVQSIIGLQX 1208.67524 Transcription intermediary factor 1-beta 
IIALDGDTK IIALDGDTB 952.53204 Transketolase 
EVFGTFGIPFLLR EVFGTFGIPFLLX 1504.83172 Ubiquitin carboxyl-terminal hydrolase 7 
FLFVDADQIVR FLFVDADQIVX 1331.71128 UDP-glucose:glycoprotein glucosyltransferase 1 
LDGFILTER LDGFILTEX 1072.57921 Serine/threonine-protein kinase ULK3 
AVAGNISDPGLQK AVAGNISDPGLQB 1276.68664 Vinculin 
HSVLLSASR HSVLLSASX 978.54859 Wee1-like protein kinase 
AVGHPFVIQLGR AVGHPFVIQLGX 1302.74358 Exportin-1 
LICCDILDVLDK LIZZDILDVLDB 1483.75056 14-3-3 protein epsilon 
WYFDVTEGK WYFDVTEGB 1151.53786 Amyloid beta A4 protein 
SIDDEITEAK SIDDEITEAB 1127.54373 5'-AMP-activated protein kinase catalytic subunit alpha-1 
DYETATLSEIK DYETATLSEIB 1276.6278 Alpha-actinin-1 
LAILGIHNEVSK LAILGIHNEVSB 1300.75941 Alpha-actinin-1 
GSWQGENVAVK GSWQGENVAVB 1181.59202 Activin receptor type-1 
AAVVTSPPPTTAPHK AAVVTSPPPTTAPHB 1480.8129 Alpha-adducin 
SLLAGLLK SLLAGLLB 821.54657 RAC-beta serine/threonine-protein kinase 
EPLVDVVDPK EPLVDVVDPB 1117.61101 Protein arginine N-methyltransferase 1 
LQSSNIFTVAK LQSSNIFTVAB 1214.67503 AP-1 complex subunit beta-1 
GQVYILGR GQVYILGX 914.52131 Argininosuccinate synthase 
IDIVENR IDIVENX 867.46894 Argininosuccinate synthase 
DTQLQQIVDK DTQLQQIVDB 1194.63356 Calcineurin subunit B type 1 
EFIEGVSQFSVK EFIEGVSQFSVB 1376.70671 Calcineurin subunit B type 1 
LGTLSALDILIK LGTLSALDILIB 1263.78931 Cullin-associated NEDD8-dissociated protein 1 
SVILEAFSSPSEEVK SVILEAFSSPSEEVB 1628.83884 Cullin-associated NEDD8-dissociated protein 1 
LNQDQLDAVSK LNQDQLDAVSB 1237.63937 Caprin-1 
SPEVLLGSAR SPEVLLGSAX 1037.57446 Cyclin-dependent kinase 1 
IGEGTYGTVFK IGEGTYGTVFB 1178.60627 Cyclin-dependent kinase 5 
LDFLGEGQFATVYK LDFLGEGQFATVYB 1594.81223 Cyclin-dependent kinase 7 
IGQGTFGEVFK IGQGTFGEVFB 1189.62225 Cyclin-dependent kinase 9 
WLLLTGISAQQNR WLLLTGISAQQNX 1508.83387 Clathrin heavy chain 1 
EVEIAYSDVAK EVEIAYSDVAB 1230.62231 Chloride intracellular channel protein 4 
VEVLAGDLR VEVLAGDLX 980.55299 Contactin-2 
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NEQVEIR NEQVEIX 896.45911 Complement C3 
LTVTAYDCGK LTVTAYDZGB 1134.54705 Calsyntenin-1 
QSGESIDIITR QSGESIDIITX 1227.63344 DNA damage-binding protein 1 
HCILDVSANAVR HZILDVSANAVX 1363.69057 Disks large homolog 4 
EFLLIFR EFLLIFX 946.55154 EF-hand domain-containing protein D2 
LGDDIDLIVR LGDDIDLIVX 1137.62688 Eukaryotic translation initiation factor 3 subunit D 
LFIFETFCR LFIFETFZX 1241.61422 Eukaryotic translation initiation factor 3 subunit E 
EGDLLFTVAK EGDLLFTVAB 1099.60045 Eukaryotic translation initiation factor 3 subunit I 
LIINSLYK LIINSLYB 970.59426 Endoplasmin 
IHVLEAQDLIAK IHVLEAQDLIAB 1356.78562 Extended synaptotagmin-1 
GNFGEVYK GNFGEVYB 920.44832 Tyrosine-protein kinase Fer 
LIGVCTQR LIGVZTQX 955.51485 Tyrosine-protein kinase Fer 
DNCCILDER DNZZILDEX 1203.48877 Fibrinogen gamma chain 
GPATVEDLPSAFEEK GPATVEDLPSAFEEB 1596.77623 PDZ domain-containing protein GIPC1 
NPDELAEALDER NPDELAEALDEX 1380.63963 PDZ domain-containing protein GIPC1 
ITPSYVAFTPEGER ITPSYVAFTPEGEX 1575.78082 78 kDa glucose-regulated protein 
CVLIFGVPSR ZVLIFGVPSX 1156.6302 Delta-aminolevulinic acid dehydratase 
DYAFIHFDER DYAFIHFDEX 1321.59665 Heterogeneous nuclear ribonucleoprotein Q 
EQILEEFSK EQILEEFSB 1129.57464 Heterogeneous nuclear ribonucleoprotein Q 
DQVANSAFVER DQVANSAFVEX 1244.60247 Heat shock protein HSP 90-alpha 
SEGGFIWACK SEGGFIWAZB 1161.53681 Isocitrate dehydrogenase [NADP] cytoplasmic 
IIWQFIK IIWQFIB 954.57821 Isocitrate dehydrogenase [NADP], mitochondrial 
AAVENLPTFLVELSR AAVENLPTFLVELSX 1667.91216 Importin subunit beta-1 
YETELNLR YETELNLX 1046.52719 Keratin, type I cytoskeletal 14 
HNIQALLK HNIQALLB 943.56944 cAMP-dependent protein kinase type I-alpha regulatory subunit 
LIFQVLDAVK LIFQVLDAVB 1152.69977 Calcium/calmodulin-dependent protein kinase type 1 
FYFENLLAK FYFENLLAB 1151.61063 Calcium/calmodulin-dependent protein kinase type II subunit beta 
NSQGEEVAQR NSQGEEVAQX 1126.52423 Lamin-B1 
QLLAPGNSAGAFLIR QLLAPGNSAGAFLIX 1536.86515 Tyrosine-protein kinase Lyn 
GANLLIDSTGQR GANLLIDSTGQX 1253.66032 Mitogen-activated protein kinase kinase kinase 1 
DLATDLSLIEVK DLATDLSLIEVB 1323.73767 Microtubule-associated protein 2 
LTVEDLEK LTVEDLEB 953.51606 Microtubule-associated protein RP/EB family member 1 
ELIFQETAR ELIFQETAX 1115.58503 Mitogen-activated protein kinase 3 
ISELGAGNGGVVFK ISELGAGNGGVVFB 1354.73358 Dual specificity mitogen-activated protein kinase kinase 1 
ELDDATEANEGLSR ELDDATEANEGLSX 1528.68804 Myosin-10 
ATNDEIFSILK ATNDEIFSILB 1257.6696 Nuclear cap-binding protein subunit 1 
DYYECTGIYK DYYEZTGIYB 1318.5631 Neprilysin 
IPLITATPR IPLITATPX 990.61012 Sialidase-1 
GLSEDTTEETLK GLSEDTTEETLB 1329.63909 Nucleolin 
TLGDFAAEYAK TLGDFAAEYAB 1192.58553 Poly [ADP-ribose] polymerase 1 
ELLDTVNNVFK ELLDTVNNVFB 1298.69615 Programmed cell death protein 10 
IVQAEGEAEAAK IVQAEGEAEAAB 1222.62845 Prohibitin-2 
ALDEGDIALLK ALDEGDIALLB 1164.64812 26S protease regulatory subunit 7 
VEIATLTR VEIATLTX 911.53154 Proteasome subunit alpha type-4 
NGYELSPTAAANFTR NGYELSPTAAANFTX 1620.77714 Proteasome subunit beta type-2 
AIYQATYR AIYQATYX 994.51115 Proteasome subunit beta type-5 
LNILDTLSK LNILDTLSB 1023.60555 26S proteasome non-ATPase regulatory subunit 2 
NIEEHASADVEK NIEEHASADVEB 1348.635 Ras-related protein Rab-8A 
AEEILEK AEEILEB 838.45273 60S ribosomal protein L11 
LYDIDVAK LYDIDVAB 943.51058 60S ribosomal protein L23a 
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GCTATLGNFAK GZTATLGNFAB 1146.55828 40S ribosomal protein S2 
HVVFIAQR HVVFIAQX 978.56384 40S ribosomal protein S7 
LLVVTDPR LLVVTDPX 921.55227 40S ribosomal protein SA 
ILQDGGLQVVEK ILQDGGLQVVEB 1305.73834 D-3-phosphoglycerate dehydrogenase 
GVVEVTHDLQK GVVEVTHDLQB 1231.66518 Serpin H1 
LNEQASEEILK LNEQASEEILB 1280.67033 Protein SET 
VEVTEFEDIK VEVTEFEDIB 1215.61141 Protein SET 
LLLNAENPR LLLNAENPX 1048.59045 Proto-oncogene tyrosine-protein kinase Src 
AIVPILLDANVSTYDK AIVPILLDANVSTYDB 1738.95962 Syntaxin-binding protein 1 
EVLLDEDDDLWIALR EVLLDEDDDLWIALX 1823.91802 Syntaxin-binding protein 1 
GFVEIQTPK GFVEIQTPB 1025.56368 Aspartate--tRNA ligase, cytoplasmic 
IYLYLTK IYLYLTB 920.54625 Glycine--tRNA ligase 
IDVGEAEPR IDVGEAEPX 994.49587 Tyrosine--tRNA ligase, cytoplasmic 
VLIDLIQR VLIDLIQX 978.61012 Serine/threonine-protein kinase TAO3 
AVFVDLEPTVIDEIR AVFVDLEPTVIDEIX 1724.92238 Tubulin alpha-4A chain 
TSASIILR TSASIILX 869.52098 T-complex protein 1 subunit alpha 
VIDPATATSVDLR VIDPATATSVDLX 1366.73314 T-complex protein 1 subunit delta 
LDQLIYIPLPDEK LDQLIYIPLPDEB 1563.86393 Transitional endoplasmic reticulum ATPase 
IGAGFFSEVYK IGAGFFSEVYB 1224.627 Dual specificity testis-specific protein kinase 1 
TIVLQESIGK TIVLQESIGB 1094.64266 TGF-beta receptor type-1 
HENILQFLTAEER HENILQFLTAEEX 1608.81352 TGF-beta receptor type-2 
LVIIESDLER LVIIESDLEX 1195.66875 Tropomyosin alpha-1 chain 
NFPNAIEHTLQWAR NFPNAIEHTLQWAX 1705.85639 Ubiquitin-like modifier-activating enzyme 1 
LTLSALLDGK LTLSALLDGB 1037.62119 Voltage-dependent anion-selective channel protein 1 
VESLEQEAANER VESLEQEAANEX 1383.65054 Amyloid beta A4 protein 
EAYPEEAYIADLDAK EAYPEEAYIADLDAB 1704.79736 ATP-citrate synthase 
GVSCSEVTASSLIK GVSZSEVTASSLIB 1444.73228 Beta-adducin 
TIEEVVGR TIEEVVGX 911.49515 Aldehyde dehydrogenase, mitochondrial 
ALQASALAAWGGK ALQASALAAWGGB 1250.68624 Fructose-bisphosphate aldolase B 
DLSTVEALQNLK DLSTVEALQNLB 1337.72818 Acidic leucine-rich nuclear phosphoprotein 32 family member E 
ATNSSWVVVFK ATNSSWVVVFB 1244.66446 Clathrin coat assembly protein AP180 
GIVIATGDR GIVIATGDX 910.51113 Sodium/potassium-transporting ATPase subunit alpha-2 
HALIIYDDLSK HALIIYDDLSB 1294.70123 ATP synthase subunit alpha, mitochondrial 
TVLELQYVLDK TVLELQYVLDB 1327.74785 Caprin-1 
YEIVGNLGEGTFGK YEIVGNLGEGTFGB 1490.74963 Dual specificity protein kinase CLK3 
ATSVALTWSR ATSVALTWSX 1100.58537 Contactin-1 
LFLVQLQEK LFLVQLQEB 1124.66848 Cleavage and polyadenylation specificity factor subunit 5 
QENGASVILR QENGASVILX 1095.59118 Elongation factor 1-delta 
STFVLDEFK STFVLDEFB 1092.55826 Elongation factor 1-gamma 
WFLTCINQPQFR WFLTZINQPQFX 1618.79538 Elongation factor 1-gamma 
VQAINVSSR VQAINVSSX 982.54351 EF-hand domain-containing protein D2 
ISCTIANR ISZTIANX 943.47847 Fibronectin 
TQLAVCQQR TQLAVZQQX 1112.5636 Peptidyl-prolyl cis-trans isomerase FKBP4 
VQVQVVER VQVQVVEX 965.55334 Flotillin-1 
QTLPVIYVK QTLPVIYVB 1067.64702 Glycogen synthase kinase-3 beta 
INEILSNALK INEILSNALB 1121.65356 Heterogeneous nuclear ribonucleoprotein M 
EFSITDVVPYPISLR EFSITDVVPYPISLX 1744.92748 Heat shock 70 kDa protein 4 
VLGVLEVSR VLGVLEVSX 980.58938 Integrin-linked kinase-associated serine/threonine phosphatase 2C 
LENEIQTYR LENEIQTYX 1174.58577 Keratin, type I cytoskeletal 10 
QETVECLR QETVEZLX 1043.49451 Calcium/calmodulin-dependent protein kinase type II subunit gamma 
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GSGTAEVELK GSGTAEVELB 997.51712 Pyruvate kinase PKM 
AANILVSDTLSCK AANILVSDTLSZB 1398.7268 Tyrosine-protein kinase Lck 
EAALSTALSEK EAALSTALSEB 1126.5961 Prelamin-A/C 
ALYETELADAR ALYETELADAX 1260.62253 Lamin-B1 
HENVIGLLDVFTPAR HENVIGLLDVFTPAX 1689.90774 Mitogen-activated protein kinase 14 
AAEDLFVNIR AAEDLFVNIX 1156.61157 Nck-associated protein 1 
GWNILTNSEK GWNILTNSEB 1168.59678 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 
LELSVLYK LELSVLYB 971.57827 Ubiquitin thioesterase OTUB1 
LVVLDYIIR LVVLDYIIX 1112.68328 Phosphatidylinositol 4-kinase type 2-alpha 
LAPEYEAAATR LAPEYEAAATX 1200.6014 Protein disulfide-isomerase A3 
TQEEIVAK TQEEIVAB 924.50075 Protein disulfide-isomerase A4 
TLSQFTDALVTIR TLSQFTDALVTIX 1473.80665 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, 
mitochondrial 
DLQNVNITLR DLQNVNITLX 1194.6596 Prohibitin 
LLNDEDPVVVTK LLNDEDPVVVTB 1348.73292 Junction plakoglobin 
HINPVAASLIQK HINPVAASLIQB 1297.75975 Serine/threonine-protein kinase PLK1 
SPIAEAVFR SPIAEAVFX 998.54243 Low molecular weight phosphotyrosine protein phosphatase 
DVFISAAER DVFISAAEX 1016.51661 Proteasome subunit beta type-1 
VNAADIENR VNAADIENX 1010.50203 Tyrosine-protein phosphatase non-receptor type 6 
SLQSVAEER SLQSVAEEX 1027.51735 60S ribosomal protein L15 
LVILANNCPALR LVILANNZPALX 1362.76809 60S ribosomal protein L30 
VCTLAIIDPGDSDIIR VZTLAIIDPGDSDIIX 1766.91117 60S ribosomal protein L30 
EAIEGTYIDK EAIEGTYIDB 1145.56955 40S ribosomal protein S11 
ECLPLIIFLR EZLPLIIFLX 1282.73466 40S ribosomal protein S4, X isoform 
LTPEEEEILNK LTPEEEEILNB 1321.68564 40S ribosomal protein S8 
FAAATGATPIAGR FAAATGATPIAGX 1212.64901 40S ribosomal protein SA 
VPAINVNDSVTK VPAINVNDSVTB 1263.6914 Adenosylhomocysteinase 
STLINSLFLTDLYPER STLINSLFLTDLYPEX 1890.99663 Septin-2 
GGIVDEGALLR GGIVDEGALLX 1108.61156 D-3-phosphoglycerate dehydrogenase 
HLAGLGLTEAIDK HLAGLGLTEAIDB 1344.74923 Serpin H1 
QYDQEIENLEK QYDQEIENLEB 1415.66598 STE20-like serine/threonine-protein kinase 
NVLVTLYER NVLVTLYEX 1115.62142 SPARC 
EFLVAGGEDFK EFLVAGGEDFB 1218.60117 Serine-threonine kinase receptor-associated protein 
LAVEAVLR LAVEAVLX 879.5417 T-complex protein 1 subunit beta 
APGLGLVLER APGLGLVLEX 1033.61592 tRNA pseudouridine synthase A, mitochondrial 
VDVIFCDK VDVIFZDB 1002.49355 Ubiquitin carboxyl-terminal hydrolase 7 
LGSGTYATVYK LGSGTYATVYB 1166.60628 Serine/threonine-protein kinase ULK3 
VTQSNFAVGYK VTQSNFAVGYB 1220.62808 Voltage-dependent anion-selective channel protein 1 
FLNWIPLGYIFETK FLNWIPLGYIFETB 1747.94285 Exportin-1 
SDFEVFDALK SDFEVFDALB 1177.57463 5'-AMP-activated protein kinase subunit beta-2 
VGNLTVVGK VGNLTVVGB 893.54255 Aspartate aminotransferase, cytoplasmic 
VNLGVGAYR VNLGVGAYX 957.52712 Aspartate aminotransferase, cytoplasmic 
TIAIIAEGIPEALTR TIAIIAEGIPEALTX 1576.90634 ATP-citrate synthase 
DNTINLIHTFR DNTINLIHTFX 1352.70761 Actin-related protein 2/3 complex subunit 2 
TPFLLVGTQIDLR TPFLLVGTQIDLX 1481.84811 Cell division control protein 42 homolog 
LTGEVVALK LTGEVVALB 936.57351 Cyclin-dependent kinase 2 
VGLQVVAVK VGLQVVAVB 919.59458 60 kDa heat shock protein, mitochondrial 
LLGYVATLK LLGYVATLB 984.6099 Cold shock domain-containing protein E1 
GAEIVADTFR GAEIVADTFX 1087.55372 N(G),N(G)-dimethylarginine dimethylaminohydrolase 2 
YLATLNFVHR YLATLNFVHX 1242.67485 Epithelial discoidin domain-containing receptor 1 
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GVIALCIEDGSIHR GVIALZIEDGSIHX 1548.79575 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial 
ALQGASQIIAEIR ALQGASQIIAEIX 1378.78076 Dynamin-1-like protein 
DTLQSELVGQLYK DTLQSELVGQLYB 1500.79151 Dynamin-1-like protein 
VNFLPEIITLSK VNFLPEIITLSB 1380.81078 Cytoplasmic dynein 1 heavy chain 1 
DITAALAAER DITAALAAEX 1039.55372 Dynamin-1 
TTLTAAITK TTLTAAITB 926.55279 Elongation factor Tu, mitochondrial 
NLFNVVDCK NLFNVVDZB 1115.55247 Eukaryotic translation initiation factor 3 subunit B 
GAVIATELK GAVIATELB 908.54221 Eukaryotic translation initiation factor 3 subunit D 
FAFQAEVNR FAFQAEVNX 1090.5435 Endoplasmin 
ALTLGALTLPLAR ALTLGALTLPLAX 1318.82116 Extended synaptotagmin-1 
DADIGVAEAER DADIGVAEAEX 1154.54427 Flotillin-2 
HSVGVVIGR HSVGVVIGX 932.5431 Far upstream element-binding protein 2 
GFCFITYTDEEPVK GFZFITYTDEEPVB 1712.7847 Heterogeneous nuclear ribonucleoprotein D-like 
ALFAISCLVR ALFAISZLVX 1158.64585 Hsp70-binding protein 1 
YLEAGAAGLR YLEAGAAGLX 1029.54824 Hsp70-binding protein 1 
AGGIETIANEYSDR AGGIETIANEYSDX 1504.7033 Heat shock 70 kDa protein 4 
SQIHDIVLVGGSTR SQIHDIVLVGGSTX 1490.80804 Heat shock cognate 71 kDa protein 
ASGVEGADVVK ASGVEGADVVB 1038.54366 Hexokinase-1 
IAEFAFEYAR IAEFAFEYAX 1225.60067 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 
ASSVIFGLK ASSVIFGLB 928.5473 Integrin-linked kinase-associated serine/threonine phosphatase 2C 
LAATNALLNSLEFTK LAATNALLNSLEFTB 1612.89155 Importin subunit beta-1 
LQSEVAELK LQSEVAELB 1023.56916 IST1 homolog 
LFENFLVDICR LFENFLVDIZX 1434.72047 Inositol 1,4,5-trisphosphate receptor type 1 
SENEEFVEVGR SENEEFVEVGX 1303.59196 cAMP-dependent protein kinase type I-alpha regulatory subunit 
NTGIICTIGPASR NTGIIZTIGPASX 1368.70589 Pyruvate kinase PKM 
GLTSVINQK GLTSVINQB 966.55894 L-lactate dehydrogenase B chain 
IVVVTAGVR IVVVTAGVX 922.5839 L-lactate dehydrogenase B chain 
LNFITEYIK LNFITEYIB 1147.63685 LIM domain kinase 1 
FQDNFEFVQWFK FQDNFEFVQWFB 1641.77071 Microtubule-associated protein RP/EB family member 1 
ATISALEAK ATISALEAB 910.52148 Myosin-10 
NLFLVIFQR NLFLVIFQX 1158.67887 Nuclear cap-binding protein subunit 1 
SATYVNTEGR SATYVNTEGX 1106.52317 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 
TEDIVAVQK TEDIVAVQB 1009.55351 Neprilysin 
GTLLAFAEAR GTLLAFAEAX 1057.57954 Sialidase-1 
AETYEGVYQCTAR AETYEGVYQZTAX 1556.68047 Neuronal cell adhesion molecule 
VLDDGELLVQQTK VLDDGELLVQQTB 1464.7915 Vesicle-fusing ATPase 
NTLLIAGLQAR NTLLIAGLQAX 1178.70106 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa 
subunit 
EADDIVNWLK EADDIVNWLB 1209.61208 Protein disulfide-isomerase 
IEELQLIVNDK IEELQLIVNDB 1320.73801 26S protease regulatory subunit 8 
LYQVEYAFK LYQVEYAFB 1167.60555 Proteasome subunit alpha type-6 
SSDEAVILCK SSDEAVILZB 1128.55761 26S proteasome non-ATPase regulatory subunit 13 
LSLDGQNIYNACCTLR LSLDGQNIYNAZZTLX 1906.89048 Polypyrimidine tract-binding protein 1 
IDTIEIITDR IDTIEIITDX 1197.64802 Heterogeneous nuclear ribonucleoproteins A2/B1 
GTGIVSAPVPK GTGIVSAPVPB 1032.60587 40S ribosomal protein S2 
TPVEPEVAIHR TPVEPEVAIHX 1256.67523 40S ribosomal protein S20 
LNNLVLFDK LNNLVLFDB 1082.62153 40S ribosomal protein S25 
TEIIILATR TEIIILATX 1038.63125 40S ribosomal protein S3 
LSNIFVIGK LSNIFVIGB 997.60515 40S ribosomal protein S4, X isoform 
ADGYVLEGK ADGYVLEGB 958.48509 40S ribosomal protein S8 
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VNIVPVIAK VNIVPVIAB 959.62588 Septin-2 
EAAIWELEER EAAIWELEEX 1254.61196 STE20-like serine/threonine-protein kinase 
ELPTAFDYVEFTR ELPTAFDYVEFTX 1596.76992 Spectrin alpha chain, non-erythrocytic 1 
EAGDVCYADVQK EAGDVZYADVQB 1361.60126 Serine/arginine-rich splicing factor 9 
FDEISFVNFAR FDEISFVNFAX 1353.65925 FACT complex subunit SSRP1 
GEFTIETEGK GEFTIETEGB 1117.53825 Glycine--tRNA ligase 
NGTCCIADLGLAVR NGTZZIADLGLAVX 1528.73653 TGF-beta receptor type-1 
AVELAANTK AVELAANTB 923.51673 Transketolase 
VEEEIVTLR VEEEIVTLX 1096.60034 Tumor protein D54 
DNPGVVTCLDEAR DNPGVVTZLDEAX 1454.66989 Ubiquitin-like modifier-activating enzyme 1 
YLAEVATGEK YLAEVATGEB 1087.56407 14-3-3 protein gamma 
QITLLECVGK QITLLEZVGB 1167.64128 Activin receptor type-1 
VNILGEVVEK VNILGEVVEB 1106.64265 Beta-adducin 
ATLYVTAIEDR ATLYVTAIEDX 1260.65892 Protein arginine N-methyltransferase 1 
ALGVLAQLIWSR ALGVLAQLIWSX 1335.7902 Citrate synthase, mitochondrial 
AQQVAVQEQEIAR AQQVAVQEQEIAX 1478.77166 Flotillin-1 
HVVPNEVVVQR HVVPNEVVVQX 1284.71777 Gelsolin 
ELEEIVQPIISK ELEEIVQPIISB 1404.79552 78 kDa glucose-regulated protein 
EFVEAVLELR EFVEAVLELX 1213.65818 Core histone macro-H2A.1 
LAEVALAYAK LAEVALAYAB 1055.61062 Delta-aminolevulinic acid dehydratase 
FVVQNVSAQK FVVQNVSAQB 1126.6226 Heat shock protein 105 kDa 
SVLDAAQIVGLNCLR SVLDAAQIVGLNZLX 1637.87982 Heat shock protein 105 kDa 
IEAACFATIK IEAAZFATIB 1130.58851 Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial 
LLVPTQYVGAIIGK LLVPTQYVGAIIGB 1478.89517 Insulin-like growth factor 2 mRNA-binding protein 1 
AYAALAALEK AYAALAALEB 1027.57932 Interleukin enhancer-binding factor 3 
AVLNPTNADILIETK AVLNPTNADILIETB 1618.90211 Inositol 1,4,5-trisphosphate receptor type 1 
VSHLLGINVTDFTR VSHLLGINVTDFTX 1580.85499 Myosin-9 
ILGAWLAEETSSLR ILGAWLAEETSSLX 1554.8281 Neurochondrin 
EVAGDTIIFR EVAGDTIIFX 1129.60067 Neurofascin 
ENIVIQCEAK ENIVIQZEAB 1210.61071 Neuronal cell adhesion molecule 
VFSATLGLVDIVK VFSATLGLVDIVB 1368.81077 Poly [ADP-ribose] polymerase 1 
TGEAIVDAALSALR TGEAIVDAALSALX 1395.75968 Protein disulfide-isomerase A6 
VTNEFVHINNLK VTNEFVHINNLB 1434.77105 Serine/threonine-protein phosphatase 6 catalytic subunit 
LLHVAVSDVNDDVR LLHVAVSDVNDDVX 1560.81351 26S proteasome non-ATPase regulatory subunit 1 
AVPLALALISVSNPR AVPLALALISVSNPX 1529.91685 26S proteasome non-ATPase regulatory subunit 2 
DIICQIAYAR DIIZQIAYAX 1231.62585 60S ribosomal protein L5 
ELGITALHIK ELGITALHIB 1101.66372 40S ribosomal protein S14 
LLEPVLLLGK LLEPVLLLGB 1101.72525 40S ribosomal protein S16 
VADIGLAAWGR VADIGLAAWGX 1137.61698 Adenosylhomocysteinase 
DVNAAIAAIK DVNAAIAAIB 992.57457 Tubulin alpha-4A chain 
AVAQALEVIPR AVAQALEVIPX 1175.69015 T-complex protein 1 subunit gamma 
VPITAVIAAK VPITAVIAAB 989.63644 Tripeptidyl-peptidase 2 
IDQYQGADAVGLEEK IDQYQGADAVGLEEB 1642.79295 Thioredoxin-like protein 1 
SLVQGELVTASK SLVQGELVTASB 1238.69615 Alpha-adducin 
TVEGVLIVHEHR TVEGVLIVHEHX 1397.76544 Cleavage and polyadenylation specificity factor subunit 5 
ELLIIGGVAAR ELLIIGGVAAX 1120.68433 ATP-dependent RNA helicase DDX1 
GTQGVVTNFEIFR GTQGVVTNFEIFX 1476.76003 Eukaryotic translation initiation factor 3 subunit B 
GAALITAVGVR GAALITAVGVX 1036.62682 Hexokinase-1 
GCDVVVIPAGVPR GZDVVVIPAGVPX 1347.72079 Malate dehydrogenase, mitochondrial 
IFGVTTLDIVR IFGVTTLDIVX 1242.72112 Malate dehydrogenase, mitochondrial 
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FGLEGCEVLIPALK FGLEGZEVLIPALB 1552.84141 2-oxoglutarate dehydrogenase, mitochondrial 
DLSHIGDAVVISCAK DLSHIGDAVVISZAB 1591.81191 Proliferating cell nuclear antigen 
LLLGAGAVAYGVR LLLGAGAVAYGVX 1268.74799 Prohibitin-2 
TVEIVHIDIADR TVEIVHIDIADX 1389.74912 Phosphatidylinositol transfer protein beta isoform 
SVLFVCLGNICR SVLFVZLGNIZX 1446.73508 Low molecular weight phosphotyrosine protein phosphatase 
AANGVVLATEK AANGVVLATEB 1079.6066 Proteasome subunit alpha type-2 
VSTAVLSITAK VSTAVLSITAB 1096.65831 26S proteasome non-ATPase regulatory subunit 1 
EIVLADVIDNDSWR EIVLADVIDNDSWX 1653.82374 Multifunctional protein ADE2 
DLTTAGAVTQCYR DLTTAGAVTQZYX 1464.69064 60S ribosomal protein L18a 
TALALAIAQELGSK TALALAIAQELGSB 1392.80675 RuvB-like 1 
SDVWSFGILLTELTTK SDVWSFGILLTELTTB 1816.97019 Proto-oncogene tyrosine-protein kinase Src 
AATAAADFTAK AATAAADFTAB 1044.5331 Serine-threonine kinase receptor-associated protein 
NLLLALVGEVGELAELFQ
WK 
NLLLALVGEVGELAELFQ
WB 
2249.25505 dCTP pyrophosphatase 1 
 Appendix chapter 4 table 2 1000 labelled peptide standards. 
 
 
Appendix chapter 5 figure 1 Cell viability of HepG2 cells in cultured in hydrogel 
(0/0.4% HA/L-pNIPAM) at cell seeding density 1x106 cell/mL. 
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Appendix chapter 5 figure 2 Cell viability of HepG2 cells in cultured in hydrogel 
(0/0.4% HA/L-pNIPAM) at cell seeding density 4x106 cell/mL. 
 
Appendix chapter 5 figure 3 Cell viability of HepG2 cells in cultured in hydrogel 
(0/0.4% HA/L-pNIPAM) at cell seeding density 8x106 cell/mL. 
 
 
 
 
255 
 
Appendix chapter 5 figure 4 MSI of small molecule species (m/z=198.0881) 
present within the hydrogel at cell locations. 
 
Appendix chapter 5 figure 5 MSI of small molecule species (m/z=206.0541) 
present within the hydrogel at cell locations. 
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Appendix chapter 5 figure 6 MSI of small molecule species (m/z=286.9889) 
present within the hydrogel at cell locations. 
 
Appendix chapter 5 figure 7 MSI of small molecule species (m/z=478.3269) 
present within the hydrogel at cell locations. 
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Appendix chapter 5 figure 8 MSI of small molecule species (m/z=549.4863) 
present within the hydrogel at cell locations. 
 
Appendix chapter 5 figure 9  MSI of small molecule species (m/z=577.5177) 
present within the hydrogel at cell locations. 
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Appendix chapter 5 figure 10  MSI of small molecule species (m/z=599.4990) 
present within the hydrogel at cell locations. 
 
Appendix chapter 5 figure 11  MSI of small molecule species (m/z=754.5301) 
present within the hydrogel at cell locations. 
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Appendix chapter 5 figure 12 MSI of small molecule species (m/z=780.5467) 
present within the hydrogel at cell locations. 
 
Appendix chapter 5 figure 13 MSI of small molecule species (m/z=808.5781) 
present within the hydrogel at cell locations.  
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